Approaches to treat immune hot, altered and cold tumo immunotherapies

Nature Reviews Drug Discovery

18, 197-218

DOI: 10.1038/s41573-018-0007-y

Citation Report

#	Article	IF	Citations
1	Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence. Nature Communications, 2019, 10, 3745.	5.8	108
2	The role of dendritic cells in cancer. International Review of Cell and Molecular Biology, 2019, 348, 123-178.	1.6	110
3	STING modulators: Predictive significance in drug discovery. European Journal of Medicinal Chemistry, 2019, 182, 111591.	2.6	31
4	miR-448 targets IDO1 and regulates CD8+ T cell response in human colon cancer. , 2019, 7, 210.		71
5	Microenvironmental Regulation of Tumor Progression and Therapeutic Response in Brain Metastasis. Frontiers in Immunology, 2019, 10, 1713.	2.2	144
6	Emerging Roles of Th9 Cells as an Anti-tumor Helper T Cells. International Reviews of Immunology, 2019, 38, 204-211.	1.5	15
7	Low Photosensitizer Dose and Early Radiotherapy Enhance Antitumor Immune Response of Photodynamic Therapy-Based Dendritic Cell Vaccination. Frontiers in Oncology, 2019, 9, 811.	1.3	47
8	Innovative Linker Strategies for Tumorâ€Targeted Drug Conjugates. Chemistry - A European Journal, 2019, 25, 14740-14757.	1.7	68
9	Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: an ATC-like and a PDTC-like. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3557-3575.	1.8	41
10	Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer. Frontiers in Immunology, 2019, 10, 1654.	2.2	101
11	Computational approaches for characterizing the tumor immune microenvironment. Immunology, 2019, 158, 70-84.	2.0	30
12	Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. Drug Resistance Updates, 2019, 45, 13-29.	6.5	82
13	Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front. Oncogene, 2019, 38, 5921-5932.	2.6	27
14	Mismatch Repairâ€“Proficient Colorectal Cancer: Finding the Right TiME to Respond. Clinical Cancer Research, 2019, 25, 5185-5187.	3.2	10
15	Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation. Cancers, 2019, 11, 911.	1.7	40
16	Tumor Microenvironment as A â€œGame Changerâ€•in Cancer Radiotherapy. International Journal of Molecular Sciences, 2019, 20, 3212.	1.8	286
17	Targeting the tumor microenvironment and TÂcell metabolism for effective cancer immunotherapy. European Journal of Immunology, 2019, 49, 1147-1152.	1.6	32
18	MildÂphotothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy. Nature Communications, 2019, 10, 4871.	5.8	377

#	Article	IF	Citations
19	A Designer Scaffold with Immune Nanoconverters for Reverting Immunosuppression and Enhancing Immune Checkpoint Blockade Therapy. Advanced Materials, 2019, 31, e1903242.	11.1	88
20	Exploiting autoimmunity unleashed by lowâ€dose immune checkpoint blockade to treat advanced cancer. Scandinavian Journal of Immunology, 2019, 90, e12821.	1.3	20
21	TLR9 acts as a sensor for tumor-released DNA to modulate anti-tumor immunity after chemotherapy. , 2019, 7, 260.		25
22	Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials. Targeted Oncology, 2019, 14, 631-637.	1.7	1
23	Noninvasive imaging in cancer immunotherapy: The way to precision medicine. Cancer Letters, 2019, 466, 13-22.	3.2	19
24	Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. Signal Transduction and Targeted Therapy, 2019, 4, 41.	7.1	150
25	Investigating the STING Pathway to Explain Mechanisms of BCG Failures in Non-Muscle Invasive Bladder Cancer: Prognostic and Therapeutic Implications. Bladder Cancer, 2019, 5, 225-234.	0.2	7
26	Comprehensive Analysis of ERK1/2 Substrates for Potential Combination Immunotherapies. Trends in Pharmacological Sciences, 2019, 40, 897-910.	4.0	35
27	Imaging of T-cells and their responses during anti-cancer immunotherapy. Theranostics, 2019, 9, 7924-7947.	4.6	77
28	Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga. Trends in Cancer, 2019, 5, 779-788.	3.8	22
29	Amplified Cancer Immunotherapy of a Surface-Engineered Antigenic Microparticle Vaccine by Synergistically Modulating Tumor Microenvironment. ACS Nano, 2019, 13, 12553-12566.	7.3	74
30	Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients. , 2019, 7, 293.		45
31	Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics, 2019, 9, 7906-7923.	4.6	100
32	Close to the Bone: Tissue-Specific Checkpoint Immunotherapy Evasion. Cell, 2019, 179, 1010-1012.	13.5	0
33	Precision medicine in colorectal surgery: coming to a hospital near you. ANZ Journal of Surgery, 2019, 89, 995-996.	0.3	0
34	Prognostic value and clinicopathological roles of phenotypes of tumour-associated macrophages in colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3005-3019.	1.2	31
35	The tumor immune microenvironment in gastroenteropancreatic neuroendocrine neoplasms. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1872, 188311.	3.3	30
36	Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors. Cancer and Metastasis Reviews, 2019, 38, 417-430.	2.7	27

#	Article	IF	Citations
37	Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. Seminars in Cancer Biology, 2019, 59, 290-297.	4.3	78
38	Tumor neoantigens: from basic research to clinical applications. Journal of Hematology and Oncology, 2019, 12, 93.	6.9	266
39	Inflammation, cardiovascular disease, and cancer: a common link with far-reaching implications. European Heart Journal, 2019, 40, 3910-3912.	1.0	30
40	The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987036.	1.4	45
41	High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status. , 2019, 7, 236.		22
42	A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Frontiers in Oncology, 2019, 9, 873.	1.3	36
43	Next-generation computational tools for interrogating cancer immunity. Nature Reviews Genetics, 2019, 20, 724-746.	7.7	131
44	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. Journal of Clinical Medicine, 2019, 8, 1534.	1.0	41
45	Ovarian Cancer Immunotherapy: Turning up the Heat. International Journal of Molecular Sciences, 2019, 20, 2927.	1.8	116
46	A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer. OncoImmunology, 2019, 8, e1624130.	2.1	23
47	Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature, 2019, 571, 570-575.	13.7	227
48	Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers, 2019, 11, 714.	1.7	79
49	Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma. Frontiers in Immunology, 2019, 10, 1114.	2.2	41
50	Network-based cancer precision medicine: A new emerging paradigm. Cancer Letters, 2019, 458, 39-45.	3.2	28
51	Combining Nanomedicine and Immunotherapy. Accounts of Chemical Research, 2019, 52, 1543-1554.	7.6	310
52	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
53	Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade. , 2019, 7, 125.		32
54	Quantitative Systems Pharmacology: An Exemplar Modelâ€Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 380-395.	1.3	33

#	Article	IF	Citations
55	Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology. Frontiers in Immunology, 2019, 10, 924.	2.2	31
56	Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. OncoImmunology, 2019, 8, e1581556.	2.1	68
57	ADAR and Immune Silencing in Cancer. Trends in Cancer, 2019, 5, 272-282.	3.8	49
58	CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy. International Journal of Molecular Sciences, 2019, 20, 1903.	1.8	15
59	Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers. Clinical Science, 2019, 133, 953-970.	1.8	79
60	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. Journal of Hematology and Oncology, 2019, 12, 42.	6.9	58
61	The role of immune infiltrates as prognostic biomarkers in patients with breast cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1671-1680.	2.0	56
62	Engineering Protein Delivery Depots for Cancer Immunotherapy. Bioconjugate Chemistry, 2019, 30, 515-524.	1.8	20
63	The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. , 2019, 7, 103.		79
64	Telomerase-Targeted Cancer Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 1823.	1.8	80
65	High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. Lung Cancer, 2019, 130, 35-41.	0.9	17
66	Evolving trends in pancreatic cancer therapeutic development. Annals of Pancreatic Cancer, 2019, 2, 17-17.	1.2	1
67	New emerging targets in cancer immunotherapy: the role of neoantigens. ESMO Open, 2019, 4, e000684.	2.0	20
68	New emerging targets in cancer immunotherapy: the role of GITR. ESMO Open, 2019, 4, e000738.	2.0	40
69	Know Thy Model: Charting Molecular Homology in Stromal Reprogramming Between Canine and Human Mammary Tumors. Frontiers in Cell and Developmental Biology, 2019, 7, 348.	1.8	10
70	Dual Checkpoint Inhibition: An Approach for STK11 and KRAS Co-Mutated Lung Adenocarcinoma?. JCO Precision Oncology, 2019, 3, 1-3.	1.5	4
71	Predicting Tumor Mutational Burden from Liver Cancer Pathological Images Using Convolutional Neural Network. , 2019, , .		12
72	Hepatic metastasis from colorectal cancer. Journal of Gastrointestinal Oncology, 2019, 10, 1274-1298.	0.6	108

#	Article	IF	Citations
74	Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. , 2019, 7, 333.		129
75	Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy. Theranostics, 2019, 9, 7981-8000.	4.6	106
76	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. Journal of Biomedical Science, 2019, 26, 96.	2.6	26
77	Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial. , 2019, 7, 318.		12
78	Biomarker for personalized immunotherapy. Translational Lung Cancer Research, 2019, 8, S308-S317.	1.3	7
79	Immunotherapy â€“ Strategies for Expanding Its Role in the Treatment of All Major Tumor Sites. Cureus, 2019, 11, e5938.	0.2	9
80	Tumor Mutational Burden Is Site Specific in Nonâ€“Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases. JCO Precision Oncology, 2019, 3, 1-13.	1.5	13
81	The emerging role of epigenetic therapeutics in immuno-oncology. Nature Reviews Clinical Oncology, 2020, 17, 75-90.	12.5	260
82	Combination therapy with PD-1 or PD-L1 inhibitors for cancer. International Journal of Clinical Oncology, 2020, 25, 818-830.	1.0	86
83	Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model. Hepatology, 2020, 71, 1297-1315.	3.6	41
84	Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. Regenerative Engineering and Translational Medicine, 2020, 6, 29-49.	1.6	16
85	A Nanoscale Metalâ€“Organic Framework to Mediate Photodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Enhance Antigen Presentation and Cancer Immunotherapy. Angewandte Chemie, 2020, 132, 1124-1128.	1.6	34
86	Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium. Cancer Letters, 2020, 469, 102-110.	3.2	67
87	New Approaches on Cancer Immunotherapy. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036863.	2.9	17
88	The Immunoscore: Colon Cancer and Beyond. Clinical Cancer Research, 2020, 26, 332-339.	3.2	255
89	A Nanoscale Metalâ€“Organic Framework to Mediate Photodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Enhance Antigen Presentation and Cancer Immunotherapy. Angewandte Chemie - International Edition, 2020, 59, 1108-1112.	7.2	144
90	Preoperative, biopsyâ€based assessment of the tumour microenvironment in patients with primary operable colorectal cancer. Journal of Pathology: Clinical Research, 2020, 6, 30-39.	1.3	11
91	Antiâ€tumour immune response in GL261 glioblastoma generated by Temozolomide Immuneâ€Enhancing Metronomic Schedule monitored with MRSIâ€based nosological images. NMR in Biomedicine, 2020, 33, e4229.	1.6	15

#	Article	IF	Citations
92	Ultrafast Low-Temperature Photothermal Therapy Activates Autophagy and Recovers Immunity for Efficient Antitumor Treatment. ACS Applied Materials & Interfaces, 2020, 12, 4265-4275.	4.0	48
93	Eliciting an immune hot tumor niche with biomimetic drug-based multi-functional nanohybrids augments immune checkpoint blockade-based breast cancer therapy. Nanoscale, 2020, 12, 3317-3329.	2.8	30
94	Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy. Seminars in Cancer Biology, 2020, 65, 140-154.	4.3	66
95	Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. Hepatology, 2020, 72, 965-981.	3.6	159
96	The local inflammatory response in colorectal cancer â€“ Type, location or density? A systematic review and meta-analysis. Cancer Treatment Reviews, 2020, 83, 101949.	3.4	38
97	Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1119-1128.	3.3	140
98	Immune Therapy for Liver Cancers. Cancers, 2020, 12, 77.	1.7	49
99	Identification of Distinct Immune Subtypes in Colorectal Cancer Based on the Stromal Compartment. Frontiers in Oncology, 2019, 9, 1497.	1.3	38
100	Transcriptome Profiling Reveals New Insights into the Immune Microenvironment and Upregulation of Novel Biomarkers in Metastatic Uveal Melanoma. Cancers, 2020, 12, 2832.	1.7	27
101	Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. AAPS Journal, 2020, 22, 132.	2.2	27
102	Seven-Gene Signature Based on Glycolysis Is Closely Related to the Prognosis and Tumor Immune Infiltration of Patients With Gastric Cancer. Frontiers in Oncology, 2020, 10, 1778.	1.3	41
103	Enhancing the efficacy of immunotherapy using radiotherapy. Clinical and Translational Immunology, 2020, 9, e1169.	1.7	40
104	Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers. Cancer Letters, 2020, 495, 89-99.	3.2	38
105	Combination of Fruquintinib and Antiâ€“PD-1 for the Treatment of Colorectal Cancer. Journal of Immunology, 2020, 205, 2905-2915.	0.4	35
106	Sarcoma treatment in the era of molecular medicine. EMBO Molecular Medicine, 2020, 12, e11131.	3.3	154
107	Dually regulating the proliferation and the immune microenvironment of melanomaviananoparticle-delivered siRNA targeting onco-immunologic CD155. Biomaterials Science, 2020, 8, 6683-6694.	2.6	12
108	Radiomic Immunophenotyping of GSEA-Assessed Immunophenotypes of Glioblastoma and Its Implications for Prognosis: A Feasibility Study. Cancers, 2020, 12, 3039.	1.7	18
109	Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy. , 2020, 8, e001358.		44

#	Article	IF	Citations
110	Identification of a Novel Signature and Construction of a Nomogram Predicting Overall Survival in Clear Cell Renal Cell Carcinoma. Frontiers in Genetics, 2020, 11, 1017.	1.1	6
111	Senescent Tumor CD8+ T Cells: Mechanisms of Induction and Challenges to Immunotherapy. Cancers, 2020, 12, 2828.	1.7	10
113	The Resistance Mechanisms of Lung Cancer Immunotherapy. Frontiers in Oncology, 2020, 10, 568059.	1.3	47
114	Biomineralized Bacterial Outer Membrane Vesicles Potentiate Safe and Efficient Tumor Microenvironment Reprogramming for Anticancer Therapy. Advanced Materials, 2020, 32, e2002085.	11.1	118
115	p.P476S mutation of RBPJL inhibits the efficacy of antiâ€PDâ€1 therapy in oesophageal squamous cell carcinoma by blunting Tâ€cell responses. Clinical and Translational Immunology, 2020, 9, e1172.	1.7	1
116	The Ins and Outs of TAPBPR. Current Opinion in Immunology, 2020, 64, 146-151.	2.4	8
117	Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis. IScience, 2020, 23, 101499.	1.9	33
118	Immune escape: A critical hallmark in solid tumors. Life Sciences, 2020, 258, 118110.	2.0	91
119	Immunoscore Guided Cold Tumors to Acquire â€œTemperatureâ€•Through Integrating Physicochemical and Biological Methods. BIO Integration, 2020, 1, .	0.9	13
120	Synthesis, Characterization, and DNA-Binding Kinetics of New Pd(II) and Pt(II) Thiosemicarbazone Complexes: Spectral, Structural, and Anticancer Evaluation. Journal of Chemistry, 2020, 2020, 1-17.	0.9	7
121	CSC Radioresistance: A Therapeutic Challenge to Improve Radiotherapy Effectiveness in Cancer. Cells, 2020, 9, 1651.	1.8	107
122	New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. Cancers, 2020, 12, 1869.	1.7	41
123	Combinatorial Immunotherapies for Metastatic Colorectal Cancer. Cancers, 2020, 12, 1875.	1.7	19
124	Sindbis Virus with Anti-OX40 Overcomes the Immunosuppressive Tumor Microenvironment of Low-Immunogenic Tumors. Molecular Therapy - Oncolytics, 2020, 17, 431-447.	2.0	13
125	Role of Telomeres and Telomeric Proteins in Human Malignancies and Their Therapeutic Potential. Cancers, 2020, 12, 1901.	1.7	34
126	Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy. Pharmaceutics, 2020, 12, 663.	2.0	24
127	Protein drug-drug interactions for therapeutic modalities. , 2020, , 387-416.		1
128	Advances in Development of mRNA-Based Therapeutics. Current Topics in Microbiology and Immunology, 2020, , 1.	0.7	6

#	Article	IF	Citations
129	Induction of Immune Response against Metastatic Tumors via Vaccination of Mannanâ€BAM, TLR Ligands, and Antiâ€CD40 Antibody (MBTA). Advanced Therapeutics, 2020, 3, 2000044.	1.6	11
130	Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma. Cancers, 2020, 12, 3344.	1.7	19
131	Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer. Cancers, 2020, 12, 3377.	1.7	35
132	Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling. Cancers, 2020, 12, 3380.	1.7	71
133	A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy. Frontiers in Immunology, 2020, 11, 584723.	2.2	22
134	Technical Advancements for Studying Immune Regulation of Disseminated Dormant Cancer Cells. Frontiers in Oncology, 2020, 10, 594514.	1.3	10
135	Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors. Antibodies, 2020, 9, 65.	1.2	13
136	Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches. International Journal of Molecular Sciences, 2020, 21, 8775.	1.8	14
137	Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death and Disease, 2020, 11, 1013.	2.7	466
138	Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma. Nature Communications, 2020, 11, 5992.	5.8	87
139	Loco-regional drug delivery in oncology: current clinical applications and future translational opportunities. Expert Opinion on Drug Delivery, 2021, 18, 607-623.	2.4	10
140	New insights into the interaction of the immune system with non-small cell lung carcinomas. Translational Lung Cancer Research, 2020, 9, 2199-2213.	1.3	11
141	Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs. Cancers, 2020, 12, 3301.	1.7	22
142	The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors. Frontiers in Oncology, 2020, 10, 569202.	1.3	22
143	Major Histocompatibility Complex Genes as Therapeutic Opportunity for Immune Cold Molecular Cancer Subtypes. Journal of Immunology Research, 2020, 2020, 1-9.	0.9	2
144	Nicotinamide N-Methyltransferase Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric Cancer. Frontiers in Genetics, 2020, 11, 580299.	1.1	11
145	Transcriptome and methylome analysis reveals three cellular origins of pituitary tumors. Scientific Reports, 2020, 10, 19373.	1.6	30
146	Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies. Frontiers in Oncology, 2020, 10, 582884.	1.3	23

#	Article	IF	Citations
147	Autophagy mediated danger signaling regulates tumor immunosurveillance and may potentiate the effects of anti-cancer immunotherapy through increased adjuvanticity. , 2020, , 119-140.		1
148	Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma. International Immunopharmacology, 2020, 89, 107135.	1.7	17
149	Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nature Reviews Clinical Oncology, 2020, 17, 725-741.	12.5	701
150	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. , 2020, 8, e000883.		36
151	Necroptosis in Immuno-Oncology and Cancer Immunotherapy. Cells, 2020, 9, 1823.	1.8	109
152	Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 5521.	1.8	25
153	Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel. Nature Biomedical Engineering, 2020, 4, 1090-1101.	11.6	168
154	CD39 Identifies the CD4+ Tumor-Specific T-cell Population in Human Cancer. Cancer Immunology Research, 2020, 8, 1311-1321.	1.6	84
155	Hypoxia-driven intratumor heterogeneity and immune evasion. Cancer Letters, 2020, 492, 1-10.	3.2	39
156	Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology. , 2020, 8, e000334.		21
157	Immune Landscape of the Tumor Microenvironment Identifies Prognostic Gene Signature CD4/CD68/CSF1R in Osteosarcoma. Frontiers in Oncology, 2020, 10, 1198.	1.3	25
158	Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy. Theranostics, 2020, 10, 8382-8399.	4.6	42
159	Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. Pharmacology, 2021, 106, 123-136.	0.9	24
160	Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies. Clinical Cancer Research, 2020, 26, 6406-6411.	3.2	5
161	Translational Nanomedicine Boosts Anti-PD1 Therapy to Eradicate Orthotopic PTEN-Negative Glioblastoma. ACS Nano, 2020, 14, 10127-10140.	7.3	47
162	A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. Lung Cancer, 2020, 147, 259-268.	0.9	31
163	Clinicopathological and prognostic implications of vessels encapsulate tumor clusters with PD-L1 in intrahepatic cholangiocarcinoma patients. Translational Cancer Research, 2020, 9, 3550-3563.	0.4	4
164	Mechanisms of Cancer Resistance to Immunotherapy. Frontiers in Oncology, 2020, 10, 1290.	1.3	159

#	Article	IF	Citations
165	Predicting Peritoneal Dissemination of Gastric Cancer in the Era of Precision Medicine: Molecular Characterization and Biomarkers. Cancers, 2020, 12, 2236.	1.7	34
166	Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence. Advanced Science, 2020, 7, 2001447.	5.6	30
167	Rational Design of a Robust Antibody-like Small-Molecule Inhibitor Nanoplatform for Enhanced Photoimmunotherapy. ACS Applied Materials & Interfaces, 2020, 12, 40085-40093.	4.0	28
168	The Canadian Cancer Research Conference 2019. Current Oncology, 2020, 27, 226-230.	0.9	0
169	Treating Immunologically Cold Tumors by Precise Cancer Photoimmunotherapy with an Extendable Nanoplatform. ACS Applied Materials & Interfaces, 2020, 12, 40002-40012.	4.0	18
170	The tumor immune microenvironment transcriptomic subtypes of colorectal cancer for prognosis and development of precise immunotherapy. Gastroenterology Report, 2020, 8, 381-389.	0.6	14
171	The Tumor Microenvironment of Pancreatic Cancer. Cancers, 2020, 12, 3076.	1.7	17
172	Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumorâ€infiltrating cells. Clinical and Translational Immunology, 2020, 9, e1194.	1.7	11
173	Usefulness and robustness of Immunoscore for personalized management of cancer patients. OncoImmunology, 2020, 9, 1832324.	2.1	11
174	DNA Repair and Signaling in Immune-Related Cancer Therapy. Frontiers in Molecular Biosciences, 2020, 7, 205.	1.6	20
175	The clinical and immune features of CD14 in colorectal cancer identified via large-scale analysis. International Immunopharmacology, 2020, 88, 106966.	1.7	5
176	Multiple Primary Lung Cancers: A New Challenge in the Era of Precision Medicine . Cancer Management and Research, 2020, Volume 12, 10361-10375.	0.9	22
177	Hypoxia Promotes Syndecan-3 Expression in the Tumor Microenvironment. Frontiers in Immunology, 2020, 11, 586977.	2.2	13
178	Engineering Prodrug Nanomedicine for Cancer Immunotherapy. Advanced Science, 2020, 7, 2002365.	5.6	71
179	Lipopolysaccharide-Mediated Chronic Inflammation Promotes Tobacco Carcinogenâ€“Induced Lung Cancer and Determines the Efficacy of Immunotherapy. Cancer Research, 2021, 81, 144-157.	0.4	52
180	The Innate Immune Signalling Pathways: Turning RIG-I Sensor Activation against Cancer. Cancers, 2020, 12, 3158.	1.7	29
181	Tailoring precision immunotherapy: coming to a clinic soon?. ESMO Open, 2020, 5, e000631.	2.0	8
182	Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surgery and Nutrition, 2020, 9, 414-424.	0.7	93

#	Article	IF	Citations
183	Cancer-Specific Immune Prognostic Signature in Solid Tumors and Its Relation to Immune Checkpoint Therapies. Cancers, 2020, 12, 2476.	1.7	39
184	Smoking Status at Diagnosis and Colorectal Cancer Prognosis According to Tumor Lymphocytic Reaction. JNCI Cancer Spectrum, 2020, 4, pkaa040.	1.4	8
185	Synthetic Particles for Cancer Vaccines: Connecting the Inherent Supply Chain. Accounts of Chemical Research, 2020, 53, 2068-2080.	7.6	15
186	Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity. , 2020, 8, e001046.		16
187	New technology on the horizon: Fast analytical screening technique FNA (FASTâ€FNA) enables rapid, multiplex biomarker analysis in head and neck cancers. Cancer Cytopathology, 2020, 128, 782-791.	1.4	6
188	A pH-responsive Pickering Nanoemulsion for specified spatial delivery of Immune Checkpoint Inhibitor and Chemotherapy agent to Tumors. Theranostics, 2020, 10, 9956-9969.	4.6	40
189	Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity. Science Advances, 2020, 6, eabc3646.	4.7	92
190	Tackling Resistance to Cancer Immunotherapy: What Do We Know?. Molecules, 2020, 25, 4096.	1.7	12
191	Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer. Cells, 2020, 9, 2071.	1.8	10
192	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. Journal of Clinical Oncology, 2020, 38, 3638-3651.	0.8	130
193	Immunotherapy and NSCLC: The Long and Winding Road. Cancers, 2020, 12, 2512.	1.7	6
194	The Relationship Between Single Nucleotide Polymorphisms of SMAD3/SMAD6 and Risk of Esophageal Squamous Cell Carcinoma in Chinese Population . Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 355-363.	0.4	0
195	Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. Molecular Cancer, 2020, 19, 141.	7.9	141
196	Tumorâ€Activated Sizeâ€Enlargeable Bioinspired Lipoproteins Access Cancer Cells in Tumor to Elicit Antiâ€Tumor Immune Responses. Advanced Materials, 2020, 32, e2002380.	11.1	43
197	In-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response. Clinical and Translational Radiation Oncology, 2020, 24, 116-122.	0.9	7
198	Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy. Accounts of Chemical Research, 2020, 53, 1761-1772.	7.6	64
199	The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma. Frontiers in Oncology, 2020, 10, 545385.	1.3	14
200	Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review. Technology in Cancer Research and Treatment, 2020, 19, 153303382097970.	0.8	5

#	Article	IF	Citations
201	Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with ALK Rearrangement-Positive Large Cell Neuroendocrine Carcinoma. International Journal of Molecular Sciences, 2020, 21, 9705.	1.8	12
202	Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. OncoImmunology, 2020, 9, 1846926.	2.1	74
203	Aging and immunotherapies: New horizons for the golden ages. Aging and Cancer, 2020, 1, 30-44.	0.5	8
204	Therapeutic strategies to remodel immunologically cold tumors. Clinical and Translational Immunology, 2020, 9, e1226.	1.7	23
205	Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. Respiration, 2020, 99, 903-929.	1.2	18
206	Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer. BMC Cancer, 2020, 20, 1205.	1.1	17
207	Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors. Cancers, 2020, 12, 3630.	1.7	11
208	TGF-Î² Mediated Immune Evasion in Cancerâ€"Spotlight on Cancer-Associated Fibroblasts. Cancers, 2020, 12, 3650.	1.7	37
209	Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?. International Journal of Molecular Sciences, 2020, 21, 9300.	1.8	23
210	Precision Tools in Immuno-Oncology: Synthetic Gene Circuits for Cancer Immunotherapy. Vaccines, 2020, 8, 732.	2.1	4
211	SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. , 2020, 8, e001037.		27
212	Combining Immunoscore with Clinicopathologic Features in Cholangiocarcinoma: An Influential Prognostic Nomogram . OncoTargets and Therapy, 2020, Volume 13, 11359-11376.	1.0	7
213	Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Frontiers in Immunology, 2020, 11, 598877.	2.2	133
214	Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma. International Immunopharmacology, 2020, 89, 107162.	1.7	12
215	Few-Layer Bismuthene for Checkpoint Knockdown Enhanced Cancer Immunotherapy with Rapid Clearance and Sequentially Triggered One-for-All Strategy. ACS Nano, 2020, 14, 15700-15713.	7.3	41
216	Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma. , 2020, 8, e000807.		29
217	Abscopal effect of stereotactic radiotherapy combined with antiâ€PDâ€1/PDâ€L1 immunotherapy: Mechanisms, clinical efficacy, and issues. Cancer Communications, 2020, 40, 649-654.	3.7	14
218	Current State of Combination of Locoregional Therapies with Immune Checkpoint Inhibition. Journal of Vascular and Interventional Radiology, 2020, 31, 1740-1744.e9.	0.2	5

#	Article	IF	Citations
219	Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy. Acta Pharmacologica Sinica, 2020, 41, 986-994.	2.8	93
220	The Role of Antigen Spreading in the Efficacy of Immunotherapies. Clinical Cancer Research, 2020, 26, 4442-4447.	3.2	84
221	Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response. Journal of Drug Targeting, 2020, 28, 982-990.	2.1	4
222	Multifunctional STINGâ€Activating Mn₃O₄@Auâ€dsDNA/DOX Nanoparticle for Antitumor Immunotherapy. Advanced Healthcare Materials, 2020, 9, e2000064.	3.9	45
223	Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment. Cell Death and Disease, 2020, 11, 361.	2.7	30
224	A novel cancer immunotherapy utilizing autologous tumour tissue. Vox Sanguinis, 2020, 115, 525-535.	0.7	5
225	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. , 2020, 8, e000404.		29
226	How to select IgG subclasses in developing anti-tumor therapeutic antibodies. Journal of Hematology and Oncology, 2020, 13, 45.	6.9	105
227	Designing immunogenic nanotherapeutics for photothermal-triggered immunotherapy involving reprogramming immunosuppression and activating systemic antitumor responses. Biomaterials, 2020, 255, 120153.	5.7	68
228	Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features. Human Pathology, 2020, 101, 31-39.	1.1	9
229	Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer. Nano Letters, 2020, 20, 4393-4402.	4.5	93
230	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. Frontiers in Immunology, 2020, 11, 784.	2.2	339
231	Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo. International Journal of Molecular Sciences, 2020, 21, 3816.	1.8	17
232	Potent and Prolonged Innate Immune Activation by Enzyme-Responsive Imidazoquinoline TLR7/8 Agonist Prodrug Vesicles. Journal of the American Chemical Society, 2020, 142, 12133-12139.	6.6	52
233	Improving the Clinical Significance of Preclinical Immunotherapy Studies through Incorporating Tumor Microenvironmentâ€"like Conditions. Clinical Cancer Research, 2020, 26, 4448-4453.	3.2	14
234	Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment. Acta Pharmaceutica Sinica B, 2020, 10, 2110-2124.	5.7	80
235	Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. Frontiers in Oncology, 2020, 10, 763.	1.3	32
236	STAT3: A key signaling molecule for converting cold to hot tumors. Cancer Letters, 2020, 489, 29-40.	3.2	23

#	Article	IF	Citations
237	The distribution of immune cells within combined hepatocellular carcinoma and cholangiocarcinoma predicts clinical outcome. Clinical and Translational Medicine, 2020, 10, 45-56.	1.7	22
238	Fibroblast growth factorâ€2, derived from cancerâ€associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling. Molecular Carcinogenesis, 2020, 59, 1028-1040.	1.3	39
239	Development and clinical application of bispecific antibody in the treatment of colorectal cancer. Expert Review of Clinical Immunology, 2020, 16, 689-709.	1.3	5
240	Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. Journal of Leukocyte Biology, 2020, 108, 1455-1489.	1.5	22
241	Metabolic Traits in Cutaneous Melanoma. Frontiers in Oncology, 2020, 10, 851.	1.3	18
242	The Cancer-Immune Set Point in Oesophageal Cancer. Frontiers in Oncology, 2020, 10, 891.	1.3	15
243	The pattern and prognostic relevance of immune activity scores and tumor-infiltrating immune cells in metastatic clear cell renal cell carcinoma: Evidence from multiple datasets. International Immunopharmacology, 2020, 85, 106651.	1.7	4
244	Analysis of Gene Signatures of Tumor Microenvironment Yields Insight Into Mechanisms of Resistance to Immunotherapy. Frontiers in Bioengineering and Biotechnology, 2020, 8, 348.	2.0	4
245	Targeting Autophagy Facilitates T Lymphocyte Migration by Inducing the Expression of CXCL10 in Gastric Cancer Cell Lines. Frontiers in Oncology, 2020, 10, 886.	1.3	4
246	Wnt Signaling in Gynecologic Malignancies. International Journal of Molecular Sciences, 2020, 21, 4272.	1.8	45
247	Integrated immune gene expression signature and molecular classification in gastric cancer: New insights. Journal of Leukocyte Biology, 2020, 108, 633-646.	1.5	26
248	Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Frontiers in Immunology, 2020, 11, 369.	2.2	291
249	Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies. Frontiers in Cell and Developmental Biology, 2020, 8, 155.	1.8	32
250	Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nature Reviews Cancer, 2020, 20, 203-217.	12.8	420
251	Near-Infrared Fluorescent Macromolecular Reporters for Real-Time Imaging and Urinalysis of Cancer Immunotherapy. Journal of the American Chemical Society, 2020, 142, 7075-7082.	6.6	208
252	Reshaping Tumor Immune Microenvironment through Acidity-Responsive Nanoparticles Featured with CRISPR/Cas9-Mediated Programmed Death-Ligand 1 Attenuation and Chemotherapeutics-Induced Immunogenic Cell Death. ACS Applied Materials & Interfaces, 2020, 12, 16018-16030.	4.0	84
253	Immunoscore assay for the immune classification of solid tumors: Technical aspects, improvements and clinical perspectives. Methods in Enzymology, 2020, 636, 109-128.	0.4	13
254	Application of nanotechnology for enhancing photodynamic therapy via ameliorating, neglecting, or exploiting tumor hypoxia. View, 2020, 1, e6.	2.7	51

#	Article	IF	Citations
255	Orthotopic tongue squamous cell carcinoma (SCC) model exhibiting a different tumor-infiltrating T-cell status with margin-restricted CD8+ T cells and regulatory T cell-dominance, compared to skin SCC. Biochemical and Biophysical Research Communications, 2020, 526, 218-224.	1.0	5
256	Immunotherapeutic Potential of TGF-Î² Inhibition and Oncolytic Viruses. Trends in Immunology, 2020, 41, 406-420.	2.9	55
257	Medical Gas Plasma Jet Technology Targets Murine Melanoma in an Immunogenic Fashion. Advanced Science, 2020, 7, 1903438.	5.6	84
258	Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. Diagnostics, 2020, 10, 146.	1.3	56
259	Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. Frontiers in Immunology, 2020, 11, 223.	2.2	54
260	Combination Therapies in Solid Tumour Oncology. , 2020, , 515-578.		0
261	Multifunctional Nanomodulators Regulate Multiple Pathways To Enhance Antitumor Immunity. ACS Applied Bio Materials, 2020, 3, 4635-4642.	2.3	15
262	Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination. , 2020, 8, e000563.		23
263	A machine learning-based prognostic predictor for stage III colon cancer. Scientific Reports, 2020, 10, 10333.	1.6	35
264	Toward Systems Biomarkers of Response to Immune Checkpoint Blockers. Frontiers in Oncology, 2020, 10, 1027.	1.3	16
265	Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches . OncoTargets and Therapy, 2020, Volume 13, 6109-6129.	1.0	54
266	Clinical Translation of Nanomedicine and Biomaterials for Cancer Immunotherapy: Progress and Perspectives. Advanced Therapeutics, 2020, 3, 1900215.	1.6	62
267	Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, 286-294.	0.4	16
268	Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series. European Journal of Surgical Oncology, 2020, 46, e33-e39.	0.5	24
269	Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?. Cells, 2020, 9, 1525.	1.8	13
270	Immunotherapy combinations for the treatment of patients with solid tumors. Future Oncology, 2020, 16, 1715-1736.	1.1	6
271	Dexamethasone premedication suppresses vaccine-induced immune responses against cancer. OncoImmunology, 2020, 9, 1758004.	2.1	17
272	Converting Immune Cold into Hot by Biosynthetic Functional Vesicles to Boost Systematic Antitumor Immunity. IScience, 2020, 23, 101341.	1.9	34

#	Article	IF	Citations
273	Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-Î¹B inhibitor for antitumor immunotherapy. Science Advances, 2020, 6, eaay7785.	4.7	95
274	The Impact of Focused Ultrasound in Two Tumor Models: Temporal Alterations in the Natural History on Tumor Microenvironment and Immune Cell Response. Cancers, 2020, 12, 350.	1.7	11
275	Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS ONE, 2020, 15, e0224775.	1.1	15
276	An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscleâ€invasive bladder cancer (MIBC). Cancer Medicine, 2020, 9, 2774-2790.	1.3	63
277	Computational deconvolution of transcriptomic data for the study of tumor-infiltrating immune cells. International Journal of Biological Markers, 2020, 35, 20-22.	0.7	5
278	Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody. RSC Advances, 2020, 10, 8074-8079.	1.7	13
279	Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications. Cancer Immunology, Immunotherapy, 2020, 69, 1057-1069.	2.0	31
280	Tracing tumorigenesis in a solid tumor model at single-cell resolution. Nature Communications, 2020, 11, 991.	5.8	44
281	Patient-derived model systems and the development of next-generation anticancer therapeutics. Current Opinion in Chemical Biology, 2020, 56, 72-78.	2.8	10
282	Cryoablation and immunotherapy of cancer. Current Opinion in Biotechnology, 2020, 65, 60-64.	3.3	36
283	Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro. Cancer Immunology, Immunotherapy, 2020, 69, 1015-1027.	2.0	29
284	Immunoactivating the tumor microenvironment enhances immunotherapy as predicted by integrative computational model. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4447-4449.	3.3	21
285	Remodeling of Metastatic Vasculature Reduces Lung Colonization and Sensitizes Overt Metastases to Immunotherapy. Cell Reports, 2020, 30, 714-724.e5.	2.9	51
286	Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. Annals of Surgical Oncology, 2020, 27, 1533-1545.	0.7	6
287	Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic. Current Cancer Drug Targets, 2020, 20, 3-18.	0.8	43
288	Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. International Journal of Cancer, 2020, 147, 1509-1518.	2.3	44
289	Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. Journal of Clinical Medicine, 2020, 9, 286.	1.0	50
290	Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment. Advanced Therapeutics, 2020, 3, 1900136.	1.6	23

#	Article	IF	Citations
291	Cancer immunotherapy: Pros, cons and beyond. Biomedicine and Pharmacotherapy, 2020, 124, 109821.	2.5	337
292	Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. Immunity, 2020, 52, 36-54.	6.6	127
293	Top 10 Challenges in Cancer Immunotherapy. Immunity, 2020, 52, 17-35.	6.6	1,177
294	Tumor Immunology and Tumor Evolution: Intertwined Histories. Immunity, 2020, 52, 55-81.	6.6	357
295	Autophagy regulation as a promising approach for improving cancer immunotherapy. Cancer Letters, 2020, 475, 34-42.	3.2	32
296	Loading of Primary Human T Lymphocytes with Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles Does Not Impair Their Activation after Polyclonal Stimulation. Cells, 2020, 9, 342.	1.8	14
297	Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2020, 6, 856.	3.4	103
298	Integrating the immune microenvironment of prostate cancerÂinduced bone disease. Molecular Carcinogenesis, 2020, 59, 822-829.	1.3	9
299	Pan-Cancer Analysis of Radiotherapy Benefits and Immune Infiltration in Multiple Human Cancers. Cancers, 2020, 12, 957.	1.7	10
300	Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma. Cancer Science, 2020, 111, 1899-1909.	1.7	54
301	Contribution of Macrophages and T Cells in Skeletal Metastasis. Cancers, 2020, 12, 1014.	1.7	19
302	Combination therapy based on nano codelivery for overcoming cancer drug resistance. Medicine in Drug Discovery, 2020, 6, 100024.	2.3	66
303	Development of a prognostic index of colon adenocarcinoma based on immunogenomic landscape analysis. Annals of Translational Medicine, 2020, 8, 284-284.	0.7	3
304	The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis. European Journal of Cancer, 2020, 132, 71-84.	1.3	110
305	In Situ Immune Profiling of HeartÂTransplant Biopsies Improves Diagnostic Accuracy and Rejection Risk Stratification. JACC Basic To Translational Science, 2020, 5, 328-340.	1.9	13
306	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	13.5	334
307	Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC. Lung Cancer, 2020, 144, 30-39.	0.9	23
308	Nano Codelivery of Oxaliplatin and Folinic Acid Achieves Synergistic Chemo-Immunotherapy with 5-Fluorouracil for Colorectal Cancer and Liver Metastasis. ACS Nano, 2020, 14, 5075-5089.	7.3	144

#	Article	IF	Citations
309	A gene signature for immune subtyping of desert, excluded, and inflamed ovarian tumors. American Journal of Reproductive Immunology, 2020, 84, e13244.	1.2	18
310	Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer. Cell, 2020, 181, 442-459.e29.	13.5	741
311	The Effects of Neoadjuvant Treatment on the Tumor Microenvironment in Rectal Cancer: Implications for Immune Activation and Therapy Response. Clinical Colorectal Cancer, 2020, 19, e164-e180.	1.0	11
312	Biomimetic nanoscale metalâ€“organic framework harnesses hypoxia for effective cancer radiotherapy and immunotherapy. Chemical Science, 2020, 11, 7641-7653.	3.7	78
314	Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy. Nature Communications, 2020, 11, 1879.	5.8	29
315	Control over Imidazoquinoline Immune Stimulation by pH-Degradable Poly(norbornene) Nanogels. Biomacromolecules, 2020, 21, 2246-2257.	2.6	21
316	Dilemma and Challenge of Immunotherapy for Pancreatic Cancer. Digestive Diseases and Sciences, 2021, 66, 359-368.	1.1	43
317	Heterogeneity of MSI-H gastric cancer identifies a subtype with worse survival. Journal of Medical Genetics, 2021, 58, 12-19.	1.5	22
318	Immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma: Relationship with histopathological and molecular classifications. Hepatology Research, 2021, 51, 5-18.	1.8	29
319	PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential. Human Vaccines and Immunotherapeutics, 2021, 17, 546-553.	1.4	49
320	PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a 177Lu-labeled Î±PD-L1 antibody. Theranostics, 2021, 11, 304-315.	4.6	22
321	Manipulating the Wnt/Î²-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy. Gynecologic Oncology, 2021, 160, 285-294.	0.6	30
322	Electromagnetic Nanomedicines for Combinational Cancer Immunotherapy. Angewandte Chemie, 2021, 133, 12792-12815.	1.6	14
323	Genomic profile and immune contexture in colorectal cancerâ€”relevance for prognosis and immunotherapy. Clinical and Experimental Medicine, 2021, 21, 195-204.	1.9	5
324	Sequential changes in histone modifications shape transcriptional responses underlying microglia polarization by glioma. Glia, 2021, 69, 109-123.	2.5	10
325	Electromagnetic Nanomedicines for Combinational Cancer Immunotherapy. Angewandte Chemie - International Edition, 2021, 60, 12682-12705.	7.2	151
326	Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors. Trends in Molecular Medicine, 2021, 27, 75-90.	3.5	5
327	TGFÎ²-Directed Therapeutics: 2020. , 2021, 217, 107666.		52

#	Article	IF	Citations
328	Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer. British Journal of Cancer, 2021, 124, 414-424.	2.9	38
329	Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities. Molecular Therapy, 2021, 29, 555-570.	3.7	130
330	Sendai virus acts as a nano-booster to excite dendritic cells for enhancing the efficacy of CD47-directed immune checkpoint inhibitors against breast carcinoma. Materials Chemistry Frontiers, 2021, 5, 223-237.	3.2	4
331	Bioengineering of nano metal-organic frameworks for cancer immunotherapy. Nano Research, 2021, 14, 1244-1259.	5.8	37
332	Corn-like Au/Ag nanorod-mediated NIR-II photothermal/photodynamic therapy potentiates immune checkpoint antibody efficacy by reprogramming the cold tumor microenvironment. Biomaterials, 2021, 268, 120582.	5.7	69
333	Nanodelivery of immunogenic cell death-inducers for cancer immunotherapy. Drug Discovery Today, 2021, 26, 651-662.	3.2	23
334	Understanding the tumor microenvironment for effective immunotherapy. Medicinal Research Reviews, 2021, 41, 1474-1498.	5.0	130
335	The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?. Expert Opinion on Drug Discovery, 2021, 16, 391-410.	2.5	20
336	Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastomaâ€"backbone or add-on in immune-oncology?. Cancer and Metastasis Reviews, 2021, 40, 153-171.	2.7	23
337	Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration. Journal of Controlled Release, 2021, 330, 1118-1129.	4.8	58
338	Macrophageâ€Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention. Advanced Functional Materials, 2021, 31, 2006220.	7.8	63
339	Activatable Polymeric Nanoprobe for Nearâ€Infrared Fluorescence and Photoacoustic Imaging of Tâ€...Lymphocytes. Angewandte Chemie - International Edition, 2021, 60, 5921-5927.	7.2	140
340	Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC. Molecular Therapy - Nucleic Acids, 2021, 23, 89-100.	2.3	25
341	Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nature Cancer, 2021, 2, 18-33.	5.7	74
342	Water/pH dual responsive in situ calcium supplement collaborates simvastatin for osteoblast promotion mediated osteoporosis therapy via oral medication. Journal of Controlled Release, 2021, 329, 121-135.	4.8	21
343	Immune response drives outcomes in prostate cancer: implications for immunotherapy. Molecular Oncology, 2021, 15, 1358-1375.	2.1	48
344	Antiâ€pyroptotic function of TGFâ€Î²2 is suppressed by a synthetic dsRNA analogue in triple negative breast cancer cells. Molecular Oncology, 2021, 15, 1289-1307.	2.1	14
345	Nanomedicines: Redefining traditional medicine. Biomedicine and Pharmacotherapy, 2021, 134, 111103.	2.5	62

#	Article	IF	Citations
346	Developmental pathways of myeloid-derived suppressor cells in neoplasia. Cellular Immunology, 2021, 360, 104261.	1.4	4
347	Activatable Polymeric Nanoprobe for Nearâ€Infrared Fluorescence and Photoacoustic Imaging of Tâ€…Lymphocytes. Angewandte Chemie, 2021, 133, 5986-5992.	1.6	43
348	Tumor-on-a-chip platforms to study cancerâ€“immune system crosstalk in the era of immunotherapy. Lab on A Chip, 2021, 21, 234-253.	3.1	34
349	Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance. Molecular Therapy - Oncolytics, 2021, 20, 12-22.	2.0	6
350	Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes. Pathology, 2021, 53, 56-66.	0.3	22
351	Continuous inertial cavitation evokes massive ROS for reinforcing sonodynamic therapy and immunogenic cell death against breast carcinoma. Nano Today, 2021, 36, 101009.	6.2	140
352	Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer. Expert Opinion on Drug Discovery, 2021, 16, 89-99.	2.5	14
353	Interleukinâ€6â€mediated resistance to immunotherapy is linked to impaired myeloid cell function. International Journal of Cancer, 2021, 148, 211-225.	2.3	13
354	Evaluation Challenges in the Validation of B7-H3 as Oral Tongue Cancer Prognosticator. Head and Neck Pathology, 2021, 15, 469-478.	1.3	1
355	Lymphopenia During Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Association with Dosimetric Parameters and Patient Outcomes. Oncologist, 2021, 26, e425-e434.	1.9	20
356	Prognostic assessment of resected colorectal liver metastases integrating pathological features, <scp>RAS</scp> mutation and Immunoscore. Journal of Pathology: Clinical Research, 2021, 7, 27-41.	1.3	24
357	Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. British Journal of Cancer, 2021, 124, 359-367.	2.9	590
358	Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly EffectiveIn Vivowithout Systemic Immune Activation. Cancer Discovery, 2021, 11, 158-175.	7.7	57
359	The prognostic value and potential subtypes of immune activity scores in three major urological cancers. Journal of Cellular Physiology, 2021, 236, 2620-2630.	2.0	3
360	Nano-immunotherapy: Overcoming tumour immune evasion. Seminars in Cancer Biology, 2021, 69, 238-248.	4.3	47
361	The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies. Seminars in Cancer Biology, 2021, 72, 76-89.	4.3	87
362	Evasion before invasion: Pre-cancer immunosurveillance. OncoImmunology, 2021, 10, 1912250.	2.1	9
363	Predictive Systems Biomarkers of Response to Immune Checkpoint Inhibitors. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
364	Radiation Response in the Tumour Microenvironment: Predictive Biomarkers and Future Perspectives. Journal of Personalized Medicine, 2021, 11, 53.	1.1	17
365	Low-dose total body irradiation facilitates antitumoral Th1 immune responses. Theranostics, 2021, 11, 7700-7714.	4.6	7
366	Fluorescent Agâ€“Inâ€“S/ZnS Quantum Dots for Tumor Drainage Lymph Node Imaging In Vivo. ACS Applied Nano Materials, 2021, 4, 1029-1037.	2.4	10
367	Clonal dynamics of tumor-infiltrating T-cell receptor beta-chain repertoires in the peripheral blood in response to concurrent chemoradiotherapy for Epsteinâ€“Barr virus-associated nasopharyngeal carcinoma. OncoImmunology, 2021, 10, 1968172.	2.1	3
368	Developing a risk scoring system based on immune-related lncRNAs for patients with gastric cancer. Bioscience Reports, 2021, 41, .	1.1	6
369	Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes. Hereditas, 2021, 158, 1.	0.5	11
370	Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. British Journal of Surgery, 2021, 108, 1417-1425.	0.1	57
371	Successful Treatment of Advanced Gastric Cancer with Brain Metastases through an Abscopal Effect by Radiation and Immune Checkpoint Inhibitor Therapy. Journal of Gastric Cancer, 2021, 21, 319-324.	0.9	5
372	Immun-Checkpoint-Blockade bei fortgeschrittenem kutanen Plattenepithelkarzinom: Was wissen wir derzeit im Jahr 2020?. Karger Kompass Dermatologie, 2021, 9, 114-128.	0.0	0
373	Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis. Theranostics, 2021, 11, 7308-7321.	4.6	20
374	m⁶A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer. Theranostics, 2021, 11, 2201-2217.	4.6	148
375	Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy. Frontiers in Immunology, 2020, 11, 612202.	2.2	66
376	Tumor cytotoxicity and immunogenicity of a novel V-jet neon plasma source compared to the kINPen. Scientific Reports, 2021, 11, 136.	1.6	23
377	Immunotherapy in colorectal cancer: current achievements and future perspective. International Journal of Biological Sciences, 2021, 17, 3837-3849.	2.6	132
378	Oxygenâ€Evolving Manganese Ferrite Nanovesicles for Hypoxiaâ€Responsive Drug Delivery and Enhanced Cancer Chemoimmunotherapy. Advanced Functional Materials, 2021, 31, 2008078.	7.8	65
379	Monocytes in the Tumor Microenvironment. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 93-122.	9.6	126
380	OSCAR facilitates malignancy with enhanced metastasis correlating to inhibitory immune microenvironment in multiple cancer types. Journal of Cancer, 2021, 12, 3769-3780.	1.2	3
381	Quantification of Immune Variables from Liquid Biopsy in Breast Cancer Patients Links VÎ´2+ Î³Î´ T Cell Alterations with Lymph Node Invasion. Cancers, 2021, 13, 441.	1.7	6

#	Article	IF	Citations
382	The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling. Theranostics, 2021, 11, 3565-3579.	4.6	20
383	Decoding Immune Heterogeneity of Melanoma and identifying immune-prognostic hub genes. Journal of Cancer, 2021, 12, 703-716.	1.2	3
384	Expand to shield: IL-15 and in situ lymphocytic proliferation. OncoImmunology, 2021, 10, 1886726.	2.1	6
385	Spontaneously occurring canine cancer as a relevant animal model for developing novel treatments for human cancers. Translational and Regulatory Sciences, 2021, 3, 51-59.	0.2	1
386	Protagonist of Immuno-Profiling, Immuno-Scoring, and Immunotherapy Towards Colitis-Associated Cancer. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 24-37.	0.1	0
387	Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics, 2021, 11, 5365-5386.	4.6	324
388	Phenotypic profiling and prognostic significance of immune infiltrates in esophageal squamous cell carcinoma. OncoImmunology, 2021, 10, 1883890.	2.1	16
389	Revisiting immunogenic cell death to improve treatment response in cancer. , 2021, , 65-90.		4
390	Myron Gordon Award paper: Microbes, Tâ€cell diversity and pigmentation. Pigment Cell and Melanoma Research, 2021, 34, 244-255.	1.5	4
392	Cancer-Associated Fibroblasts and T Cells: From Mechanisms to Outcomes. Journal of Immunology, 2021, 206, 310-320.	0.4	35
393	Metformin Mediated PDâ€Ł1 Downregulation in Combination with Photodynamicâ€Immunotherapy for Treatment of Breast Cancer. Advanced Functional Materials, 2021, 31, 2007149.	7.8	89
394	PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma. OncoImmunology, 2021, 10, 1960729.	2.1	8
395	Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?. Cancers, 2021, 13, 394.	1.7	19
396	Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy. Frontiers in Pharmacology, 2020, 11, 586599.	1.6	20
397	Immunomodulatory nanomedicine for colorectal cancer treatment: a landscape to be explored?. Biomaterials Science, 2021, 9, 3228-3243.	2.6	6
398	Minimal Residual Disease, Metastasis and Immunity. Biomolecules, 2021, 11, 130.	1.8	21
399	Beyond DNA-targeting in Cancer Chemotherapy. Emerging Frontiers - A Review. Current Topics in Medicinal Chemistry, 2021, 21, 28-47.	1.0	6
400	Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy. Frontiers in Immunology, 2020, 11, 622509.	2.2	148

#	Article	IF	Citations
401	Immunotherapy in non-small cell lung cancer: advancements and challenges. Chinese Medical Journal, 2021, 134, 1135-1137.	0.9	4
402	Role of Methylation in Pro- and Anti-Cancer Immunity. Cancers, 2021, 13, 545.	1.7	53
403	Development of a Prognostic Signature Based on Single-Cell RNA Sequencing Data of Immune Cells in Intrahepatic Cholangiocarcinoma. Frontiers in Genetics, 2020, 11, 615680.	1.1	7
404	Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety. Cancer, 2021, 127, 1553-1567.	2.0	33
405	Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass. Frontiers in Cell and Developmental Biology, 2021, 9, 636498.	1.8	6
407	Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-photothermal therapy of early- and late-stage metastatic cancer. Biomaterials, 2021, 269, 120629.	5.7	34
408	Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy. Frontiers in Immunology, 2021, 12, 613492.	2.2	57
409	Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve. , 2021, 9, e001691.		34
410	Relaxin gene delivery modulates macrophages to resolve cancer fibrosis and synergizes with immune checkpoint blockade therapy. Science Advances, 2021, 7, .	4.7	23
411	Targeting Innate Immunity in Cancer Therapy. Vaccines, 2021, 9, 138.	2.1	57
412	Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology. Cancers, 2021, 13, 761.	1.7	68
413	Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors. Clinical Cancer Research, 2021, 27, 2755-2763.	3.2	29
414	Targeting DNA damage response pathways to activate the STING innate immune signaling pathway in human cancer cells. FEBS Journal, 2021, 288, 4507-4540.	2.2	22
415	Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles. Journal of Nanobiotechnology, 2021, 19, 58.	4.2	67
416	Tumor Immune Microenvironment Characterization in Hepatocellular Carcinoma Identifies Four Prognostic and Immunotherapeutically Relevant Subclasses. Frontiers in Oncology, 2020, 10, 610513.	1.3	17
417	Modulation of the Vascular-Immune Environment in Metastatic Cancer. Cancers, 2021, 13, 810.	1.7	12
418	Reduction of Lung Metastases in a Mouse Osteosarcoma Model Treated With Carbon Ions and Immune Checkpoint Inhibitors. International Journal of Radiation Oncology Biology Physics, 2021, 109, 594-602.	0.4	48
419	TTN/OBSCN â€˜Doubleâ€Hitâ€™ predicts favourable prognosis, â€˜immuneâ€hotâ€™ subtype and potentially better immunotherapeutic efficacy in colorectal cancer. Journal of Cellular and Molecular Medicine, 2021, 25, 3239-3251.	1.6	34

#	Article	IF	Citations
420	Case Report: Transformation From Cold to Hot Tumor in a Case of NSCLC Neoadjuvant Immunochemotherapy Pseudoprogression. Frontiers in Immunology, 2021, 12, 633534.	2.2	6
421	Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment. Advanced Biology, 2021, 5, e1900311.	1.4	8
422	ImmunoPET imaging of human CD8+ T cells with novel 68Ga-labeled nanobody companion diagnostic agents. Journal of Nanobiotechnology, 2021, 19, 42.	4.2	30
423	Recent Advances in Cell Membraneâ€Derived Biomimetic Nanotechnology for Cancer Immunotherapy. Advanced Healthcare Materials, 2021, 10, e2002081.	3.9	78
424	Long Non-coding RNA Expression Patterns in Stomach Adenocarcinoma Serve as an Indicator of Tumor Mutation Burden and Are Associated With Tumor-Infiltrating Lymphocytes and Microsatellite Instability. Frontiers in Cell and Developmental Biology, 2021, 9, 618313.	1.8	6
425	Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib. Current Oncology Reports, 2021, 23, 45.	1.8	15
426	Immune Cell Infiltration-Based Characterization of Triple-Negative Breast Cancer Predicts Prognosis and Chemotherapy Response Markers. Frontiers in Genetics, 2021, 12, 616469.	1.1	12
427	The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy. Journal of Controlled Release, 2021, 331, 321-334.	4.8	35
428	miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy. Cancers, 2021, 13, 1587.	1.7	47
429	Human-interpretable image features derived from densely mapped cancer pathology slides predict diverse molecular phenotypes. Nature Communications, 2021, 12, 1613.	5.8	114
430	Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges. Frontiers in Oncology, 2021, 11, 616629.	1.3	33
431	Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy. International Journal of Nanomedicine, 2021, Volume 16, 1631-1661.	3.3	19
432	Immunotherapy in Advanced Biliary Tract Cancers. Cancers, 2021, 13, 1569.	1.7	19
433	Nanoengineered CARâ€T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermalâ€Remodeling Strategy. Small, 2021, 17, e2007494.	5.2	44
434	Recent Advancements in Nanomedicine for â€˜Coldâ€™ Tumor Immunotherapy. Nano-Micro Letters, 2021, 13, 92.	14.4	41
435	Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 646982.	1.8	7
436	Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. Frontiers in Oncology, 2021, 11, 626818.	1.3	13
437	Predicting gastric cancer outcome from resected lymph node histopathology images using deep learning. Nature Communications, 2021, 12, 1637.	5.8	65

#	Article	IF	Citations
438	The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Frontiers in Oncology, 2021, 11, 610303.	1.3	118
439	Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile. Frontiers in Immunology, 2021, 12, 596646.	2.2	11
440	Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19â€“IL2 cures poorly immunogenic tumors when combined with radiotherapy. , 2021, 9, e001764.		23
441	Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies. Cancers, 2021, 13, 1188.	1.7	27
442	Pulsed-Focused Ultrasound Slows B16 Melanoma and 4T1 Breast Tumor Growth through Differential Tumor Microenvironmental Changes. Cancers, 2021, 13, 1546.	1.7	7
443	A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma. Communications Biology, 2021, 4, 383.	2.0	20
444	Promises and challenges of adoptive T-cell therapies for solid tumours. British Journal of Cancer, 2021, 124, 1759-1776.	2.9	113
445	Inhibition of LDH-A by Oxamate Enhances the Efficacy of Anti-PD-1 Treatment in an NSCLC Humanized Mouse Model. Frontiers in Oncology, 2021, 11, 632364.	1.3	44
446	The Role of Macrophages in Oral Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 611115.	1.3	18
447	Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential. Frontiers in Immunology, 2021, 12, 652160.	2.2	12
448	Sexual Difference Matters: Females with High Microsatellite Instability Show Increased Survival after Neoadjuvant Chemotherapy in Gastric Cancer. Cancers, 2021, 13, 1048.	1.7	10
449	Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy. Cancers, 2021, 13, 1148.	1.7	19
450	Immune-Inhibitory Gene Expression is Positively Correlated with Overall Immune Activity and Predicts Increased Survival Probability of Cervical and Head and Neck Cancer Patients. Frontiers in Molecular Biosciences, 2021, 8, 622643.	1.6	13
452	Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 653846.	1.3	2
453	Biomarker Technologies to Support Early Clinical Immuno-oncology Development: Advances and Interpretation. Clinical Cancer Research, 2021, 27, 4147-4159.	3.2	5
454	Emerging nanotechnological strategies to reshape tumor microenvironment for enhanced therapeutic outcomes of cancer immunotherapy. Biomedical Materials (Bristol), 2021, 16, 042001.	1.7	6
455	Classification of pediatric gliomas based on immunological profiling: Implications for immunotherapy strategies. Molecular Therapy - Oncolytics, 2021, 20, 34-47.	2.0	18
456	Tumor Immunometabolism Characterization in Ovarian Cancer With Prognostic and Therapeutic Implications. Frontiers in Oncology, 2021, 11, 622752.	1.3	9

#	Article	IF	Citations
457	Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers, 2021, 13, 1558.	1.7	8
458	Association of MUC19 Mutation With Clinical Benefits of Anti-PD-1 Inhibitors in Non-small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 596542.	1.3	6
459	Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches. Cancer Discovery, 2021, 11, 1024-1039.	7.7	56
460	The immune landscape during the tumorigenesis of cervical cancer. Cancer Medicine, 2021, 10, 2380-2395.	1.3	22
461	Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment. Cancer Immunology, Immunotherapy, 2021, 70, 2835-2850.	2.0	18
462	A Nano â€œImmuneâ€Guideâ€•Recruiting Lymphocytes and Modulating the Ratio of Macrophages from Different Origins to Enhance Cancer Immunotherapy. Advanced Functional Materials, 2021, 31, 2009116.	7.8	24
463	Functional Assessment of Four Novel Immune-Related Biomarkers in the Pathogenesis of Clear Cell Renal Cell Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 621618.	1.8	7
464	Reversing Immunosuppression in Hypoxic and Immuneâ€Cold Tumors with Ultrathin Oxygen Selfâ€Supplementing Polymer Nanosheets under Near Infrared Light Irradiation. Advanced Functional Materials, 2021, 31, 2100354.	7.8	25
465	The Immune-Related Gene HCST as a Novel Biomarker for the Diagnosis and Prognosis of Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 630706.	1.3	5
466	Assessing Preclinical Research Models for Immunotherapy for Gynecologic Malignancies. Cancers, 2021, 13, 1694.	1.7	1
467	Risk and impact of radiation related lymphopenia in lung cancer: A systematic review and meta-analysis. Radiotherapy and Oncology, 2021, 157, 225-233.	0.3	32
468	The tumour immune microenvironment in oesophageal cancer. British Journal of Cancer, 2021, 125, 479-494.	2.9	17
469	The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. Vaccines, 2021, 9, 422.	2.1	8
470	Tumor Immune Microenvironment during Epithelialâ€“Mesenchymal Transition. Clinical Cancer Research, 2021, 27, 4669-4679.	3.2	138
471	pH-Triggered Copper-Free Click Reaction-Mediated Micelle Aggregation for Enhanced Tumor Retention and Elevated Immunoâ€“Chemotherapy against Melanoma. ACS Applied Materials & Interfaces, 2021, 13, 18033-18046.	4.0	13
472	Integrated Analysis of Immune Infiltration Features for Cervical Carcinoma and Their Associated Immunotherapeutic Responses. Frontiers in Cell and Developmental Biology, 2021, 9, 573497.	1.8	19
473	Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy. Pharmaceutics, 2021, 13, 520.	2.0	25
474	Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients. Molecular Cancer Research, 2021, 19, 950-956.	1.5	19

#	Article	IF	Citations
475	An Immune Model to Predict Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy Based on Support Vector Machine. Frontiers in Oncology, 2021, 11, 651809.	1.3	3
476	CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade. Cancers, 2021, 13, 1935.	1.7	15
477	Transformation of a cold to hot tumor and a durable response to immunotherapy in a patient with non-small cell lung cancer after chemoradiotherapy: a case report. Annals of Palliative Medicine, 2021, 10, 4982-4986.	0.5	3
479	Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress. Advanced Therapeutics, 2021, 4, 2100035.	1.6	42
480	Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives. Journal of Nanobiotechnology, 2021, 19, 110.	4.2	16
481	IFNÎ³ Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation. Frontiers in Immunology, 2021, 12, 645770.	2.2	25
482	Bloodâ€“brain barrier opening by intracarotid artery hyperosmolar mannitol induces sterile inflammatory and innate immune responses. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	33
483	The challenges of combinatory immunotherapy for biliary tract cancer. Expert Opinion on Investigational Drugs, 2021, 30, 591-594.	1.9	1
484	Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Cancer Cell International, 2021, 21, 196.	1.8	18
485	Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy. Nature Communications, 2021, 12, 2425.	5.8	75
486	Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors. Cancer Research, 2021, 81, 3319-3332.	0.4	18
487	Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity. Cancer Letters, 2021, 502, 84-96.	3.2	80
488	Endogenous Stimuliâ€Activatable Nanomedicine for Immune Theranostics for Cancer. Advanced Functional Materials, 2021, 31, 2100386.	7.8	36
489	Multimodal Molecular Imaging Detects Early Responses to Immune Checkpoint Blockade. Cancer Research, 2021, 81, 3693-3705.	0.4	15
490	Immune Response: A Missed Opportunity Between Vitamin D and Radiotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 646981.	1.8	2
491	Evolutionary genetic algorithm identifies IL2RB as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer. NAR Genomics and Bioinformatics, 2021, 3, lqab016.	1.5	10
492	PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity. Genome Biology, 2021, 22, 104.	3.8	42
493	Progress and Prospects of Regulatory Functions Mediated by Nitric Oxide on Immunity and Immunotherapy. Advanced Therapeutics, 2021, 4, 2100032.	1.6	10

#	Article	IF	Citations
494	TOX Acts as a Tumor Suppressor by Inhibiting mTOR Signaling in Colorectal Cancer. Frontiers in Immunology, 2021, 12, 647540.	2.2	14
495	Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?. , 2021, 9, e002038.		124
497	Immune Landscape of Thyroid Cancers: New Insights. Frontiers in Endocrinology, 2020, 11, 637826.	1.5	30
498	Gene Expression Classifier Reveals Prognostic Osteosarcoma Microenvironment Molecular Subtypes. Frontiers in Immunology, 2021, 12, 623762.	2.2	15
499	Perioperative chemotherapy and regional hyperthermia for high-risk adult-type soft tissue sarcomas. European Journal of Cancer, 2021, 147, 164-169.	1.3	13
500	Addressing resistance to immune checkpoint inhibitor therapy:Âan urgent unmet need. Future Oncology, 2021, 17, 1401-1439.	1.1	17
501	Strategies for the Construction of Mouse Models With Humanized Immune System and Evaluation of Tumor Immune Checkpoint Inhibitor Therapy. Frontiers in Oncology, 2021, 11, 673199.	1.3	6
502	Nivolumab monotherapy after induction chemotherapy, bioradiotherapy, and cetuximab monotherapy leading to complete remission of locoregional advanced tongue cancer: A case report. Oral Science International, 2022, 19, 72-76.	0.3	3
503	Tenascinâ€€ immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression. EMBO Molecular Medicine, 2021, 13, e13270.	3.3	27
505	Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy. Vaccines, 2021, 9, 509.	2.1	14
506	Potential Impact of ALKBH5 and YTHDF1 on Tumor Immunity in Colon Adenocarcinoma. Frontiers in Oncology, 2021, 11, 670490.	1.3	20
507	Chemokines and the immune response to cancer. Immunity, 2021, 54, 859-874.	6.6	254
508	Polarization of Tumor-Associated Macrophages by Nanoparticle-Loaded Escherichia coli Combined with Immunogenic Cell Death for Cancer Immunotherapy. Nano Letters, 2021, 21, 4231-4240.	4.5	149
509	Development and Validation of a CD8+ T Cell Infiltration-Related Signature for Melanoma Patients. Frontiers in Immunology, 2021, 12, 659444.	2.2	17
510	Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPÎ± and TIGIT/PVR Pathways for Cancer Immuno-Therapy. Biomolecules, 2021, 11, 706.	1.8	21
511	Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[18F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4054-4066.	3.3	8
512	Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma. Cancers, 2021, 13, 2564.	1.7	16
513	Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. , 2021, 9, e002198.		18

#	Article	IF	Citations
514	Multiomics characteristics of neurogenesis-related gene are dysregulated in tumor immune microenvironment. Npj Genomic Medicine, 2021, 6, 37.	1.7	7
516	Imaging of T-cell Responses in the Context of Cancer Immunotherapy. Cancer Immunology Research, 2021, 9, 490-502.	1.6	8
517	Transformable Nanosensitizer with Tumor Microenvironmentâ€Activated Sonodynamic Process and Calcium Release for Enhanced Cancer Immunotherapy. Angewandte Chemie, 2021, 133, 14170-14178.	1.6	14
518	Analyzing and Validating the Prognostic Value of a TNF-Related Signature in Kidney Renal Clear Cell Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 689037.	1.6	5
519	Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy. Cancer Discovery, 2021, 11, 2602-2619.	7.7	90
520	Magnetic Nanostructures as Emerging Therapeutic Tools to Boost Anti-Tumour Immunity. Cancers, 2021, 13, 2735.	1.7	21
521	Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics. Cell Reports, 2021, 35, 109165.	2.9	75
522	The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. Clinical Immunology, 2021, 226, 108707.	1.4	127
523	Near infrared photoimmunotherapy of cancer; possible clinical applications. Nanophotonics, 2021, 10, 3135-3151.	2.9	19
524	Immune and metabolic checkpoints blockade: Dual wielding against tumors. International Immunopharmacology, 2021, 94, 107461.	1.7	13
525	Arid5a Promotes Immune Evasion by Augmenting Tryptophan Metabolism and Chemokine Expression. Cancer Immunology Research, 2021, 9, 862-876.	1.6	15
526	Clinical Perspectives to Overcome Acquired Resistance to Antiâ€“Programmed Death-1 and Antiâ€“Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer. Molecules and Cells, 2021, 44, 363-373.	1.0	13
527	Immunology of Cell Death in Cancer Immunotherapy. Cells, 2021, 10, 1208.	1.8	10
528	The ups, downs and new trends of IDO1 inhibitors. Bioorganic Chemistry, 2021, 110, 104815.	2.0	24
529	Applications of single-cell and bulk RNA sequencing in onco-immunology. European Journal of Cancer, 2021, 149, 193-210.	1.3	62
530	Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 5736.	1.8	29
531	Hypermutated tumours across 11 cancer types show three distinct immune subtypes. European Journal of Cancer, 2021, 148, 230-238.	1.3	1
532	How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance. International Journal of Molecular Sciences, 2021, 22, 5761.	1.8	19

#	Article	IF	Citations
533	Association of RYR2 Mutation With Tumor Mutation Burden, Prognosis, and Antitumor Immunity in Patients With Esophageal Adenocarcinoma. Frontiers in Genetics, 2021, 12, 669694.	1.1	34
535	Prediction of treatment response from the microenvironment of tumor immunity in cervical cancer patients treated with chemoradiotherapy. Medical Molecular Morphology, 2021, 54, 245-252.	0.4	8
536	ZIF-8 nano confined protein-titanocene complex core-shell MOFs for efficient therapy of Neuroblastoma: Optimization, molecular dynamics and toxicity studies. International Journal of Biological Macromolecules, 2021, 178, 444-463.	3.6	18
537	An update on immunotherapy in uro-oncology. Expert Review of Precision Medicine and Drug Development, 2021, 6, 229-233.	0.4	2
538	The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo. Cancer Immunology, Immunotherapy, 2021, 70, 3629-3642.	2.0	11
539	Transformable Nanosensitizer with Tumor Microenvironmentâ€Activated Sonodynamic Process and Calcium Release for Enhanced Cancer Immunotherapy. Angewandte Chemie - International Edition, 2021, 60, 14051-14059.	7.2	152
540	The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment. Viruses, 2021, 13, 1200.	1.5	14
541	TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	57
542	Ovarian tumors orchestrate distinct cellular compositions. Immunity, 2021, 54, 1107-1109.	6.6	9
543	Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges. Cancer Communications, 2021, 41, 830-850.	3.7	42
544	Cocktail strategy for â€˜coldâ€™ tumors therapy via active recruitment of CD8+ T cells and enhancing their function. Journal of Controlled Release, 2021, 334, 413-426.	4.8	18
545	Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy. Genes and Immunity, 2021, 22, 108-119.	2.2	17
546	Prevalence of proliferating CD8+ cells in normal lymphatic tissues, inflammation and cancer. Aging, 2021, 13, 14590-14603.	1.4	5
547	The Hostâ€Defenseâ€Peptideâ€Mimicking Synthetic Polypeptides Effectively Enhance Antitumor Immunity through Promoting Immunogenic Tumor Cell Death. Macromolecular Bioscience, 2021, 21, e2100171.	2.1	6
548	Valeur pronostique et prÃ©dictive de lâ€™Immunoscore dans les cancers du cÃ1on et de la vessie. HEGEL - HEpato-GastroEntÃ©rologie LibÃ©rale, 2021, NÂ° 2, 113-118.	0.0	0
549	Osteoimmuno-Oncology: Therapeutic Opportunities for Targeting Immune Cells in Bone Metastasis. Cells, 2021, 10, 1529.	1.8	11
550	Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma. Molecular Therapy - Oncolytics, 2021, 21, 288-302.	2.0	25
551	Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer. Frontiers in Oncology, 2021, 11, 671629.	1.3	3

#	Article	IF	Citations
552	Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors. Viruses, 2021, 13, 1234.	1.5	10
553	The Pyroptosis-Related Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Gastric Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 676485.	1.8	129
554	Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity. Molecular Cancer Therapeutics, 2021, 20, 1723-1734.	1.9	5
555	Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell, 2021, 39, 845-865.e7.	7.7	503
556	A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors. Frontiers in Immunology, 2021, 12, 693314.	2.2	10
557	Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment. Quantitative Imaging in Medicine and Surgery, 2021, 11, 2837-2860.	1.1	4
558	Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer. Chinese Medical Journal, 2021, 134, 1780-1788.	0.9	7
559	Cancerâ€associated fibroblasts: Key players in shaping the tumor immune microenvironment. Immunological Reviews, 2021, 302, 241-258.	2.8	87
560	CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Cancer Gene Therapy, 2022, 29, 722-733.	2.2	10
561	Checkpoint Kinase 1 (Chk1) inhibition fails to activate the Stimulator of Interferon Genes (STING) innate immune signalling in a human coculture cancer system. Molecular Biomedicine, 2021, 2, 19.	1.7	3
562	Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. Translational Lung Cancer Research, 2021, 10, 2842-2857.	1.3	28
563	Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy. Npj Precision Oncology, 2021, 5, 52.	2.3	24
564	Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers, 2021, 13, 2786.	1.7	44
565	Multifaceted Role of the Transforming Growth Factor Î² on Effector T Cells and the Implication for CAR-T Cell Therapy. Immuno, 2021, 1, 160-173.	0.6	4
566	Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment. Frontiers in Bioengineering and Biotechnology, 2021, 9, 689245.	2.0	16
567	Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome. Frontiers in Immunology, 2021, 12, 651086.	2.2	9
568	Advancing to the era of cancer immunotherapy. Cancer Communications, 2021, 41, 803-829.	3.7	90
569	ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC. Cancer Immunology, Immunotherapy, 2022, 71, 219-228.	2.0	5

#	Article	IF	Citations
570	Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer. Scientific Reports, 2021, 11, 11427.	1.6	3
571	A paradigm shift in cancer nanomedicine: from traditional tumor targeting to leveraging the immune system. Drug Discovery Today, 2021, 26, 1482-1489.	3.2	12
572	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2ndâ€“3rd,) Tj ETQq0 0 0 rgBT /Overlock 10	1.8	1
573	Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy. Expert Opinion on Biological Therapy, 2021, 21, 1635-1646.	1.4	15
574	Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). Vaccines, 2021, 9, 689.	2.1	9
576	Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer. , 2021, 9, e002356.		35
577	Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides. Trends in Cancer, 2021, 7, 557-572.	3.8	33
578	Bio-Responsive nanoparticle for tumor targeting and enhanced photo-immunotherapy. Colloids and Surfaces B: Biointerfaces, 2021, 202, 111681.	2.5	11
579	T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 339-352.	2.0	2
580	An immune-related model based on INHBA, JAG2 and CCL19 to predict the prognoses of colon cancer patients. Cancer Cell International, 2021, 21, 299.	1.8	4
581	Cancer environmental immunotherapy: starving tumor cell to death by targeting TGFB on immune cell. , 2021, 9, e002823.		8
582	Distinct Responsiveness of Tumor-Associated Macrophages to Immunotherapy of Tumors with Different Mechanisms of Major Histocompatibility Complex Class I Downregulation. Cancers, 2021, 13, 3057.	1.7	3
583	Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation. Translational Lung Cancer Research, 2021, 10, 2858-2864.	1.3	12
584	Establishment and experimental validation of an immune miRNA signature for assessing prognosis and immune landscape of patients with colorectal cancer. Journal of Cellular and Molecular Medicine, 2021, 25, 6874-6886.	1.6	29
585	Conventional NK cells and tissue-resident ILC1s join forces to control liver metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	63
586	Cancer Immunotherapies: From Efficacy to Resistance Mechanisms â€“ Not Only Checkpoint Matters. Frontiers in Immunology, 2021, 12, 690112.	2.2	42
587	Stereoselective and Divergent Aza-Adenosine and Aza-Guanosine Syntheses from Xylofuranose, the Key Fragments of a STING Cyclic Dinucleotide Agonist. Journal of Organic Chemistry, 2021, , .	1.7	1
588	ILT4 in Colorectal Cancer Cells Induces Suppressive T Cell Contexture and Disease Progression. OncoTargets and Therapy, 2021, Volume 14, 4239-4254.	1.0	8

#	Article	IF	Citations
589	Cancer Physical Hallmarks as New Targets for Improved Immunotherapy. Trends in Cell Biology, 2021, 31, 520-524.	3.6	16
590	Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody. Frontiers in Immunology, 2021, 12, 701668.	2.2	13
591	Immune infiltration profiling in gastric cancer and their clinical implications. Cancer Science, 2021, 112, 3569-3584.	1.7	38
592	A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done. Translational Lung Cancer Research, 2021, 10, 3369-3384.	1.3	11
593	Injectable Supramolecular Hydrogel for Locoregional Immune Checkpoint Blockade and Enhanced Cancer Chemo-Immunotherapy. ACS Applied Materials & Interfaces, 2021, 13, 33874-33884.	4.0	38
594	Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 3001-3013.	2.0	17
595	Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 7201.	1.8	8
596	The mechanisms of action of Plasmodium infection against cancer. Cell Communication and Signaling, 2021, 19, 74.	2.7	7
597	The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 671874.	1.3	14
598	Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach. International Journal of Molecular Sciences, 2021, 22, 8035.	1.8	30
599	Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer. Aging, 2021, 13, 17970-17970.	1.4	69
600	GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer. , 2021, 9, e002383.		26
601	Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma. Cancers, 2021, 13, 3676.	1.7	13
602	Intestinal microbiota: A potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors. Cancer Letters, 2021, 509, 53-62.	3.2	13
603	Immunological tumor heterogeneity and diagnostic profiling for advanced and immune therapies. Advances in Cell and Gene Therapy, 2021, 4, e113.	0.6	3
604	Transcriptomic signatures of tumors undergoing T cell attack. Cancer Immunology, Immunotherapy, 2021, , 1.	2.0	6
605	Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nature Cancer, 2021, 2, 693-708.	5.7	102
606	An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nature Medicine, 2021, 27, 1250-1261.	15.2	159

#	Article	IF	Citations
607	Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy. Frontiers in Oncology, 2021, 11, 679095.	1.3	7
608	ERO1L Is a Novel and Potential Biomarker in Lung Adenocarcinoma and Shapes the Immune-Suppressive Tumor Microenvironment. Frontiers in Immunology, 2021, 12, 677169.	2.2	10
609	Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients. Modern Pathology, 2021, 34, 2229-2241.	2.9	25
610	The therapeutic and prognostic implications of immunobiology in colorectal cancer: a review. British Journal of Cancer, 2021, 125, 1341-1349.	2.9	21
611	Normalization in tumor ecosystem: Opportunities and challenges. Cell Biology International, 2021, 45, 2017-2030.	1.4	33
612	Advanced and Innovative Nano-Systems for Anticancer Targeted Drug Delivery. Pharmaceutics, 2021, 13, 1151.	2.0	62
613	Immunoscore Signatures in Surgical Specimens and Tumor-Infiltrating Lymphocytes in Pretreatment Biopsy Predict Treatment Efficacy and Survival in Esophageal Cancer. Annals of Surgery, 2023, 277, e528-e537.	2.1	18
614	NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nature Communications, 2021, 12, 4536.	5.8	51
616	Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1739.	3.3	19
617	Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell, 2021, 39, 928-944.e6.	7.7	158
618	Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy. Nature Nanotechnology, 2021, 16, 1130-1140.	15.6	84
619	Agony of choice: How anesthetics affect the composition and function of extracellular vesicles. Advanced Drug Delivery Reviews, 2021, 175, 113813.	6.6	3
620	Identification of Immune Cell Infiltration Landscape and Their Prognostic Significance in Uveal Melanoma. Frontiers in Cell and Developmental Biology, 2021, 9, 713569.	1.8	12
621	In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV. Viruses, 2021, 13, 1740.	1.5	15
622	Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment. ACS Nano, 2021, 15, 12567-12603.	7.3	112
623	Analysis of Bulk RNA Sequencing Data Reveals Novel Transcription Factors Associated With Immune Infiltration Among Multiple Cancers. Frontiers in Immunology, 2021, 12, 644350.	2.2	6
624	Avances en citometrÃa de masas y aplicabilidad en patologÃa digital para estudios clÃnico-traslacionales en oncologÃa. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2022, 3, 17-29.	0.1	0
625	Trinity immune enhancing nanoparticles for boosting antitumor immune responses of immunogenic chemotherapy. Nano Research, 2022, 15, 1183-1192.	5.8	7

#	Article	IF	Citations
626	Interpretable systems biomarkers predict response to immune-checkpoint inhibitors. Patterns, 2021, 2, 100293.	3.1	47
627	Identification of prognostic biomarkers related to the tumor microenvironment in thyroid carcinoma. Scientific Reports, 2021, 11, 16239.	1.6	7
628	N6-methyladenosine (m6A) regulatory gene divides hepatocellular carcinoma into three subtypes. Journal of Gastrointestinal Oncology, 2021, 12, 1860-1872.	0.6	6
629	Precision strategies for cancer treatment by modifying the tumor-related bacteria. Applied Microbiology and Biotechnology, 2021, 105, 6183-6197.	1.7	9
630	Ginseng-derived nanoparticles potentiate immune checkpoint antibody efficacy by reprogramming the cold tumor microenvironment. Molecular Therapy, 2022, 30, 327-340.	3.7	52
631	The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications. Genes and Diseases, 2022, 9, 1208-1219.	1.5	9
632	Advances in technology and applications of nanoimmunotherapy for cancer. Biomarker Research, 2021, 9, 63.	2.8	7
633	Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity. Frontiers in Immunology, 2021, 12, 726492.	2.2	17
634	Engineering Chameleon Prodrug Nanovesicles to Increase Antigen Presentation and Inhibit PDâ€L1 Expression for Circumventing Immune Resistance of Cancer. Advanced Materials, 2021, 33, e2102668.	11.1	36
635	Systemic Inflammation Associates With a Myeloid Inflamed Tumor Microenvironment in Primary Resected Colon Cancerâ€"May Cold Tumors Simply Be Too Hot?. Frontiers in Immunology, 2021, 12, 716342.	2.2	11
636	Firing up the Tumor Microenvironment with Nanoparticle-Based Therapies. Pharmaceutics, 2021, 13, 1338.	2.0	2
637	Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities. Journal of Hematology and Oncology, 2021, 14, 125.	6.9	42
638	Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models. Advanced Drug Delivery Reviews, 2021, 175, 113791.	6.6	16
639	IL-33 Induces Sema4A Expression in Dendritic Cells and Exerts Antitumor Immunity. Journal of Immunology, 2021, 207, 1456-1467.	0.4	7
640	Nanotechnology-based immunotherapies to combat cancer metastasis. Molecular Biology Reports, 2021, 48, 6563-6580.	1.0	8
641	Tissue distribution of Î³Î´ T cell subsets in oesophageal adenocarcinoma. Clinical Immunology, 2021, 229, 108797.	1.4	9
643	Dendrimers for cancer immunotherapy: Avidityâ€based drug delivery vehicles for effective antiâ€tumor immune response. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1752.	3.3	13
644	Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?. Biomedicines, 2021, 9, 1048.	1.4	6

#	Article	IF	Citations
645	Emerging role of natural products in cancer immunotherapy. Acta Pharmaceutica Sinica B, 2022, 12, 1163-1185.	5.7	71
646	Application of Immunotherapy in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 699060.	1.3	8
647	Paving the Way for Immunotherapy in Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward. Cancers, 2021, 13, 4364.	1.7	5
648	Perforated appendicitis induced by pembrolizumab. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	5
649	Biocompatible zinc gallogermanate persistent luminescent nanoparticles for fast tumor drainage lymph node imaging in vivo. Colloids and Surfaces B: Biointerfaces, 2021, 205, 111887.	2.5	4
650	Versatile effects of epigenetic reprogramming in immune restoration and tumor therapy. Annals of Blood, 0, 6, 22-22.	0.4	0
651	Efficacy and safety of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitor versus chemotherapy for advanced lung cancer. Medicine (United States), 2021, 100, e27121.	0.4	3
652	A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT. Acta Pharmaceutica Sinica B, 2021, 11, 3925-3934.	5.7	6
653	A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype. Frontiers in Immunology, 2021, 12, 749459.	2.2	30
654	Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nature Communications, 2021, 12, 5668.	5.8	91
655	Salvage pulmonary resection in stages IIIbâ€“IV lung cancer after treatment with immune checkpoint inhibitors case series and literature review. Journal of Surgical Oncology, 2022, 125, 290-298.	0.8	8
656	Repurposing macitentan with nanoparticle modulates tumor microenvironment to potentiate immune checkpoint blockade. Biomaterials, 2021, 276, 121058.	5.7	13
657	Polymersome Nanoreactorâ€Mediated Combination Chemodynamicâ€Immunotherapy via ROS Production and Enhanced STING Activation. Advanced Therapeutics, 2021, 4, 2100130.	1.6	15
658	Engineering Cellâ€Based Systems for Smart Cancer Therapy. Advanced Intelligent Systems, 2022, 4, 2100134.	3.3	14
659	Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov. , 2021, 9, e002920.		7
660	Dysregulation of tumor microenvironment promotes malignant progression and predicts risk of metastasis in bladder cancer. Annals of Translational Medicine, 2021, 9, 1438-1438.	0.7	4
661	N6-Methyladenosine RNA Modification: An Emerging Immunotherapeutic Approach to Turning Up Cold Tumors. Frontiers in Cell and Developmental Biology, 2021, 9, 736298.	1.8	7
662	Ferroptosis in the tumor microenvironment: perspectives for immunotherapy. Trends in Molecular Medicine, 2021, 27, 856-867.	3.5	141

#	Article	IF	Citations
663	Oncolytic viruses for triple negative breast cancer and beyond. Biomarker Research, 2021, 9, 71.	2.8	12
664	Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer. Frontiers in Oncology, 2021, 11, 744679.	1.3	7
665	Concepts in Oncolytic Adenovirus Therapy. International Journal of Molecular Sciences, 2021, 22, 10522.	1.8	40
666	Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody. Frontiers in Immunology, 2021, 12, 749204.	2.2	5
667	Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer. Materials Today, 2021, 50, 149-169.	8.3	33
668	Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy. Cancers, 2021, 13, 4803.	1.7	6
669	Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 646355.	1.3	27
670	A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models. Science Translational Medicine, 2021, 13, eaba7791.	5.8	49
671	Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell, 2021, 184, 5482-5496.e28.	13.5	116
672	Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy. , 2021, 9, e003032.		20
673	Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma. Cancers, 2021, 13, 4704.	1.7	9
674	Systematic review of the immunological landscape of Wilms tumors. Molecular Therapy - Oncolytics, 2021, 22, 454-467.	2.0	25
675	Classification and immune invasion analysis of breast cancer based on m6A genes. Annals of Translational Medicine, 2021, 9, 1418-1418.	0.7	6
676	Immunomodulating Therapies in Breast Cancerâ€"From Prognosis to Clinical Practice. Cancers, 2021, 13, 4883.	1.7	15
677	PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. Cancer Cell, 2021, 39, 1214-1226.e10.	7.7	72
678	Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors. Molecular Oncology, 2021, 15, 2910-2922.	2.1	23
679	Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies. Cancers, 2021, 13, 4893.	1.7	19
680	Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer. Frontiers in Oncology, 2021, 11, 710596.	1.3	5

#	Article	IF	Citations
681	DNA Methylation Regulator-Meditated Modification Patterns Define the Distinct Tumor Microenvironment in Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 734873.	1.3	2
682	High-Throughput Strategies for the Discovery of Anticancer Drugs by Targeting Transcriptional Reprogramming. Frontiers in Oncology, 2021, 11, 762023.	1.3	5
683	Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?. International Journal of Molecular Sciences, 2021, 22, 10672.	1.8	5
684	The role of PET in imaging of the tumour microenvironment and response to immunotherapy. Clinical Radiology, 2021, 76, 784.e1-784.e15.	0.5	4
685	Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody. Cancer Letters, 2021, 518, 49-58.	3.2	17
686	Thermal-sensitive lipid nanoparticles potentiate anti-PD therapy through enhancing drug penetration and T lymphocytes infiltration in metastatic tumor. Cancer Letters, 2021, 522, 238-254.	3.2	14
687	Delivery strategies to overcome tumor immunotherapy resistance. , 2022, , 529-547.		0
688	Comparison of therapeutic strategies for immuno-oncology. , 2022, , 439-461.		0
689	Engineering approaches for studying immune-tumor cell interactions and immunotherapy. IScience, 2021, 24, 101985.	1.9	52
690	Immunologic â€œColdâ€•Squamous Cell Carcinomas of the Head and Neck Are Associated With an Unfavorable Prognosis. Frontiers in Medicine, 2021, 8, 622330.	1.2	23
691	An experimental model of anti-PD-1 resistance exhibits activation of TGFÃŸ and Notch pathways and is sensitive to local mRNA immunotherapy. OncoImmunology, 2021, 10, 1881268.	2.1	18
692	A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response. Theranostics, 2021, 11, 6936-6949.	4.6	16
693	Is there a role for Gallium-67 SPECT in distinguishing progression and pseudoprogresion in oncologic patients receiving immunotherapy?. Cancer Treatment and Research Communications, 2021, 28, 100441.	0.7	1
694	License to kill: microsatellite instability and immune contexture. OncoImmunology, 2021, 10, 1905935.	2.1	10
695	Natural products in drug discovery: advances and opportunities. Nature Reviews Drug Discovery, 2021, 20, 200-216.	21.5	1,990
696	A four-in-one pure nanomedicine for synergistic multi-target therapy against breast cancer. Journal of Materials Chemistry B, 2021, 9, 8809-8822.	2.9	3
697	Bioinformatics workflows for clinical applications in precision oncology. Seminars in Cancer Biology, 2022, 84, 103-112.	4.3	8
698	A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with TP53 mutation. Translational Cancer Research, 2021, 10, 3963-3978.	0.4	4

#	Article	IF	Citations
699	NOX66 as Monotherapy, and in Combination With Carboplatin, in Patients With Refractory Solid Tumors: Phase Ia/b Study. Current Therapeutic Research, 2021, 94, 100631.	0.5	2
700	Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes. OncoImmunology, 2021, 10, 1940676.	2.1	4
701	IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110365.	1.4	24
702	Self-adjuvanting photosensitizer nanoparticles for combination photodynamic immunotherapy. Biomaterials Science, 2021, 9, 6940-6949.	2.6	9
703	Circadian clock genes promote glioma progression by affecting tumour immune infiltration and tumour cell proliferation. Cell Proliferation, 2021, 54, e12988.	2.4	54
704	Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. Molecular Cancer, 2021, 20, 10.	7.9	70
705	Extracellular Vesicles. Learning Materials in Biosciences, 2020, , 219-229.	0.2	3
706	CAR T Cell Therapy Progress and Challenges for Solid Tumors. Cancer Treatment and Research, 2020, 180, 297-326.	0.2	23
707	The Role of the Immune Infiltrate in Distinct Cancer Types and Its Clinical Implications. Cancer Treatment and Research, 2020, 180, 197-211.	0.2	4
708	Drugs repurposed to potentiate immunotherapy for cancer treatment. , 2020, , 311-334.		1
709	Phenotyping of tumor infiltrating immune cells using mass-cytometry (CyTOF). Methods in Enzymology, 2020, 632, 339-368.	0.4	17
710	Light-triggered OVA release based on CuS@poly(lactide-co-glycolide acid) nanoparticles for synergistic photothermal-immunotherapy of tumor. Pharmacological Research, 2020, 158, 104902.	3.1	17
711	The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer. Urologic Clinics of North America, 2020, 47, e17-e54.	0.8	39
712	Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics. Acta Pharmacologica Sinica, 2020, 41, 881-894.	2.8	19
713	IDO1+ Paneth cells promote immune escape of colorectal cancer. Communications Biology, 2020, 3, 252.	2.0	26
714	Fluorine assembly nanocluster breaks the shackles of immunosuppression to turn the cold tumor hot. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 32962-32969.	3.3	52
715	In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology. International Journal of Hyperthermia, 2020, 37, 4-17.	1.1	12
716	TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Research, 2020, 48, W509-W514.	6.5	2,546

#	Article	IF	Citations
722	Macrophage targeting in cancer. Annals of the New York Academy of Sciences, 2021, 1499, 18-41.	1.8	134
723	The Combinatorial Effect of Cisplatin and Moxibustion on Tumor Growth Inhibition with Special Reference to Modulation of the Immune Microenvironment in Lewis Lung Cancer Mice. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-14.	0.5	6
724	Rapid Depletion of Intratumoral Regulatory T Cells Induces Synchronized CD8 T- and NK-cell Activation and IFNÎ³-Dependent Tumor Vessel Regression. Cancer Research, 2021, 81, 3092-3104.	0.4	20
725	Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3â€“CD8+ T cells. JCI Insight, 2020, 5, .	2.3	30
726	Immune profiling of pediatric solid tumors. Journal of Clinical Investigation, 2020, 130, 3391-3402.	3.9	27
727	Density of CD3+ and CD8+ cells in gingivo-buccal oral squamous cell carcinoma is associated with lymph node metastases and survival. PLoS ONE, 2020, 15, e0242058.	1.1	17
728	THERAPY OF ENDOCRINE DISEASE Immunotherapy of advanced thyroid cancer: from bench to bedside. European Journal of Endocrinology, 2020, 183, R41-R55.	1.9	20
729	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needs. Endocrine-Related Cancer, 2020, 27, T27-T39.	1.6	6
730	The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitors. Endocrine-Related Cancer, 2020, 27, R329-R343.	1.6	13
731	Tumour vessel remodelling: new opportunities in cancer treatment. Vascular Biology (Bristol,) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.2	19
732	Elevated lymphocyte specific protein 1 expression is involved in the regulation of leukocyte migration and immunosuppressive microenvironment in glioblastoma. Aging, 2020, 12, 1656-1684.	1.4	20
733	Identification of novel prognosis-related genes in the endometrial cancer immune microenvironment. Aging, 2020, 12, 22152-22173.	1.4	15
734	Identification and validation of an immune-related gene signature predictive of overall survival in colon cancer. Aging, 2020, 12, 26095-26120.	1.4	35
735	Decoding cancerâ€™s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. , 2020, 3, 832-853.		7
736	Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers. Cancer Biology and Medicine, 2020, 17, 1026-1038.	1.4	26
737	Identification of the right cell sources for the production of therapeutically active extracellular vesicles in ischemic stroke. Annals of Translational Medicine, 2019, 7, 188-188.	0.7	21
738	Characterization of PD-L1 protein expression and CD8+ tumor-infiltrating lymphocyte density, and their associations with clinical outcome in small-cell lung cancer. Translational Lung Cancer Research, 2019, 8, 748-759.	1.3	22
739	Harnessing Tumor Immune Ecosystem Dynamics to Personalize Radiation Therapy. SSRN Electronic Journal, 0, , .	0.4	2

#	Article	IF	Citations
740	A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1Âinhibitor: a case report and literature review. Immunotherapy, 2020, 12, 555-561.	1.0	11
741	Immunoscore and its introduction in clinical practice. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 152-161.	0.4	48
742	Cancer management in the era of immunotherapy: much more than meets the eye. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 141-142.	0.4	1
743	Combinations using checkpoint blockade to overcome resistance. Ecancermedicalscience, 2020, 14, 1148.	0.6	11
744	Identification of an Immune-Related Prognostic Signature Associated With Immune Infiltration in Melanoma. Frontiers in Genetics, 2020, 11, 1002.	1.1	16
745	Understanding the Effects of Radiotherapy on the Tumour Immune Microenvironment to Identify Potential Prognostic and Predictive Biomarkers of Radiotherapy Response. Cancers, 2020, 12, 2835.	1.7	8
746	Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs. Current Oncology, 2021, 28, 159-183.	0.9	11
747	Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid Cancers. Endocrinology and Metabolism, 2020, 35, 44.	1.3	21
748	Tripleâ€'negative breast cancer therapy: Current and future perspectives (Review). International Journal of Oncology, 2020, 57, 1245-1261.	1.4	196
749	Advances in personalized neoantigen vaccines for cancer immunotherapy. BioScience Trends, 2020, 14, 349-353.	1.1	8
750	Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. ELife, 2019, 8, .	2.8	69
751	GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab. ELife, 2020, 9, .	2.8	41
752	Light-responsive hyaluronic acid nanomicelles co-loaded with an IDO inhibitor focus targeted photoimmunotherapy against â€œimmune coldâ€•cancer. Biomaterials Science, 2021, 9, 8019-8031.	2.6	18
753	The Wnt/Î²-catenin signaling pathway in the tumor microenvironment of hepatocellular carcinoma. Cancer Biology and Medicine, 2021, 18, 0-0.	1.4	9
754	The â€œImmunoscoreâ€•in rectal cancer: could we search quality beyond quantity of life?. Oncotarget, 2022, 13, 18-31.	0.8	3
755	Two step promotion of a hot tumor immune environment by gold decorated iron oxide nanoflowers and light-triggered mild hyperthermia. Nanoscale, 2021, 13, 18483-18497.	2.8	11
756	A nanodrug incorporating siRNA PD-L1 and Birinapant for enhancing tumor immunotherapy. Biomaterials Science, 2021, 9, 8007-8018.	2.6	7
757	A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment. Cells, 2021, 10, 2700.	1.8	25

#	Article	IF	Citations
758	Activation of Cascadeâ€Like Antitumor Immune Responses through In Situ Doxorubicin Stimulation and Blockade of Checkpoint Coinhibitory Receptor TIGIT. Advanced Healthcare Materials, 2022, 11, e2102080.	3.9	5
760	Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. , 2021, 9, e003499.		23
761	Nanomedicine potentiates mild photothermal therapy for tumor ablation. Asian Journal of Pharmaceutical Sciences, 2021, 16, 738-761.	4.3	43
762	Identification of Pathway-Based Biomarkers with Crosstalk Analysis for Overall Survival Risk Prediction in Breast Cancer. Frontiers in Genetics, 2021, 12, 689715.	1.1	0
763	Targeted Enrichment of Enzymeâ€Instructed Assemblies in Cancer Cell Lysosomes Turns Immunologically Cold Tumors Hot. Angewandte Chemie, 0, , .	1.6	2
764	T Cellâ€Signalingâ€Responsive Conjugate of Antibody with siRNA to Overcome Acquired Resistance to antiâ€PDâ€1 Immunotherapy. Advanced Therapeutics, 2022, 5, 2100161.	1.6	6
765	Comprehensive Analysis of Ferroptosis-Related LncRNAs in Breast Cancer Patients Reveals Prognostic Value and Relationship With Tumor Immune Microenvironment. Frontiers in Surgery, 2021, 8, 742360.	0.6	17
766	Characterization of immune cell infiltrate in tumor stroma and epithelial compartments in oral squamous cell carcinomas of Sudanese patients. Clinical and Experimental Dental Research, 2022, 8, 130-140.	0.8	4
767	Assessment of the immune landscapes of advanced ovarian cancer in an optimized in vivo model. Clinical and Translational Medicine, 2021, 11, e551.	1.7	3
768	Diverse â€˜just-rightâ€™ levels of chromosomal instability and their clinical implications in neoadjuvant treated gastric cancer. British Journal of Cancer, 2021, 125, 1621-1631.	2.9	9
769	Targeted Enrichment of Enzymeâ€Instructed Assemblies in Cancer Cell Lysosomes Turns Immunologically Cold Tumors Hot. Angewandte Chemie - International Edition, 2021, 60, 26994-27004.	7.2	47
770	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Frontiers in Oncology, 2021, 11, 737497.	1.3	22
771	Immunological configuration of ovarian carcinoma: features and impact on disease outcome. , 2021, 9, e002873.		30
772	Elucidating the Innate Immunological Effects of Mild Magnetic Hyperthermia on U87 Human Glioblastoma Cells: An In Vitro Study. Pharmaceutics, 2021, 13, 1668.	2.0	15
773	The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma. European Urology, 2022, 81, 145-148.	0.9	20
774	Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer. Frontiers in Oncology, 2021, 11, 754881.	1.3	15
775	PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification. ACS Nano, 2021, 15, 15992-16010.	7.3	17
776	Ferroptosis-related gene AKR1C1 predicts the prognosis of non-small cell lung cancer. Cancer Cell International, 2021, 21, 567.	1.8	11

#	Article	IF	Citations
777	Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. European Journal of Cancer, 2021, 158, 47-62.	1.3	32
778	Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial. European Journal of Cancer, 2021, 158, 123-132.	1.3	11
779	A pyroptosis-related lncRNA signature predicts prognosis and immune microenvironment in head and neck squamous cell carcinoma. International Immunopharmacology, 2021, 101, 108268.	1.7	27
780	A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors. Cancer Treatment Reviews, 2021, 101, 102300.	3.4	8
781	Immunoepidemiology of Cancer. , 2019, , 215-224.		0
788	Using the TCGA Database to Predict and Analyze Tumor Microenvironment Genes Related to Poor Prognosis of Colon Cancer. Medical Science Monitor, 2020, 26, e923707.	0.5	2
791	m6A-Mediated Tumor Invasion and Methylation Modification in Breast Cancer Microenvironment. Journal of Oncology, 2021, 2021, 1-17.	0.6	10
792	Applying nanotechnology to boost cancer immunotherapy by promoting immunogenic cell death. Chinese Chemical Letters, 2022, 33, 1718-1728.	4.8	42
793	Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy. , 2021, 9, e003671.		15
794	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. Cancers, 2021, 13, 5415.	1.7	13
796	An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer. Breast Cancer Research, 2021, 23, 100.	2.2	20
797	Comprehensive Multi-Omics Identification of Interferon-Î³ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma. Frontiers in Immunology, 2021, 12, 734646.	2.2	13
801	CRC: A Darwinian model of cellular immunoselection. , 2022, , 529-541.		0
802	Identification of an Immune Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer. SSRN Electronic Journal, 0, , .	0.4	0
803	Spatial heterogeneity of immune infiltration predicts the prognosis of nasopharyngeal carcinoma patients. OncoImmunology, 2021, 10, 1976439.	2.1	8
804	CHAPTER 14. Cell and Immune Therapy. RSC Detection Science, 2020, , 303-344.	0.0	0
805	The Interplay of Autophagy and the Immune System in the Tumor Microenvironment. , 2020, , 183-202.		0
806	Tumor hypoxic stress, cellular plasticity and RKIP. , 2020, , 115-120.		0

#	Article	IF	Citations
807	A Study on the Description of Anticancer Drug Combination Therapy in the Package Insert in Japan. BPB Reports, 2020, 3, 157-165.	0.1	0
809	Phenotyping tumor-immune microenvironment (TiME) in vivo in patients using reflectance confocal microscopy. , 2021, , .		0
811	Clinical Value and Potential Mechanisms of Oxysterol-Binding Protein Like 3 (OSBPL3) in Human Tumors. Frontiers in Molecular Biosciences, 2021, 8, 739978.	1.6	5
812	Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. JCO Precision Oncology, 2021, 5, 1625-1638.	1.5	10
813	Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of Ovarian Cancer Patients. Frontiers in Immunology, 2021, 12, 751594.	2.2	13
814	LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency. Med, 2021, 2, 1231-1252.e10.	2.2	19
815	Oncolytic reovirus-mediated killing of mouse cancer-associated fibroblasts. International Journal of Pharmaceutics, 2021, 610, 121269.	2.6	2
816	Single-Cell Transcriptomic Analysis Reveals a Tumor-Reactive T Cell Signature Associated With Clinical Outcome and Immunotherapy Response In Melanoma. Frontiers in Immunology, 2021, 12, 758288.	2.2	13
817	VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes. Cancers, 2021, 13, 5559.	1.7	2
818	Necroptosis-Related lncRNAs: Predicting Prognosis and the Distinction between the Cold and Hot Tumors in Gastric Cancer. Journal of Oncology, 2021, 2021, 1-16.	0.6	140
819	A lipid metabolism-related genes prognosis biomarker associated with the tumor immune microenvironment in colorectal carcinoma. BMC Cancer, 2021, 21, 1182.	1.1	9
820	Robust immune response stimulated by in situ injection of CpG/Î±OX40/cGAMP in Î±PD-1-resistant malignancy. Cancer Immunology, Immunotherapy, 2022, 71, 1597-1609.	2.0	2
821	Tumorâ€immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas. Journal of Pathology, 2022, 256, 282-296.	2.1	11
822	Potential Prognostic Biomarkers of OSBPL Family Genes in Patients with Pancreatic Ductal Adenocarcinoma. Biomedicines, 2021, 9, 1601.	1.4	13
823	Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1. Cancers, 2021, 13, 5508.	1.7	9
824	Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer. EBioMedicine, 2021, 73, 103664.	2.7	5
825	In Silico Model Estimates the Clinical Trial Outcome of Cancer Vaccines. Cells, 2021, 10, 3048.	1.8	4
828	The actual management of colorectal liver metastases. Minerva Chirurgica, 2020, 75, 328-344.	0.8	0

#	Article	IF	Citations
829	Immune battle at the premalignant stage of colorectal cancer: focus on immune cell compositions, functions and cytokine products. American Journal of Cancer Research, 2020, 10, 1308-1320.	1.4	4
830	Fueling chimeric antigen receptor T cells with cytokines. American Journal of Cancer Research, 2020, 10, 4038-4055.	1.4	5
831	Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study. Technology in Cancer Research and Treatment, 2021, 20, 153303382110396.	0.8	4
832	Advances in mass cytometry and its applicability to digital pathology in clinical-translational cancer research. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2022, 3, 5-16.	0.1	1
833	MCAM/MUC18/CD146 as a Multifaceted Warning Marker of Melanoma Progression in Liquid Biopsy. International Journal of Molecular Sciences, 2021, 22, 12416.	1.8	9
834	Expression of nonâ€homologous end joining factor, Ku80, is negatively correlated with PDâ€L1 expression in cancer cells after Xâ€ray irradiation. Oncology Letters, 2021, 23, 29.	0.8	7
835	Nanoparticle-based delivery systems modulate the tumor microenvironment in pancreatic cancer for enhanced therapy. Journal of Nanobiotechnology, 2021, 19, 384.	4.2	27
836	The relationship of GITR, Lag-3 and PD-1 expression with the main indicators of systemic and local immunity in patients with breast cancer. Journal of Modern Oncology, 2021, 23, 457-465.	0.1	3
837	Sequential modulation of the Wnt/Î²-catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance. Gynecologic Oncology, 2022, 164, 170-180.	0.6	10
838	Tailoring Aggregation Extent of Photosensitizers to Boost Phototherapy Potency for Eliciting Systemic Antitumor Immunity. Advanced Materials, 2022, 34, e2106390.	11.1	65
839	Hypoxia: The Cornerstone of Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 12608.	1.8	62
840	Directing the Future Breakthroughs in Immunotherapy: The Importance of a Holistic Approach to the Tumour Microenvironment. Cancers, 2021, 13, 5911.	1.7	1
841	Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid HÃ¼rthle Cell Carcinoma: A Case Report and Literature Review. Frontiers in Oncology, 2021, 11, 782646.	1.3	5
842	Pyroptosis-Mediated Molecular Subtypes and Tumor Microenvironment Infiltration Characterization in Colon Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 766503.	1.8	8
843	The effect of spacers in dual drug-polymer conjugates toward combination therapeutic efficacy. Scientific Reports, 2021, 11, 22116.	1.6	3
844	Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response. BMC Cancer, 2021, 21, 1222.	1.1	28
845	Comprehensive Analysis of the Immune and Prognostic Implication of MMP14 in Lung Cancer. Disease Markers, 2021, 2021, 1-21.	0.6	4
846	Natural Killer and T Cell Infiltration in Canine Osteosarcoma: Clinical Implications and Translational Relevance. Frontiers in Veterinary Science, 2021, 8, 771737.	0.9	1

#	Article	IF	Citations
847	Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer. Clinical and Translational Oncology, 2022, 24, 556-567.	1.2	11
848	Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer. Frontiers in Oncology, 2021, 11, 773420.	1.3	10
849	Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers. Cancers, 2021, 13, 5819.	1.7	4
850	HLA AND CANCER. Physical and Rehabilitation Medicine Medical Rehabilitation, 0, , .	0.1	0
851	Translational Development and Testing of Theranostics in Combination with Immunotherapies. , 2022, , 267-280.		0
852	Oncolytic Virotherapy: From Bench to Bedside. Frontiers in Cell and Developmental Biology, 2021, 9, 790150.	1.8	29
853	Targeting hypoxia and hypoxiaâ€inducible factorâ€1 in the tumor microenvironment for optimal cancer immunotherapy. Journal of Cellular Physiology, 2022, 237, 1285-1298.	2.0	20
854	Prognostic and immune infiltration signatures of proteasome 26S subunit, non-ATPase (PSMD) family genes in breast cancer patients. Aging, 2021, 13, 24882-24913.	1.4	25
855	Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment. Molecular Therapy - Oncolytics, 2021, 23, 488-500.	2.0	4
856	Prognostic value of immune-related genes and comparative analysis of immune cell infiltration in lung adenocarcinoma: sex differences. Biology of Sex Differences, 2021, 12, 64.	1.8	8
857	Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology. Cancers, 2021, 13, 6052.	1.7	15
858	Rational Combination with an Immunotherapy Backbone in Genitourinary Cancers. Urological Science, 2020, 31, 4-7.	0.2	4
860	Single-Cell Atlas of Infiltrating B Cells and Their Clinical Outcomes in Colorectal Cancer. SSRN Electronic Journal, 0, , .	0.4	0
861	Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer. Frontiers in Immunology, 2021, 12, 812713.	2.2	3
862	A size/charge/targeting changeable nano-booster to realize synergistic photodynamic-immunotherapy with high safety. Chemical Engineering Journal, 2022, 434, 134585.	6.6	14
863	Immunotherapy for prostate cancer: Requirements for a successful regime transfer. Investigative and Clinical Urology, 2022, 63, 3.	1.0	8
864	Antitumor Peptide-Based Vaccine in the Limelight. Vaccines, 2022, 10, 70.	2.1	10
865	STING orchestrates the crosstalk between polyunsaturated fatty acid metabolism and inflammatory responses. Cell Metabolism, 2022, 34, 125-139.e8.	7.2	49

#	Article	IF	Citations
866	NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models. Translational Oncology, 2022, 16, 101322.	1.7	12
867	The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. Immunotherapy, 2022, 14, 155-167.	1.0	7
868	A Case Report: Internal Carotid Artery Dissection Presenting as Hoarseness Secondary to Vocal Cord Palsy. European Medical Journal Neurology, 0, , 66-71.	0.0	1
869	Pyroptosis-Mediated Molecular Subtypes are Characterized by Distinct Tumor Microenvironment Infiltration Characteristics in Breast Cancer. Journal of Inflammation Research, 2022, Volume 15, 345-362.	1.6	9
871	Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity. Clinical Cancer Research, 2022, 28, 2038-2049.	3.2	16
872	Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. Theranostics, 2022, 12, 747-766.	4.6	28
873	Canine Oral Melanoma Genomic and Transcriptomic Study Defines Two Molecular Subgroups with Different Therapeutical Targets. Cancers, 2022, 14, 276.	1.7	3
874	Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma. Cancers, 2022, 14, 546.	1.7	5
875	CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors. Frontiers in Immunology, 2021, 12, 813832.	2.2	15
876	Loss of NFE2L3 protects against inflammation-induced colorectal cancer through modulation of the tumor microenvironment. Oncogene, 2022, 41, 1563-1575.	2.6	13
877	RNF135 Promoter Methylation Is Associated With Immune Infiltration and Prognosis in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 752511.	1.3	6
878	The emerging role of Arid5a in cancer: A new target for tumors. Genes and Diseases, 2022, , .	1.5	0
879	Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma. Clinical Cancer Research, 2022, 28, 1999-2019.	3.2	20
880	T- and B-Cells in the Inner Invasive Margin of Hepatocellular Carcinoma after Resection Associate with Favorable Prognosis. Cancers, 2022, 14, 604.	1.7	4
881	Identification and validation of a novel signature for prediction the prognosis and immunotherapy benefit in bladder cancer. PeerJ, 2022, 10, e12843.	0.9	8
882	Radiotherapy for HPV-related cancers: prediction of therapeutic effects based on the mechanism of tumor immunity and the application of immunoradiotherapy. Japanese Journal of Radiology, 2022, 40, 458-465.	1.0	2
883	LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion. Nature Genetics, 2022, 54, 180-193.	9.4	39
884	Identification of Tumor Antigens and Design of mRNA Vaccine for Colorectal Cancer Based on the Immune Subtype. Frontiers in Cell and Developmental Biology, 2021, 9, 783527.	1.8	14

#	Article	IF	Citations
885	Methylation Pattern Mediated by m6A Regulator and Tumor Microenvironment Invasion in Lung Adenocarcinoma. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-15.	1.9	25
886	A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer. Cancer Immunology, Immunotherapy, 2022, , 1.	2.0	8
887	Metabolic Understanding of the Genetic Dysregulation in the Tumor Microenvironment of Kidney Renal Clear Cell Carcinoma. Disease Markers, 2022, 2022, 1-17.	0.6	3
888	Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Frontiers in Immunology, 2021, 12, 799455.	2.2	76
889	Histologic-Based Tumor-Associated Immune Cells Status in Clear Cell Renal Cell Carcinoma Correlates with Gene Signatures Related to Cancer Immunity and Clinical Outcomes. Biomedicines, 2022, 10, 323.	1.4	6
890	Bimetallic metalâ€“organic frameworks for tumor inhibition via combined photothermal-immunotherapy. Chemical Communications, 2022, , .	2.2	4
891	Dissecting the heterogeneity of the microenvironment in primary and recurrent nasopharyngeal carcinomas using single-cell RNA sequencing. OncoImmunology, 2022, 11, 2026583.	2.1	15
892	Discovering dominant tumor immune archetypes in a pan-cancer census. Cell, 2022, 185, 184-203.e19.	13.5	70
893	Synthetic Matrix Scaffolds Engineer the In Vivo Tumor Immune Microenvironment for Immunotherapy Screening. Advanced Materials, 2022, 34, e2108084.	11.1	13
894	Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature. Oncology and Therapy, 2022, 10, 291-300.	1.0	1
895	Adenosine 2A receptor and TIM3 suppress cytolytic killing of tumor cells via cytoskeletal polarization. Communications Biology, 2022, 5, 9.	2.0	4
896	Recent Advances in the Role of Arid5a in Immune Diseases and Cancer. Frontiers in Immunology, 2021, 12, 827611.	2.2	6
897	Metal-free bioorthogonal click chemistry in cancer theranostics. Chemical Society Reviews, 2022, 51, 1336-1376.	18.7	76
898	Crosstalk Between Four Types of RNA Modification Writers Characterizes the Tumor Immune Microenvironment Infiltration Patterns in Skin Cutaneous Melanoma. Frontiers in Cell and Developmental Biology, 2022, 10, 821678.	1.8	0
899	Vectorized Treg-depleting Î±CTLA-4 elicits antigen cross-presentation and CD8⁺ T cell immunity to reject â€˜coldâ€™ tumors. , 2022, 10, e003488.		14
900	Tumor-Infiltrating Lymphocytes as Biomarkers of Treatment Response and Long-Term Survival in Patients with Rectal Cancer: A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 636.	1.7	10
901	Clinical Significance and Immune Landscape of Recurrence-Associated Ferroptosis Signature in Early-Stage Lung Adenocarcinoma. Frontiers in Oncology, 2022, 12, 794293.	1.3	0
902	Characterization of Interplay Between Autophagy and Ferroptosis and Their Synergistical Roles on Manipulating Immunological Tumor Microenvironment in Squamous Cell Carcinomas. Frontiers in Immunology, 2021, 12, 739039.	2.2	35

#	Article	IF	Citations
903	Immune subtypes and neoantigen-related immune evasion in advanced colorectal cancer. IScience, 2022, 25, 103740.	1.9	4
904	Harnessing self-assembling peptide nanofibers to prime robust tumor-specific CD8 T cell responses in mice. International Immunopharmacology, 2022, 104, 108522.	1.7	2
905	Extracellular matrix modulates T cell clearance of malignant cells in vitro. Biomaterials, 2022, 282, 121378.	5.7	8
906	IgD ligation allows peritoneal cavity B cell proliferation. Immunobiology, 2022, 227, 152181.	0.8	0
907	A mathematical model to study the impact of intra-tumour heterogeneity on anti-tumour CD8+ T cell immune response. Journal of Theoretical Biology, 2022, 538, 111028.	0.8	12
908	Inhibition of tumor recurrence and metastasis <i>via</i> a surgical tumor-derived personalized hydrogel vaccine. Biomaterials Science, 2022, 10, 1352-1363.	2.6	18
909	ç”Ÿç‰©åŒ»ç”¨ç³ç±³æææ–™åœ¨å¢žå¼ºè¸ç˜ç»†èƒžå…ç–«åŽŸæ€§æ»äº¡ä¸çš„åº”ç”¨. Chinese Science Bulletin, 2022, , .	2.4	0
910	Prognostic implication and immunotherapy response prediction of a costimulatory molecule signature in kidney renal clear cell carcinoma. Immunogenetics, 2022, , 1.	1.2	2
911	Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nature Communications, 2022, 13, 767.	5.8	128
912	Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduction and Targeted Therapy, 2022, 7, 39.	7.1	158
913	Mesenchymal stromal cells equipped by IFNÎ± empower T cells with potent anti-tumor immunity. Oncogene, 2022, 41, 1866-1881.	2.6	9
914	Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment. Frontiers in Oncology, 2022, 12, 809304.	1.3	23
915	Adoptive cell therapies in thoracic malignancies. Cancer Immunology, Immunotherapy, 2022, 71, 2077-2098.	2.0	4
916	Immune sunrise: from the immunome to the cancer immune landscape. OncoImmunology, 2022, 11, 2019896.	2.1	5
917	Combined Consideration of Tumor-Associated Immune Cell Density and Immune Checkpoint Expression in the Peritumoral Microenvironment for Prognostic Stratification of Non-Small-Cell Lung Cancer Patients. Frontiers in Immunology, 2022, 13, 811007.	2.2	4
918	Comprehensive analysis of immune cell infiltration and significant genes in head and neck squamous cell carcinoma. Oral Oncology, 2022, 126, 105755.	0.8	5
919	Fluorescence imaging of tumor immune contexture in immune checkpoint blockade therapy. International Immunopharmacology, 2022, 106, 108617.	1.7	5
920	A Combination of Cabozantinib and Radiation Does Not Lead to an Improved Growth Control of Tumors in a Preclinical 4T1 Breast Cancer Model. Frontiers in Oncology, 2021, 11, 788182.	1.3	4

#	Article	IF	Citations
921	Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers. , 2021, 9, e003414.		14
922	Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nature Communications, 2021, 12, 7338.	5.8	104
923	New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer. Current Oncology, 2022, 29, 38-55.	0.9	7
924	Prognostic biomarkers related to tumoral microenvironment in pancreatic ductal adenocarcinoma: a systematic review. Romanian Journal of Morphology and Embryology, 2021, 62, 671-678.	0.4	1
927	Efficacy of Bivalent <i>CEACAM6/4-1BBL</i> Genetic Vaccine Combined with Anti-PD1 Antibody in MC38 Tumor Model of Mice. SSRN Electronic Journal, 0, , .	0.4	0
928	Identification of Necroptosis-Related Long Noncoding Rnas for Immunotherapy Selection and Prognosis Prediction in Patients with Colorectal Cancer. SSRN Electronic Journal, 0, , .	0.4	0
929	Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer. Expert Reviews in Molecular Medicine, 2022, 24, e16.	1.6	1
930	Multifunctional theranostic nanoparticles for multi-modal imaging-guided CAR-T immunotherapy and chemo-photothermal combinational therapy of non-Hodgkin's lymphoma. Biomaterials Science, 2022, 10, 2577-2589.	2.6	10
931	Pyroptosis Predicts Immunotherapy Outcomes Across Multiple Cancer Types. SSRN Electronic Journal, 0, , .	0.4	0
932	The Correlation of HK2 Gene Expression with the Occurrence, Immune Cell Infiltration, and Prognosis of Renal Cell Carcinoma. Disease Markers, 2022, 2022, 1-11.	0.6	3
933	Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. Trends in Cancer, 2022, 8, 426-444.	3.8	13
934	Phosphatidylserine released from apoptotic cells in tumor induces M2â€like macrophage polarization through the PSRâ€STAT3â€JMJD3 axis. Cancer Communications, 2022, 42, 205-222.	3.7	20
935	Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities. Current Cancer Drug Targets, 2022, 22, 437-453.	0.8	2
936	Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions. Biomedicines, 2022, 10, 537.	1.4	9
937	The Landscape of Nanovectors for Modulation in Cancer Immunotherapy. Pharmaceutics, 2022, 14, 397.	2.0	4
938	STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma. Cancers, 2022, 14, 1154.	1.7	11
939	Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival. , 2022, 10, e004346.		15
940	Recent Advance of Nanomaterial-Mediated Tumor Therapies in the Past Five Years. Frontiers in Pharmacology, 2022, 13, 846715.	1.6	2

#	Article	IF	Citations
941	Immunoarchitectural patterns as potential prognostic factors for invasive ductal breast cancer. Npj Breast Cancer, 2022, 8, 26.	2.3	2
942	The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges. Cancers, 2022, 14, 995.	1.7	28
943	p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer. F1000Research, 0, 11, 330.	0.8	1
944	Breaking Immunosuppressive Barriers by Engineered Nanoplatforms for Turning Cold Tumor to Hot. Advanced Therapeutics, 2022, 5, .	1.6	3
945	Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. Journal of Hematology and Oncology, 2022, 15, 24.	6.9	136
946	Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies. Frontiers in Cell and Developmental Biology, 2022, 10, 830208.	1.8	13
947	Comprehensive Analysis Revealed the Potential Implications of m6A Regulators in Lung Adenocarcinoma. Frontiers in Molecular Biosciences, 2022, 9, 806780.	1.6	2
948	Glutathione Depletionâ€Induced Activation of Dimersomes for Potentiating the Ferroptosis and Immunotherapy of â€œColdâ€•Tumor. Angewandte Chemie - International Edition, 2022, 61, .	7.2	43
949	Boosting Tumor Immunotherapy by Bioactive Nanoparticles via Ca²⁺ Interference Mediated TME Reprogramming and Specific PDâ€Ł1 Depletion. Advanced Functional Materials, 2022, 32, .	7.8	32
950	Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment. International Journal of Molecular Sciences, 2022, 23, 2847.	1.8	19
951	Patient-derived pancreatic cancer-on-a-chip recapitulates the tumor microenvironment. Microsystems and Nanoengineering, 2022, 8, 36.	3.4	45
952	Semiconducting Polymer Nanoparticles for Photoactivatable Cancer Immunotherapy and Imaging of Immunoactivation. Biomacromolecules, 2022, 23, 1490-1504.	2.6	16
953	The Heterogeneity of Immune Cell Infiltration Landscape and Its Immunotherapeutic Implications in Hepatocellular Carcinoma. Frontiers in Immunology, 2022, 13, 861525.	2.2	11
954	Role of TFRC as a Novel Prognostic Biomarker and in Immunotherapy for Pancreatic Carcinoma. Frontiers in Molecular Biosciences, 2022, 9, 756895.	1.6	11
955	Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. Cancers, 2022, 14, 1735.	1.7	6
957	Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy. Frontiers in Oncology, 2022, 12, 849793.	1.3	7
958	Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report. Annals of Translational Medicine, 2022, 10, 380-380.	0.7	3
959	Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention. Cancers, 2022, 14, 1367.	1.7	10

#	Article	IF	Citations
960	Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer. Journal of Medicinal Chemistry, 2022, 65, 5675-5689.	2.9	46
961	Multi-omics reveals microbiome, host gene expression, and immune landscape in gastric carcinogenesis. IScience, 2022, 25, 103956.	1.9	19
962	Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC. Seminars in Cancer Biology, 2022, 86, 273-285.	4.3	107
963	Tumor Microenvironment-Mediated Immune Profiles Characterized by Distinct Survival Outcome and Immunotherapeutic Efficacy in Breast Cancer. Frontiers in Genetics, 2022, 13, 840348.	1.1	5
964	Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments. Biomedicines, 2022, 10, 650.	1.4	24
965	Glutathione Depletionâ€Induced Activation of Dimersomes for Potentiating the Ferroptosis and Immunotherapy of â€œColdâ€•Tumor. Angewandte Chemie, 0, , .	1.6	6
967	Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients. Journal of Pathology, 2022, , .	2.1	3
968	Current Overview on the Potency of Natural Products for Modulating Myeloid-derived Suppressor Cells Dependent Cold Tumors. Current Medicinal Chemistry, 2022, 29, 6197-6216.	1.2	0
969	AMICA1 is a diagnostic and prognostic biomarker and induces immune cells infiltration by activating cGAS-STING signaling in lung adenocarcinoma. Cancer Cell International, 2022, 22, 111.	1.8	8
970	Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy. Journal of Clinical Medicine, 2022, 11, 1500.	1.0	3
971	Platinum-Based Chemotherapy â€˜Rechallengeâ€™ in Advanced Non-ovarian Solid Malignancies. Clinical Oncology, 2022, 34, e329-e344.	0.6	6
972	Importance of the Immune Microenvironment in the Spontaneous Regression of Cervical Squamous Intraepithelial Lesions (cSIL) and Implications for Immunotherapy. Journal of Clinical Medicine, 2022, 11, 1432.	1.0	8
973	A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Antiâ€“PD-L1 mAb Combination to Enhance the Antitumor Effect. Clinical Cancer Research, 2022, 28, 2923-2937.	3.2	12
974	Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade. Journal of Experimental and Clinical Cancer Research, 2022, 41, 132.	3.5	21
975	Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target. , 2022, 10, e004302.		20
976	Identification of RNA Methylation-Related lncRNAs Signature for Predicting Hot and Cold Tumors and Prognosis in Colon Cancer. Frontiers in Genetics, 2022, 13, 870945.	1.1	10
977	BPIFB2 is highly expressed in â€œcoldâ€•lung adenocarcinoma and decreases T cell chemotaxis via activation of the STAT3 pathway. Molecular and Cellular Probes, 2022, 62, 101804.	0.9	1
978	Biomimetic Nanocarriers Guide Extracellular ATP Homeostasis to Remodel Energy Metabolism for Activating Innate and Adaptive Immunity System. Advanced Science, 2022, 9, e2105376.	5.6	27

#	Article	IF	Citations
979	C₈Mab-3: An Anti-Mouse CCR8 Monoclonal Antibody for Immunocytochemistry. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2022, 41, 110-114.	0.8	9
980	Sonosensitizer nanoplatform-mediated sonodynamic therapy induced immunogenic cell death and tumor immune microenvironment variation. Drug Delivery, 2022, 29, 1164-1175.	2.5	14
981	Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?. Cancer Treatment Reviews, 2022, 106, 102392.	3.4	11
982	Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy. Science Immunology, 2022, 7, eabk1692.	5.6	100
983	Photothermal MnO2 nanoparticles boost chemo-photothermal therapy-induced immunogenic cell death in tumor immunotherapy. International Journal of Pharmaceutics, 2022, 617, 121578.	2.6	19
984	Drivers and breaks in the cholangiocarcinoma immune microenvironment. Hepatobiliary Surgery and Nutrition, 2022, 11, 320-323.	0.7	0
985	Intranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy. Nanomaterials, 2022, 12, 1221.	1.9	4
986	Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery. Advanced Drug Delivery Reviews, 2022, 183, 114177.	6.6	67
987	Self-degradable poly(Î²-amino ester)s promote endosomal escape of antigen and agonist. Journal of Controlled Release, 2022, 345, 91-100.	4.8	15
988	Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy. Journal of Controlled Release, 2022, 345, 721-733.	4.8	25
989	Combined nano cancer immunotherapy based on immune status in a tumor microenvironment. Journal of Controlled Release, 2022, 345, 200-213.	4.8	13
990	A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors. International Journal of Biological Macromolecules, 2022, 207, 592-610.	3.6	44
991	Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma. Translational Oncology, 2022, 20, 101406.	1.7	5
992	Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response. Translational Oncology, 2022, 20, 101405.	1.7	25
993	Natural killer cell therapy: A new frontier for obesity-associated cancer. Cancer Letters, 2022, 535, 215620.	3.2	17
994	Development and Validation of a Prognostic Gene Signature Correlated With M2 Macrophage Infiltration in Esophageal Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 769727.	1.3	21
995	The dual role of neutrophils in cancer. Seminars in Immunology, 2021, 57, 101582.	2.7	26
996	Tetrahedral DNA nanostructures synergize with MnO2 to enhance antitumor immunity via promoting STING activation and M1 polarization. Acta Pharmaceutica Sinica B, 2022, 12, 2494-2505.	5.7	11

#	Article	IF	Citations
997	Identification of m6A Regulator-Associated Methylation Modification Clusters and Immune Profiles in Melanoma. Frontiers in Cell and Developmental Biology, 2021, 9, 761134.	1.8	6
998	Smart Nanoâ€PROTACs Reprogram Tumor Microenvironment for Activatable Photoâ€metabolic Cancer Immunotherapy. Angewandte Chemie - International Edition, 2022, 61, e202114957.	7.2	67
999	Smart Nanoâ€PROTACs Reprogram Tumor Microenvironment for Activatable Photoâ€metabolic Cancer Immunotherapy. Angewandte Chemie, 2022, 134, .	1.6	7
1000	Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses. Frontiers in Immunology, 2021, 12, 791621.	2.2	2
1001	Lymphoplasmacyte-rich meningioma in the central nervous system. Medicine (United States), 2021, 100, e27991.	0.4	4
1002	Auranofin and ICG-001 Emerge Synergistic Anti-tumor Effect on Canine Breast Cancer by Inducing Apoptosis via Mitochondrial Pathway. Frontiers in Veterinary Science, 2021, 8, 772687.	0.9	1
1003	Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?. Cancers, 2021, 13, 6317.	1.7	17
1004	Remodeling Chondroitin-6-Sulfateâ€"Mediated Immune Exclusion Enhances Antiâ€"PD-1 Response in Colorectal Cancer with Microsatellite Stability. Cancer Immunology Research, 2022, 10, 182-199.	1.6	8
1005	Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy. Molecules, 2022, 27, 137.	1.7	41
1006	Methods for monitoring cancer cell pyroptosis. Cancer Biology and Medicine, 2021, 19, 398-414.	1.4	18
1007	Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors. Clinical Cancer Research, 2022, 28, 2657-2668.	3.2	4
1008	Identification of Bladder Cancer Subtypes Based on Necroptosis-Related Genes, Construction of a Prognostic Model. Frontiers in Surgery, 2022, 9, 860857.	0.6	8
1009	Extracellular vesicles from triple negative breast cancer promote pro-inflammatory macrophages associated with better clinical outcome. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2107394119.	3.3	39
1010	Tumor Microenvironment Profiling Identifies Prognostic Signatures and Suggests Immunotherapeutic Benefits in Neuroblastoma. Frontiers in Cell and Developmental Biology, 2022, 10, 814836.	1.8	3
1011	Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma. Frontiers in Molecular Biosciences, 2022, 9, 777775.	1.6	3
1012	CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. Journal of Experimental Medicine, 2022, 219, .	4.2	22
1013	Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell, 2022, 185, 1521-1538.e18.	13.5	63
1014	Investigating the Prognostic Relevance of Tumor Immune Microenvironment and Immune Gene Assembly in Breast Carcinoma Subtypes. Cancers, 2022, 14, 1942.	1.7	2

#	Article	IF	Citations
1015	Copperâ€based nanomaterials for cancer theranostics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1797.	3.3	26
1016	Myeloid-Derived Suppressor Cells and Radiotherapy. Cancer Immunology Research, 2022, 10, 545-557.	1.6	32
1017	Comprehensive Characterization of the Function of Metabolic Genes and Establishment of a Prediction Model in Breast Cancer. Disease Markers, 2022, 2022, 1-18.	0.6	0
1018	Evaluation of HLA-E Expression Combined with Natural Killer Cell Status as a Prognostic Factor for Advanced Gastric Cancer. Annals of Surgical Oncology, 2022, 29, 4951-4960.	0.7	10
1019	Use of Immunotherapy in Clinical Management of Genitourinary Cancers â€“ a Review. Cancer Treatment and Research Communications, 2022, 31, 100564.	0.7	3
1020	Recent advances in nanoparticles-based photothermal therapy synergizing with immune checkpoint blockade therapy. Materials and Design, 2022, 217, 110656.	3.3	15
1050	Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2117065119.	3.3	26
1051	Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature. Journal of Translational Medicine, 2022, 20, 186.	1.8	22
1052	Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects. Theranostics, 2022, 12, 3719-3746.	4.6	23
1053	Nanoformulations Mediated Metastasis Brake in Cancer Therapy Via Photoinduced Ferroptosis and Regional Inflammation Management. SSRN Electronic Journal, 0, , .	0.4	0
1054	Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study. Clinical Cancer Research, 2022, 28, 2818-2829.	3.2	12
1055	A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study. Frontiers in Immunology, 2022, 13, 859323.	2.2	25
1056	Tumor-infiltrating ICOS⁺ Effector Regulatory T-Cells in Oral Squamous Cell Carcinoma as a Promising Biomarker for Prognosis and â€˜Hotâ€™ Tumor. Anticancer Research, 2022, 42, 2383-2393.	0.5	1
1057	Bifunctional Fusion Membraneâ€Based Hydrogel Enhances Antitumor Potency of Autologous Cancer Vaccines by Activating Dendritic Cells. Advanced Functional Materials, 2022, 32, .	7.8	17
1058	m6A Regulator-Mediated Tumour Infiltration and Methylation Modification in Cervical Cancer Microenvironment. Frontiers in Immunology, 2022, 13, 888650.	2.2	15
1059	Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy. Acta Pharmacologica Sinica, 2022, 43, 2749-2758.	2.8	16
1060	Ursolic acid-enriched kudingcha extract enhances the antitumor activity of bacteria-mediated cancer immunotherapy. BMC Complementary Medicine and Therapies, 2022, 22, 123.	1.2	1
1061	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. Clinical Cancer Research, 2022, 28, 3053-3065.	3.2	26

#	Article	IF	Citations
1062	Clinical Significance of a CD3/CD8-Based Immunoscore in Neuroblastoma Patients Using Digital Pathology. Frontiers in Immunology, 2022, 13, .	2.2	2
1063	Recent Advances in Engineering Nanomedicines for Second Near-Infrared Photothermal-Combinational Immunotherapy. Nanomaterials, 2022, 12, 1656.	1.9	9
1064	A novel oncolytic virus induces a regional cytokine storm and safely eliminates malignant ascites of colon cancer. Cancer Medicine, 2022, 11, 4297-4309.	1.3	5
1065	Deciphering the tumor microenvironment cellâ€“infiltrating landscape reveals microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC. JCI Insight, 2022, 7, .	2.3	6
1066	High-throughput single-Ñell sequencing in cancer research. Signal Transduction and Targeted Therapy, 2022, 7, 145.	7.1	39
1067	Association between high immune activity and worse prognosis in uveal melanoma and low-grade glioma in TCGA transcriptomic data. BMC Genomics, 2022, 23, 351.	1.2	5
1068	Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy. Molecular Therapy - Oncolytics, 2022, 25, 236-248.	2.0	9
1069	Self-assembled nanospheres mediate phototherapy and deliver CpG oligodeoxynucleotides to enhance cancer immunotherapy of breast cancer and melanoma. Nano Today, 2022, 44, 101498.	6.2	17
1070	Immunogenicity-boosted cancer immunotherapy based on nanoscale metal-organic frameworks. Journal of Controlled Release, 2022, 347, 183-198.	4.8	23
1071	Construction of an immune infiltration landscape based on immune-related genes in cervical cancer. Computers in Biology and Medicine, 2022, 146, 105638.	3.9	6
1072	Dual drugs decorated bacteria irradiate deep hypoxic tumor and arouse strong immune responses. Biomaterials, 2022, 286, 121582.	5.7	24
1073	Transforming â€œcoldâ€•tumors into â€œhotâ€•ones via tumor-microenvironment-responsive siRNA micelleplexes for enhanced immunotherapy. Matter, 2022, 5, 2285-2305.	5.0	62
1074	Intranasal Delivery of Recombinant S100A8 Protein Delays Lung Cancer Growth by Remodeling the Lung Immune Microenvironment. Frontiers in Immunology, 2022, 13, .	2.2	6
1075	High Mobility Group Protein B1 Decreases Surface Localization of PD-1 to Augment T-cell Activation. Cancer Immunology Research, 2022, 10, 844-855.	1.6	4
1076	Immune cell infiltration pattern in non-small cell lung cancer PDX models is a model immanent feature and correlates with a distinct molecular and phenotypic make-up. , 2022, 10, e004412.		3
1077	Association of mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors.. American Journal of Cancer Research, 2022, 12, 1766-1783.	1.4	0
1078	Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment. International Review of Cell and Molecular Biology, 2022, , 123-147.	1.6	8
1080	Mast cell marker gene signature in head and neck squamous cell carcinoma. BMC Cancer, 2022, 22, .	1.1	14

#	Article	IF	Citations
1081	Modulation of Lymphocyte Functions in the Microenvironment by Tumor Oncogenic Pathways. Frontiers in Immunology, 2022, 13, .	2.2	3
1082	Red Blood Cells-Based Vaccines for Ameliorating Cancer Chemoimmunotherapy. SSRN Electronic Journal, 0, , .	0.4	0
1083	Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends in Immunology, 2022, 43, 523-545.	2.9	176
1084	Engineering Bioinspired Nanomedicines to Mitigate the Resistance to Cancer Immunotherapy. Accounts of Materials Research, 2022, 3, 697-708.	5.9	14
1085	Zooming on T cells in cancer. Science China Life Sciences, 0, , .	2.3	2
1086	N6-methyladenosine methylation modification patterns reveal immune profiling in pancreatic adenocarcinoma. Cancer Cell International, 2022, 22, .	1.8	7
1087	Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment. Advanced Drug Delivery Reviews, 2022, 187, 114365.	6.6	30
1088	In Situ Microâ€“Nano Conversion Augmented Tumor-Localized Immunochemotherapy. ACS Applied Materials & Interfaces, 2022, 14, 27013-27027.	4.0	7
1090	Tailoring Multifunctional Small Molecular Photosensitizers to In Vivo Selfâ€Assemble with Albumin to Boost Tumorâ€Preferential Accumulation, NIR Imaging, and Photodynamic/Photothermal/Immunotherapy. Small, 2022, 18, .	5.2	11
1091	Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. Journal of Hematology and Oncology, 2022, 15, .	6.9	112
1092	Neoadjuvant immunotherapy in gastrointestinal cancers â€“ The new standard of care?. Seminars in Cancer Biology, 2022, 86, 834-850.	4.3	12
1093	Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors. Frontiers in Cellular and Infection Microbiology, 2022, 12, .	1.8	8
1094	Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. Advanced Science, 2022, 9, .	5.6	140
1097	Magnetic hyperthermia induces effective and genuine immunogenic tumor cell death with respect to exogenous heating. Journal of Materials Chemistry B, 2022, 10, 5364-5374.	2.9	16
1099	How to improve photodynamic therapy-induced antitumor immunity for cancer treatment?. Theranostics, 2022, 12, 4629-4655.	4.6	28
1100	Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPI± signal. Theranostics, 2022, 12, 4581-4598.	4.6	8
1101	Bioengineered nanogels for cancer immunotherapy. Chemical Society Reviews, 2022, 51, 5136-5174.	18.7	81
1102	Low-Dose JAK3 Inhibition Improves Antitumor T-Cell Immunity and Immunotherapy Efficacy. Molecular Cancer Therapeutics, 2022, 21, 1393-1405.	1.9	3

#	Article	IF	Citations
1103	Preclinical platforms to study therapeutic efficacy of human Î³Î˜â€cells for oncology indications. Clinical and Translational Discovery, 2022, 2, .	0.2	0
1104	Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	230
1105	Identification of Novel Tumor Antigens and the Immune Landscapes of Bladder Cancer Patients for mRNA Vaccine Development. Frontiers in Oncology, 0, 12, .	1.3	6
1106	Role of Adenoviruses in Cancer Therapy. Frontiers in Oncology, 0, 12, .	1.3	6
1107	Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability. Frontiers in Molecular Biosciences, 0, 9, .	1.6	2
1108	Transcriptome Analysis Reveals the Immune Infiltration Profiles in Cervical Cancer and Identifies KRT23 as an Immunotherapeutic Target. Frontiers in Oncology, 0, 12, .	1.3	4
1109	Natural Polyphenols-Platinum Nanocomplexes Stimulate Immune System for Combination Cancer Therapy. Nano Letters, 2022, 22, 5615-5625.	4.5	21
1110	Roles of Cadherin2 in Thyroid Cancer. Frontiers in Oncology, 0, 12, .	1.3	0
1111	Chemotherapy- and Immune-Related Gene Panel in Prognosis Prediction and Immune Microenvironment of SCLC. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	3
1112	Emerging Biomaterials Imaging Antitumor Immune Response. Advanced Materials, 2022, 34, .	11.1	22
1113	Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy. Science Advances, 2022, 8, .	4.7	16
1114	The role of pyroptosis in modulating the tumor immune microenvironment. Biomarker Research, 2022, 10, .	2.8	12
1115	Electroporation and Immunotherapyâ€”Unleashing the Abscopal Effect. Cancers, 2022, 14, 2876.	1.7	24
1116	Neoadjuvant Endocrine Therapy: A Potential Way to Make Cold Hormone Receptor-Rich Breast Cancer Hot. Combinatorial Chemistry and High Throughput Screening, 2022, 25, .	0.6	0
1117	m6A-Regulator Expression Signatures Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment. Frontiers in Immunology, 0, 13, .	2.2	2
1118	Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges. Seminars in Cancer Biology, 2022, 86, 477-490.	4.3	10
1119	Catalytical nano-immunocomplexes for remote-controlled sono-metabolic checkpoint trimodal cancer therapy. Nature Communications, 2022, 13, .	5.8	76
1120	ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain. Pharmacological Reviews, 2022, 74, 799-824.	7.1	38

#	Article	IF	Citations
1121	Cx₆Mab-1: A Novel Anti-Mouse CXCR6 Monoclonal Antibody Established by N-Terminal Peptide Immunization. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2022, 41, 133-141.	0.8	11
1123	Comprehensive Analysis of m5C Methylation Regulatory Genes and Tumor Microenvironment in Prostate Cancer. Frontiers in Immunology, 0, 13, .	2.2	12
1124	Glycosylation modification identifies novel molecular phenotypes and prognostic stratifications of glioma. Gene, 2022, 836, 146677.	1.0	0
1126	Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Theranostics, 2022, 12, 4965-4979.	4.6	18
1127	Preoperative Immune Cells Infiltration in the Tumor Microenvironment as a Prediction and Prognostic Factor for Postoperative Recurrence in Hepatocellular Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0
1128	Cancer immunoediting hypothesis: history, clinical implications and controversies. Central-European Journal of Immunology, 2022, 47, 168-174.	0.4	8
1129	The tumor immune microenvironment in peritoneal carcinomatosis. International Review of Cell and Molecular Biology, 2022, , 63-95.	1.6	6
1131	Crosstalk of RNA Adenosine Modification-Related Subtypes, Establishment of a Prognostic Model, and Immune Infiltration Characteristics in Ovarian Cancer. Frontiers in Immunology, 0, 13, .	2.2	8
1132	Characterization of Platelet Function-Related Gene Predicting Survival and Immunotherapy Efficacy in Gastric Cancer. Frontiers in Genetics, 0, 13, .	1.1	1
1133	Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing. Frontiers in Immunology, 0, 13, .	2.2	7
1134	Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer. Frontiers in Immunology, 0, 13, .	2.2	9
1135	Analysis of the Equilibrium Phase in Immune-Controlled Tumors Provides Hints for Designing Better Strategies for Cancer Treatment. Frontiers in Oncology, 0, 12, .	1.3	2
1136	Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors. International Journal of Molecular Sciences, 2022, 23, 7325.	1.8	7
1137	Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy. Pharmaceutics, 2022, 14, 1344.	2.0	8
1138	Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies. Hepatology International, 2022, 16, 868-878.	1.9	12
1139	Identification and Validation of Prognostic Related Hallmark ATP-Binding Cassette Transporters Associated With Immune Cell Infiltration Patterns in Thyroid Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	2
1140	Clustering analysis and prognostic signature of lung adenocarcinoma based on the tumor microenvironment. Scientific Reports, 2022, 12, .	1.6	0
1141	Construction of a Necroptosis-Associated Long Non-Coding RNA Signature to Predict Prognosis and Immune Response in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 0, 9, .	1.6	9

#	Article	IF	Citations
1142	Neoantigens and NK Cells: â€œTrick or Treatâ€•the Cancers?. Frontiers in Immunology, 0, 13, .	2.2	4
1143	Selfâ€Sacrificially Degradable Pseudoâ€Semiconducting Polymer Nanoparticles that Integrate NIRâ€II Fluorescence Bioimaging, Photodynamic Immunotherapy, and Photoâ€Activated Chemotherapy. Advanced Materials, 2022, 34, .	11.1	65
1144	SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer. Frontiers in Immunology, 0, 13, .	2.2	8
1146	Targeting glioblastoma through nano- and micro-particle-mediated immune modulation. Bioorganic and Medicinal Chemistry, 2022, 72, 116913.	1.4	3
1147	Pan-sarcoma characterization of lncRNAs in the crosstalk of EMT and tumour immunity identifies distinct clinical outcomes and potential implications for immunotherapy. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	3
1148	Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody. International Journal of Pharmaceutics, 2022, 624, 122034.	2.6	6
1149	Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option. Frontiers in Immunology, 0, 13, .	2.2	13
1150	Interplay Between Immune and Cancer-Associated Fibroblasts: A Path to Target Metalloproteinases in Penile Cancer. Frontiers in Oncology, 0, 12, .	1.3	2
1151	Characterization of Immune-Related Molecular Subtypes and a Prognostic Signature Correlating With the Response to Immunotherapy in Patients With Gastric Cancer. Frontiers in Immunology, 0, 13, .	2.2	0
1152	Precision cancer sono-immunotherapy using deep-tissue activatable semiconducting polymer immunomodulatory nanoparticles. Nature Communications, 2022, 13, .	5.8	70
1153	Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. Journal of Hematology and Oncology, 2022, 15, .	6.9	58
1154	Targeting DNA mismatch repair pathway by CRISPR nanosystem for boosting checkpoint blockade cancer immunotherapy. Nano Today, 2022, 45, 101555.	6.2	3
1155	Characterization of the immune cell infiltration landscape in myxofibrosarcoma to aid immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	0
1156	Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines. OncoImmunology, 2022, 11, .	2.1	9
1157	N7-methylguanosine-related lncRNAs: Predicting the prognosis and diagnosis of colorectal cancer in the cold and hot tumors. Frontiers in Genetics, 0, 13, .	1.1	6
1158	Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors. Cytokine and Growth Factor Reviews, 2022, 67, 1-10.	3.2	4
1159	CD8 T-cell heterogeneity during T-cell exhaustion and PD-1-targeted immunotherapy. International Immunology, 2022, 34, 571-577.	1.8	7
1160	Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	4

#	Article	IF	Citations
1161	Therapeutic KRAS ^{G12C} inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Science Advances, 2022, 8, .	4.7	40
1162	Genomic Landscape of RTK/RAS Pathway and Tumor Immune Infiltration as Prognostic Indicator of Lung Adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	2
1163	8-Gene signature related to CD8+ T cell infiltration by integrating single-cell and bulk RNA-sequencing in head and neck squamous cell carcinoma. Frontiers in Genetics, 0, 13, .	1.1	5
1164	Necroptosis-associated long noncoding RNAs can predict prognosis and differentiate between cold and hot tumors in ovarian cancer. Frontiers in Oncology, 0, 12, .	1.3	8
1165	A Novel Immune-Related Gene Signature to Identify the Tumor Microenvironment and Prognose Disease Among Patients With Oral Squamous Cell Carcinoma Patients Using ssGSEA: A Bioinformatics and Biological Validation Study. Frontiers in Immunology, 0, 13, .	2.2	11
1166	Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	6
1167	Tumor evolution-targeted nanomedicine^{EVT}. Scientia Sinica Chimica, 2022, 52, 2121-2155.	0.2	4
1168	Identification of Crucial Gene Modules Related to the Efficiency of Anti-PD-1/PD-L1 Therapy and Comprehensive Analyses of a Novel Signature Based on These Modules. Frontiers in Genetics, 0, 13, .	1.1	0
1169	N1-Methyladenosine-Related lncRNAs Are Potential Biomarkers for Predicting Prognosis and Immune Response in Uterine Corpus Endometrial Carcinoma. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-32.	1.9	5
1170	Crosstalk of three novel types of programmed cell death defines distinct microenvironment characterization and pharmacogenomic landscape in breast cancer. Frontiers in Immunology, 0, 13, .	2.2	2
1171	Engineered metal and their complexes for nanomedicine-elicited cancer immunotherapy. Materials Today Advances, 2022, 15, 100276.	2.5	4
1172	Singleâ€cell landscape and clinical outcomes of infiltrating B cells in colorectal cancer. Immunology, 2023, 168, 135-151.	2.0	25
1173	Molecular subtypes of osteosarcoma classified by cancer stem cell related genes define immunological cell infiltration and patient survival. Frontiers in Immunology, 0, 13, .	2.2	2
1174	A novel high-risk subpopulation identified by CTSL and ZBTB7B in gastric cancer. British Journal of Cancer, 2022, 127, 1450-1460.	2.9	5
1175	LNP-CDN: a novel nanomaterial for inflaming immune-cold malignant pleural effusion. Science Bulletin, 2022, , .	4.3	0
1177	Glycosylation modification patterns reveal distinct tumor metabolism and immune microenvironment landscape in lower-grade gliomas. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	1
1178	Secretory co-factors in next-generation cellular therapies for cancer. Frontiers in Immunology, 0, 13, .	2.2	1
1179	<scp>DDR1</scp> functions as an immune negative factor in colorectal cancer by regulating tumorâ€infiltrating T cells through <scp>IL</scp>â€18. Cancer Science, 2022, 113, 3672-3685.	1.7	15

#	Article	IF	Citations
1180	Rational Nanomedicine Design Enhances Clinically Physical Treatmentâ€Inspired or Combined Immunotherapy. Advanced Science, 2022, 9, .	5.6	23
1181	Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. , 2022, 10, e004006.		14
1182	Targeting thymidine phosphorylase alleviates resistance to dendritic cell immunotherapy in colorectal cancer and promotes antitumor immunity. Frontiers in Immunology, 0, 13, .	2.2	5
1183	Reduction Sensitive Polymers Delivering Cationic Platinum Drugs as STING Agonists for Enhanced Chemoâ€Immunotherapy. Advanced Functional Materials, 2022, 32, .	7.8	29
1184	Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients. European Journal of Cancer, 2022, 174, 287-298.	1.3	14
1185	Patient stratification based on urea cycle metabolism for exploration of combination immunotherapy in colon cancer. BMC Cancer, 2022, 22, .	1.1	0
1186	Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188775.	3.3	12
1187	Construction of a novel signature and prediction of the immune landscape in gastric cancer based on necroptosis-related genes. Scientific Reports, 2022, 12, .	1.6	2
1188	The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma. International Journal of Cancer, 2022, 151, 2278-2290.	2.3	6
1189	FLOT and CROSS chemotherapy regimens alter the frequency of CD27+ and CD69+ T cells in oesophagogastric adenocarcinomas: implications for combination with immunotherapy. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
1190	Prognostic value of 12 m7G methylation-related miRNA markers and their correlation with immune infiltration in breast cancer. Frontiers in Oncology, 0, 12, .	1.3	7
1191	m6A regulator-mediated methylation modification highlights immune infiltration patterns for predicting risk in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
1192	A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma. Scientific Reports, 2022, 12, .	1.6	3
1193	Sequential acid/reduction response of triblock copolymeric nanomicelles to release camptothecin and toll-like receptor 7/8 agonist for orchestrated chemoimmunotherapy. Journal of Nanobiotechnology, 2022, 20, .	4.2	2
1194	Immunogenic Cell Death Augmented by Manganese Zinc Sulfide Nanoparticles for Metastatic Melanoma Immunotherapy. ACS Nano, 2022, 16, 15471-15483.	7.3	71
1195	Black Phosphorus-Synergic Nitric Oxide Nanogasholder Spatiotemporally Regulates Tumor Microenvironments for Self-Amplifying Immunotherapy. ACS Applied Materials & Interfaces, 2022, 14, 37466-37477.	4.0	13
1196	Siglec receptors as new immune checkpoints in cancer. Molecular Aspects of Medicine, 2023, 90, 101112.	2.7	25
1197	Pyroptosis Remodeling Tumor Microenvironment to Enhance Pancreatic Cancer Immunotherapy Driven by Membrane Anchoring Photosensitizer. Advanced Science, 2022, 9, .	5.6	48

#	Article	IF	Citations
1198	Effector Th1 cells under <scp>PD</scp>â€1 and <scp>CTLA</scp>â€4 checkpoint blockade abrogate the upregulation of multiple inhibitory receptors and byâ€pass exhaustion. Immunology, 2022, 167, 640-650.	2.0	3
1199	Nanoformulations of Plant-Derived Compounds as Emerging Therapeutic Approach for Colorectal Cancer. Current Drug Delivery, 2023, 20, 1067-1094.	0.8	2
1200	Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors. Cancer Discovery, 2022, 12, 2606-2625.	7.7	69
1201	Neoantigenâ€based cancer vaccination using chimeric RNAâ€loaded dendritic cellâ€derived extracellular vesicles. Journal of Extracellular Vesicles, 2022, 11, .	5.5	18
1202	Complete response to pembrolizumab in a patient with recurrent and metastatic urothelial bladder carcinoma reflecting coexisting sarcomatoid subtype and glandular differentiation: a case report. International Cancer Conference Journal, 2023, 12, 24-30.	0.2	1
1203	The expression and significance of efferocytosis and immune checkpoint related molecules in pancancer samples and the correlation of their expression with anticancer drug sensitivity. Frontiers in Pharmacology, 0, 13, .	1.6	4
1204	The role of matrix stiffness in cancer stromal cell fate and targeting therapeutic strategies. Acta Biomaterialia, 2022, 150, 34-47.	4.1	11
1205	Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating the Pi3K/AKT pathway through the Serpinc1 gene. Frontiers in Oncology, 0, 12, .	1.3	5
1206	Prognostic alternative splicing events related splicing factors define the tumor microenvironment and pharmacogenomic landscape in lung adenocarcinoma. Aging, 2022, 14, 6689-6715.	1.4	2
1207	Camptothesome elicits immunogenic cell death to boost colorectal cancer immune checkpoint blockade. Journal of Controlled Release, 2022, 349, 929-939.	4.8	20
1208	Systematic pan-cancer analysis identifies APOC1 as an immunological biomarker which regulates macrophage polarization and promotes tumor metastasis. Pharmacological Research, 2022, 183, 106376.	3.1	22
1209	Combination of microtubule targeting agents with other antineoplastics for cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188777.	3.3	12
1210	Identification of necroptosis-related signature and tumor microenvironment infiltration characteristics in lung adenocarcinoma. Lung Cancer, 2022, 172, 75-85.	0.9	2
1211	Nanoformulations mediated metastasis brake in cancer therapy via photodynamic-enhanced ferroptosis and regional inflammation management. Chemical Engineering Journal, 2023, 451, 138585.	6.6	5
1212	On-demand integrated nano-engager converting cold tumors to hot via increased DNA damage and dual immune checkpoint inhibition. Acta Pharmaceutica Sinica B, 2023, 13, 1740-1754.	5.7	5
1213	Suppression of high mobility group box 1 in <scp>B16F10</scp> tumor does not inhibit the induction of neoantigenâ€specific T cells. Cancer Science, 0, , .	1.7	1
1214	A single-beam of light priming the immune responses and boosting cancer photoimmunotherapy. Journal of Controlled Release, 2022, 350, 734-747.	4.8	2
1215	Tumor immunotherapy boosted by R837 nanocrystals through combining chemotherapy and mild hyperthermia. Journal of Controlled Release, 2022, 350, 841-856.	4.8	15

#	Article	IF	Citations
1216	Igniting Hope for Tumor Immunotherapy: Promoting the â€œHot and Coldâ€•Tumor Transition. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211207.	0.6	11
1217	Autophagy-inducing nutritional interventions in experimental and clinical oncology. International Review of Cell and Molecular Biology, 2022, , 125-158.	1.6	4
1218	An assembly-inducing PDC enabling the efficient nuclear delivery of nucleic acid for cancer stem-like cell suppression. Nanoscale, 2022, 14, 15384-15392.	2.8	3
1219	Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. Theranostics, 2022, 12, 6422-6436.	4.6	36
1220	The role of chemotherapy in the treatment of advanced appendiceal cancers: summary of the literature and future directions. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211124.	1.4	5
1221	Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development. Journal of Cancer Research and Clinical Oncology, 2023, 149, 4047-4061.	1.2	2
1222	Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy. Molecules, 2022, 27, 5607.	1.7	12
1223	Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches. Pharmaceutics, 2022, 14, 1811.	2.0	9
1224	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. Cancers, 2022, 14, 4192.	1.7	6
1225	CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy. OncoImmunology, 2022, 11, .	2.1	22
1226	Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nature Medicine, 2022, 28, 1872-1882.	15.2	60
1227	Exploring dendrimer-based drug delivery systems and their potential applications in cancer immunotherapy. European Polymer Journal, 2022, 177, 111471.	2.6	39
1228	Mismatch Repair Deficiency and Microsatellite Instability. Encyclopedia, 2022, 2, 1559-1576.	2.4	9
1229	Neospora caninum inhibits tumor development by activating the immune response and destroying tumor cells in a B16F10 melanoma model. Parasites and Vectors, 2022, 15, .	1.0	6
1230	Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas. BMC Cancer, 2022, 22, .	1.1	1
1231	Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after â€œIFN-Î³ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancerâ€• British Journal of Cancer, 2023, 128, 461-467.	2.9	9
1234	Bibliometric analysis of the global research development of bone metastases in prostate cancer: A 22-year study. Frontiers in Oncology, 0, 12, .	1.3	1
1235	Pyroptosis patterns of colon cancer could aid to estimate prognosis, microenvironment and immunotherapy: evidence from multi-omics analysis. Aging, 2022, 14, 7547-7567.	1.4	1

#	Article	IF	Citations
1236	Transcriptome profiles of fatty acid metabolism-related genes and immune infiltrates identify hot tumors for immunotherapy in cutaneous melanoma. Frontiers in Genetics, 0, 13, .	1.1	1
1237	Construction of a cancer-associated fibroblasts-related long non-coding RNA signature to predict prognosis and immune landscape in pancreatic adenocarcinoma. Frontiers in Genetics, 0, 13, .	1.1	11
1238	Comprehensive analyses of a tumor-infiltrating lymphocytes-related gene signature regarding the prognosis and immunologic features for immunotherapy in bladder cancer on the basis of WGCNA. Frontiers in Immunology, 0, 13, .	2.2	4
1239	Prognostic value of immune phenotype and PD-L1 status in recurrent or metastatic renal cell carcinoma: an exploratory analysis of the ARCHERY study. Pathology, 2022, , .	0.3	0
1240	Pyroptosis: a novel signature to predict prognosis and immunotherapy response in gliomas. Human Cell, 2022, 35, 1976-1992.	1.2	2
1241	Tumor-associated macrophages are shaped by intratumoral high potassium via Kir2.1. Cell Metabolism, 2022, 34, 1843-1859.e11.	7.2	22
1242	Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). , 2022, 10, e005413.		6
1243	Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study. Cancers, 2022, 14, 4346.	1.7	4
1244	Adenosinergic axis and immune checkpoint combination therapy in tumor: A new perspective for immunotherapy strategy. Frontiers in Immunology, 0, 13, .	2.2	4
1245	Advances on the roles of tenascin-C in cancer. Journal of Cell Science, 2022, 135, .	1.2	14
1246	Selfâ€Splittable Transcytosis Nanoraspberry for NIRâ€II Photoâ€Immunometabolic Cancer Therapy in Deep Tumor Tissue. Advanced Science, 2022, 9, .	5.6	14
1247	T cell proliferation-related genes: Predicting prognosis, identifying the cold and hot tumors, and guiding treatment in clear cell renal cell carcinoma. Frontiers in Genetics, 0, 13, .	1.1	0
1248	N7-methylguanosine-related lncRNAs: Distinction between hot and cold tumors and construction of predictive models in colon adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	1
1249	Nanosized drug delivery systems modulate the immunosuppressive microenvironment to improve cancer immunotherapy. Acta Pharmacologica Sinica, 2022, 43, 3045-3054.	2.8	9
1250	Gene signature of m6A-related targets to predict prognosis and immunotherapy response in ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 593-608.	1.2	6
1251	Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma. Frontiers in Immunology, 0, 13, .	2.2	10
1252	Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis. , 2022, 19, 1153-1167.		6
1253	Mechanism and strategies of immunotherapy resistance in colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	13

#	Article	IF	Citations
1254	Characterization of glucose metabolism in breast cancer to guide clinical therapy. Frontiers in Surgery, 0, 9, .	0.6	3
1255	The Immune Contexture of Liposarcoma and Its Clinical Implications. Cancers, 2022, 14, 4578.	1.7	6
1256	Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis. British Journal of Cancer, 0, , .	2.9	2
1257	IFN-Î³ enhances the antitumor activity of attenuated salmonella-mediated cancer immunotherapy by increasing M1 macrophage and CD4 and CD8 T cell counts and decreasing neutrophil counts. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	3
1258	Identification of tumor antigens and immune subtypes in lung squamous cell carcinoma for mRNA vaccine development. Journal of Thoracic Disease, 2022, 14, 3517-3530.	0.6	4
1259	Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment. Frontiers in Immunology, 0, 13, .	2.2	12
1260	Autophagy in Cancer Immunotherapy. Cells, 2022, 11, 2996.	1.8	17
1261	Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours. Nature Communications, 2022, 13, .	5.8	2
1262	Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns Hot. Cancers, 2022, 14, 4701.	1.7	12
1263	Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma. Frontiers in Immunology, 0, 13, .	2.2	19
1264	Comprehensive analysis of the prognostic signature and tumor microenvironment infiltration characteristics of cuproptosis-related lncRNAs for patients with colon adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	6
1265	PTPN2 in the Immunity and Tumor Immunotherapy: A Concise Review. International Journal of Molecular Sciences, 2022, 23, 10025.	1.8	4
1266	Identification of Warning Transition Points from Hepatitis B to Hepatocellular Carcinoma Based on Mutation Accumulation for the Early Diagnosis and Potential Drug Treatment of HBV-HCC. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-29.	1.9	0
1267	Protein Profiling of Breast Carcinomas Reveals Expression of Immune-Suppressive Factors and Signatures Relevant for Patient Outcome. Cancers, 2022, 14, 4542.	1.7	0
1269	In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response. Nature Communications, 2022, 13, .	5.8	15
1270	Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer. Frontiers in Genetics, 0, 13, .	1.1	1
1271	Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice. Heliyon, 2022, 8, e10775.	1.4	0
1272	Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	22

#	Article	IF	Citations
1273	Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFÎ²) provides significant antitumor efficacy in immune checkpoint resistant models. OncoImmunology, 2022, 11, .	2.1	6
1274	MTAP deficiency contributes to immune landscape remodeling and tumor evasion. Immunology, 0, , .	2.0	1
1275	Importance of temperature on immunoâ€metabolic regulation and cancer progression. FEBS Journal, 2024, 291, 832-845.	2.2	3
1276	Platelet membrane camouflaged <scp>AIEgen</scp>â€mediated photodynamic therapy improves the effectiveness of <scp>antiâ€PDâ€L1</scp> immunotherapy in largeâ€burden tumors. Bioengineering and Translational Medicine, 2023, 8, .	3.9	8
1277	Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients. OncoImmunology, 2022, 11, .	2.1	1
1278	Technology meets TILs: Deciphering TÂcell function in the -omics era. Cancer Cell, 2023, 41, 41-57.	7.7	17
1279	Natural killer cell-related prognosis signature characterizes immune landscape and predicts prognosis of HNSCC. Frontiers in Immunology, 0, 13, .	2.2	62
1281	Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization. , 2022, 10, e005103.		10
1282	Immunotherapies catering to the unmet medical need of cold colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	8
1283	Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed. Frontiers in Immunology, 0, 13, .	2.2	8
1284	DKK1 Promotes Tumor Immune Evasion and Impedes Antiâ€“PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer. Cancer Immunology Research, 2022, 10, 1506-1524.	1.6	21
1285	Artificial intelligence for quantifying Crohnâ€™s-like lymphoid reaction and tumor-infiltrating lymphocytes in colorectal cancer. Computational and Structural Biotechnology Journal, 2022, 20, 5586-5594.	1.9	1
1286	Magnetic Nanodroplets for Enhanced Deep Penetration of Solid Tumors and Simultaneous Magnetothermalâ€Sensitized Immunotherapy against Tumor Proliferation and Metastasis. Advanced Healthcare Materials, 2022, 11, .	3.9	10
1287	Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy. Seminars in Cancer Biology, 2022, 86, 117-125.	4.3	30
1288	Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead. Cancer Letters, 2022, 550, 215937.	3.2	6
1289	Cancer Immunotherapy Clinical Trials. , 2022, , 1-24.		0
1290	Cancer Immunodiagnosis in Upper Gastrointestinal Cancers. , 2022, , 1-33.		0
1291	Prognostic and Immunological Role of STK38 across Cancers: Friend or Foe?. International Journal of Molecular Sciences, 2022, 23, 11590.	1.8	2

#	Article	IF	Citations
1292	Epitope Mapping of an Anti-Mouse CXCR6 Monoclonal Antibody (Cx₆Mab-1) Using the 2â€‰Ã—â€‰Alanine Scanning Method. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2022, 41, 275-278.	1.8	7
1293	Granzyme B Turns Nanoparticle Fluorescence â€œOnâ€•for Imaging Cytotoxic T Lymphocyte Activity in Vivo. ACS Nano, 2022, 16, 19328-19334.	7.3	23
1294	Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy. Journal of Hematology and Oncology, 2022, 15, .	6.9	35
1295	A Hybrid Discreteâ€“Continuum Modelling Approach to Explore the Impact of T-Cell Infiltration on Anti-tumour Immune Response. Bulletin of Mathematical Biology, 2022, 84, .	0.9	3
1296	How Risk Factors Affect Head and Neck Squamous Cell Carcinoma (HNSCC) Tumor Immune Microenvironment (TIME): Their Influence on Immune Escape Mechanisms and Immunotherapy Strategy. Biomedicines, 2022, 10, 2498.	1.4	6
1297	Activating Nanomedicines with Electromagnetic Energy for Deepâ€Tissue Induction of Immunogenic Cell Death in Cancer Immunotherapy. Small Methods, 2023, 7, .	4.6	11
1298	Cell Component and Function of Tumor Microenvironment in Thyroid Cancer. International Journal of Molecular Sciences, 2022, 23, 12578.	1.8	8
1299	Combined Immunotherapy and Targeted Therapies for Cancer Treatment: recent advances and future perspectives. Current Cancer Drug Targets, 2022, 23, .	0.8	0
1300	A novel inflammatory signature for evaluating immune microenvironment status in soft tissue sarcoma. Frontiers in Oncology, 0, 12, .	1.3	0
1301	Identification of a novel ferroptosis-related gene signature associated with prognosis, the immune landscape, and biomarkers for immunotherapy in ovarian cancer. Frontiers in Pharmacology, 0, 13, .	1.6	1
1302	Mannose and Hyaluronic Acid Dual-Modified Iron Oxide Enhances Neoantigen-Based Peptide Vaccine Therapy by Polarizing Tumor-Associated Macrophages. Cancers, 2022, 14, 5107.	1.7	6
1303	Modified hollow mesoporous silica nanoparticles as immune adjuvant-nanocarriers for photodynamically enhanced cancer immunotherapy. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	2
1304	Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	11
1305	Inhibition of HCK in myeloid cells restricts pancreatic tumor growth and metastasis. Cell Reports, 2022, 41, 111479.	2.9	8
1306	Cancer immunotherapy strategies that target the cGAS-STING pathway. Frontiers in Immunology, 0, 13, .	2.2	8
1307	Construction of m6A-based prognosis signature and prediction for immune and anti-angiogenic response. Frontiers in Molecular Biosciences, 0, 9, .	1.6	6
1308	Spatial Profiling of the Prostate Cancer Tumor Microenvironment Reveals Multiple Differences in Gene Expression and Correlation with Recurrence Risk. Cancers, 2022, 14, 4923.	1.7	3
1309	Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy. Acta Biomaterialia, 2022, 154, 401-411.	4.1	3

#	Article	IF	Citations
1310	Dissecting the Immunological Profiles in NSD3-Amplified LUSC through Integrative Multi-Scale Analyses. Cancers, 2022, 14, 4997.	1.7	3
1311	MARCH1 as a novel immune-related prognostic biomarker that shapes an inflamed tumor microenvironment in lung adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	1
1312	Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer. Cancers, 2022, 14, 4885.	1.7	5
1313	The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology. Animals, 2022, 12, 2661.	1.0	2
1314	Identification of Immune and Hypoxia Risk Classifier to Estimate Immune Microenvironment and Prognosis in Cervical Cancer. Journal of Oncology, 2022, 2022, 1-20.	0.6	2
1315	Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype. Journal of Pathology, 2023, 259, 103-114.	2.1	8
1316	Comprehensive Analysis and Validation of Solute Carrier Family 25 (SLC25) and Its Correlation with Immune Infiltration in Pan-Cancer. BioMed Research International, 2022, 2022, 1-23.	0.9	3
1317	Enhancing the Efficiency of Mild-Temperature Photothermal Therapy for Cancer Assisting with Various Strategies. Pharmaceutics, 2022, 14, 2279.	2.0	16
1318	Necroptosis-related lncRNAs: Combination of bulk and single-cell sequencing reveals immune landscape alteration and a novel prognosis stratification approach in lung adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	0
1319	Pathology of Immunotherapy-induced Responses in Cutaneous Melanoma: Current Evidences and Future Perspectives. Advances in Anatomic Pathology, 2023, 30, 218-229.	2.4	2
1320	Comprehensive Characterization of the Regulatory Landscape of Adrenocortical Carcinoma: Novel Transcription Factors and Targets Associated with Prognosis. Cancers, 2022, 14, 5279.	1.7	5
1322	An <scp>iRGD</scp>â€conjugated photothermal therapyâ€responsive gold nanoparticle system carrying <scp>siCDK7</scp> induces necroptosis and immunotherapeutic responses in lung adenocarcinoma. Bioengineering and Translational Medicine, 2023, 8, .	3.9	2
1323	Targeting the regulation of aberrant protein production pathway in gastrointestinal cancer treatment. Frontiers in Oncology, 0, 12, .	1.3	2
1324	PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis. Journal of Inflammation Research, 0, Volume 15, 6031-6046.	1.6	0
1325	Aggregationâ€Inducedâ€Emission Photosensitizerâ€Loaded Nanoâ€Superartificial Dendritic Cells with Directly Presenting Tumor Antigens and Reversed Immunosuppression for Photodynamically Boosted Immunotherapy. Advanced Materials, 2023, 35, .	11.1	16
1327	Natural products targeting glycolysis in cancer. Frontiers in Pharmacology, 0, 13, .	1.6	4
1328	Understanding the Immunoenvironment of Primary Liver Cancer: A Histopathology Perspective. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1149-1169.	1.8	3
1329	A Dualâ€Locked Tandem Fluorescent Probe for Imaging of Pyroptosis in Cancer Chemoâ€Immunotherapy. Advanced Materials, 2023, 35, .	11.1	14

#	Article	IF	Citations
1330	Pyroptosis predicts immunotherapy outcomes across multiple cancer types. Clinical Immunology, 2022, 245, 109163.	1.4	7
1331	Targeting STING for cancer immunotherapy: From mechanisms to translation. International Immunopharmacology, 2022, 113, 109304.	1.7	11
1332	The emerging roles of exosome-derived noncoding RNAs in the tumor immune microenvironment and their future applications. Biomedicine and Pharmacotherapy, 2022, 156, 113863.	2.5	5
1333	Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer. Gynecologic Oncology Reports, 2022, 44, 101084.	0.3	5
1334	The thin red line between the immune system and cancer evolution. Translational Oncology, 2023, 27, 101555.	1.7	1
1335	Immature and mature antibodies as defenders against cancer. , 0, , .		1
1336	MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis. Nature Cancer, 2022, 3, 1367-1385.	5.7	24
1337	Altered expression of m1A regulatory genes is associated with oncogenic pathways, overall survival, and infiltration of immune cells in diverse human cancers. Genes and Diseases, 2022, , .	1.5	0
1338	High-level of intratumoral GITR+ CD4 TÂcells associate with poor prognosis in gastric cancer. IScience, 2022, 25, 105529.	1.9	4
1339	Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma. Clinical Cancer Research, 2023, 29, 659-666.	3.2	6
1340	Insight into Classification and Risk Stratification of Head and Neck Squamous Cell Carcinoma in Era of Emerging Biomarkers with Focus on Histopathologic Parameters. Cancers, 2022, 14, 5514.	1.7	2
1341	CX3CL1 promotes cell sensitivity to ferroptosis and is associated with the tumor microenvironment in clear cell renal cell carcinoma. BMC Cancer, 2022, 22, .	1.1	6
1342	The role of stem cells in small-cell lung cancer: Evidence from chemoresistance to immunotherapy. Seminars in Cancer Biology, 2022, 87, 160-169.	4.3	15
1343	Single-cell transcriptome analysis of tumor immune microenvironment characteristics in colorectal cancer liver metastasis. Annals of Translational Medicine, 2022, 10, 1170-1170.	0.7	7
1344	Preclinical Study of Plasmodium Immunotherapy Combined with Radiotherapy for Solid Tumors. Cells, 2022, 11, 3600.	1.8	1
1345	cGAS-STING Pathway as the Target of Immunotherapy for Lung Cancer. Current Cancer Drug Targets, 2023, 23, 354-362.	0.8	2
1346	Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer. International Journal of Nanomedicine, 0, Volume 17, 5209-5227.	3.3	5
1347	Pan-cancerÂanalysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma. Respiratory Research, 2022, 23, .	1.4	3

#	Article	IF	Citations
1348	CAR T-cells for colorectal cancer immunotherapy: Ready to go?. Frontiers in Immunology, 0, 13, .	2.2	11
1349	Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics. Drug Discovery Today, 2022, , 103440.	3.2	1
1350	Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment. Science Translational Medicine, 2022, 14, .	5.8	57
1351	Combined pembrolizumab and bevacizumab therapyÂeffectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model. Cancer Immunology, Immunotherapy, 2023, 72, 1169-1181.	2.0	4
1353	In-situ clickable prodrug nanoplatform locally activates T lymphocytes to potentiate cancer immunotherapy. Nano Today, 2022, 47, 101661.	6.2	4
1354	Potential impact of WTAP and YTHDF2 on tumor immunity in lung adenocarcinoma. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Ov	0.4	0
1355	BSAâ€AIE Nanoparticles with Boosted ROS Generation for Immunogenic Cell Death Immunotherapy of Multiple Myeloma. Advanced Materials, 2023, 35, .	11.1	21
1357	Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15RÎ± complex. Antibody Therapeutics, 2023, 6, 38-48.	1.2	0
1358	Repeated photodynamic therapy mediates the abscopal effect through multiple innate and adaptive immune responses with and without immune checkpoint therapy. Biomaterials, 2023, 292, 121918.	5.7	13
1359	Comprehensive analysis of cuproptosis-related lncRNAs to predict prognosis and immune infiltration characteristics in colorectal cancer. Frontiers in Genetics, 0, 13, .	1.1	4
1360	Atezolizumab plus tivozanib for immunologically cold tumor types: theÂIMMCO-1 trial. Future Oncology, 0, , .	1.1	0
1361	New Approaches Targeting Immuno-oncology and Tumor Microenvironment. , 2023, , 63-90.		0
1362	Intra-Tumor Cell Heterogeneity: Different Immune Responses for Different Cells. , 2022, , 1-26.		0
1363	Boosting cancer immunotherapy by biomineralized nanovaccine with ferroptosis-inducing and photothermal properties. Biomaterials Science, 2023, 11, 518-532.	2.6	7
1364	Dynamic tagging to drive arginine nano-assembly to metabolically potentiate immune checkpoint blockade therapy. Biomaterials, 2023, 292, 121938.	5.7	11
1365	A nanoformulation for immunosuppression reversal and broad-spectrum self-amplifying antitumor ferroptosis-immunotherapy. Biomaterials, 2023, 292, 121936.	5.7	9
1366	Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade. Drug Resistance Updates, 2023, 66, 100907.	6.5	30
1367	Overcoming oxygen heterogeneity of tumor microenvironments to boost cancer immunotherapy by oxygen-switchable ROS/RNS nanogenerators. Nano Today, 2023, 48, 101696.	6.2	4

#	Article	IF	Citations
1368	The Tumor Microenvironment in Hepatocellular Carcinoma. , 2022, , 107-137.		0
1369	The Tumor Microenvironment in Pancreatic Cancer and Challenges to Immunotherapy. , 2022, , 381-401.		0
1370	Identification of genes and cellular response factors related to immunotherapy response in mismatch repair-proficient colorectal cancer: a bioinformatics analysis. Journal of Gastrointestinal Oncology, 2022, .	0.6	0
1372	Hypoxia Alleviated and One Photo-Triggered Thermal/Dynamic Nanoplatform for Immunogenic Cell Death-Initiated Cancer Immunotherapy. ACS Applied Bio Materials, 2022, 5, 5865-5876.	2.3	3
1373	p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer. F1000Research, 0, 11, 330.	0.8	2
1374	Combination of Pembrolizumab and Stereotactic Body Radiation Therapy in Recurrent Metastatic Penile Squamous Cell Carcinoma: A Case Study. Biomedicines, 2022, 10, 3033.	1.4	1
1375	Potential of Theranostics in Visualisation of the Tumour Microenvironment and Elimination of Its Immunosuppressive Components. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products, 2022, 12, 425-443.	0.1	1
1376	Cell2Grid: an efficient, spatial, and convolutional neural network-ready representation of cell segmentation data. Journal of Medical Imaging, 2022, 9, .	0.8	0
1377	Prognostic value of CD8⁺ tumorâ€infiltrating TÂcells in patients with breast cancer: A systematic review and metaâ€analysis. Oncology Letters, 2022, 25, .	0.8	7
1378	Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy. Current Pharmaceutical Design, 2023, 29, 60-78.	0.9	1
1379	PDâ€L1 Aptamerâ€Functionalized Metalâ€“Organic Framework Nanoparticles for Robust Photoâ€Immunotherapy against Cancer with Enhanced Safety. Angewandte Chemie - International Edition, 2023, 62, .	7.2	16
1380	Screening of an individualized treatment strategy for an advanced gallbladder cancer using patient-derived tumor xenograft and organoid models. Frontiers in Oncology, 0, 12, .	1.3	1
1381	Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	6
1382	DDIT4 promotes malignancy of head and neck squamous cell carcinoma. Molecular Carcinogenesis, 2023, 62, 332-347.	1.3	9
1383	Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. International Journal of Molecular Sciences, 2023, 24, 41.	1.8	6
1384	Tetrahedral DNA Nanostructure with Interferon Stimulatory DNA Delivers Highly Potent Toxins and Activates the cGASâ€STING Pathway for Robust Chemotherapy and Immunotherapy. Advanced Materials, 2023, 35, .	11.1	24
1385	Myeloid-derived suppressor cells (MDSCs) depletion by cabozantinib improves the efficacy of anti-HER2 antibody-based immunotherapy in a 4T1-HER2 murine breast cancer model. International Immunopharmacology, 2022, 113, 109470.	1.7	8
1386	Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator. Acta Pharmaceutica Sinica B, 2023, 13, 3106-3120.	5.7	1

#	Article	IF	Citations
1387	Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance. Frontiers in Immunology, 0, 13, .	2.2	6
1388	Comparative RNA-Sequencing Analysis Reveals High Complexity and Heterogeneity of Transcriptomic and Immune Profiles in Hepatocellular Carcinoma Tumors of Viral (HBV, HCV) and Non-Viral Etiology. Medicina (Lithuania), 2022, 58, 1803.	0.8	0
1389	Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells. , 2022, 10, e005200.		0
1390	NanoagonistâEMediated GSDMEâEDependent Pyroptosis Remodels the Inflammatory Microenvironment for Tumor Photoimmunotherapy. Advanced Functional Materials, 2023, 33, .	7.8	14
1391	Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	1
1392	Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy. Orthopaedic Surgery, 0, , .	0.7	3
1393	PDâEL1 AptamerâEFunctionalized MetalâE"Organic Framework Nanoparticles for Robust PhotoâEImmunotherapy against Cancer with Enhanced Safety. Angewandte Chemie, 2023, 135, .	1.6	1
1394	Leukocyte CH25H is a potential diagnostic and prognostic marker for lung adenocarcinoma. Scientific Reports, 2022, 12, .	1.6	5
1395	Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression. ESMO Open, 2022, 7, 100636.	2.0	4
1396	Discrete and continuum models for the coevolutionary dynamics between CD8+ cytotoxic T lymphocytes and tumour cells. Mathematical Medicine and Biology, 0, , .	0.8	2
1397	Potential of Z-100, extracted from Mycobacterium tuberculosis strain Aoyama B, as a hot tumor inducer. Cancer Cell International, 2022, 22, .	1.8	0
1398	The role of systemic inflammatory response index (SIRI) and tumor-infiltrating lymphocytes (TILs) in the prognosis of patients with laryngeal squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	4
1399	Radiosensitivity is associated with antitumor immunity in estrogen receptor-negative breast cancer. Breast Cancer Research and Treatment, 2023, 197, 479-488.	1.1	2
1400	Reduced MHC Class I and II Expression in HPVâ^'Negative vs. HPVâ^'Positive Cervical Cancers. Cells, 2022, 11, 3911.	1.8	6
1401	Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial. Nature Medicine, 2022, 28, 2601-2610.	15.2	34
1402	Overexpression of SMS in the tumor microenvironment is associated with immunosuppression in hepatocellular carcinoma. Frontiers in Immunology, 0, 13, .	2.2	3
1403	Ginsenoside Rg3 nanoparticles with permeation enhancing based chitosan derivatives were encapsulated with doxorubicin by thermosensitive hydrogel and anti-cancer evaluation of peritumoral hydrogel injection combined with PD-L1 antibody. Biomaterials Research, 2022, 26, .	3.2	14
1404	An immune infiltration-related long non-coding RNAs signature predicts prognosis for hepatocellular carcinoma. Frontiers in Genetics, 0, 13, .	1.1	1

#	Article	IF	Citations
1405	A pyroptosis-related gene signature for prognostic and immunological evaluation in breast cancer. Frontiers in Oncology, 0, 12, .	1.3	3
1406	Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. Nature Cancer, 2022, 3, 1513-1533.	5.7	20
1407	The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade. Frontiers in Immunology, 0, 13, .	2.2	2
1408	Comprehensive analysis identifies ARHGEF6 as a potential prognostic and immunological biomarker in lung adenocarcinoma. Computers in Biology and Medicine, 2023, 153, 106448.	3.9	3
1409	Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas. Frontiers in Immunology, 0, 13, .	2.2	1
1410	Proteomics to study cancer immunity and improve treatment. Seminars in Immunopathology, 2023, 45, 241-251.	2.8	3
1411	Piezocatalytic Medicine: An Emerging Frontier using Piezoelectric Materials for Biomedical Applications. Advanced Materials, 2023, 35, .	11.1	45
1412	Cuproptosis-related LncRNAs signature as biomarker of prognosis and immune infiltration in pancreatic cancer. Frontiers in Genetics, 0, 14, .	1.1	1
1413	Identifying Immune-Specific Subtypes of Adrenocortical Carcinoma Based on Immunogenomic Profiling. Biomolecules, 2023, 13, 104.	1.8	2
1414	Strategies for Heating Up Cold Tumors to Boost Immunotherapies. Annual Review of Cancer Biology, 2023, 7, 149-170.	2.3	10
1415	Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers. Current Opinion in Oncology, 2023, 35, 107-113.	1.1	4
1416	The abscopal effect and its implications for radiotherapy-immunotherapy combinations. Translational Cancer Research, 2023, 12, 8-12.	0.4	2
1417	Challenges and exploration for immunotherapies targeting cold colorectal cancer. World Journal of Gastrointestinal Oncology, 0, 15, 55-68.	0.8	3
1418	Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer. Cancers, 2023, 15, 418.	1.7	7
1419	Size-optimized nuclear-targeting phototherapy enhances the type I interferon response for â€œcoldâ€• tumor immunotherapy. Acta Biomaterialia, 2023, 159, 338-352.	4.1	3
1420	Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages. Cancer Cell International, 2023, 23, .	1.8	5
1421	At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. Nature Reviews Clinical Oncology, 2023, 20, 143-159.	12.5	29
1422	Expansion of interferon inducible gene pool via USP18 inhibition promotes cancer cell pyroptosis. Nature Communications, 2023, 14, .	5.8	13

#	Article	IF	Citations
1423	A Threeâ€inâ€One Nanoscale Coordination Polymer for Potent Chemoâ€Immunotherapy. Small Methods, 2023, 7, .	4.6	5
1425	Exosomes as smart drug delivery vehicles for cancer immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	19
1426	LINC00669 promotes lung adenocarcinoma growth by stimulating the Wnt/Î²â€catenin signaling pathway. Cancer Medicine, 0, , .	1.3	2
1427	The mutation in splicing factor genes correlates with unfavorable prognosis, genomic instability, anti-tumor immunosuppression and increased immunotherapy response in pan-cancer. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	0
1428	A Biodegradable Antigen Nanocapsule Promotes Antiâ€Tumor Immunity via the cGASâ€STING Pathway. Advanced Functional Materials, 2023, 33, .	7.8	3
1429	Cancer Immunotherapy Elicited by Immunogenic Cell Death Based on Smart Nanomaterials. Small Methods, 2023, 7, .	4.6	8
1430	Nonredundant Upregulation of CD112R (PVRIG) and PD-1 on Cytotoxic T Lymphocytes Located in T Cell Nests of Colorectal Cancer. Modern Pathology, 2023, 36, 100089.	2.9	3
1431	Association of Sialic Acidâ€“Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy. JAMA Network Open, 2023, 6, e2250965.	2.8	3
1432	Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity. Nature Communications, 2023, 14, .	5.8	20
1433	Myeloid-derived suppressor cells in head and neck squamous cell carcinoma. International Review of Cell and Molecular Biology, 2023, , 33-92.	1.6	2
1434	Anoikis patterns exhibit distinct prognostic and immune landscapes in Osteosarcoma. International Immunopharmacology, 2023, 115, 109684.	1.7	6
1435	CRISPR/Cas9-based genome editing for multimodal synergistic cancer nanotherapy. Nano Today, 2023, 48, 101734.	6.2	5
1436	Photothermic therapy with cuttlefish ink-based nanoparticles in combination with anti-OX40 mAb achieve remission of triple-negative breast cancer. International Immunopharmacology, 2023, 115, 109622.	1.7	3
1437	Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations. Pharmaceutics, 2023, 15, 112.	2.0	1
1438	Balancing the Risk of Adverse Events against the Efficacy of Immunotherapy in Advanced Thymic Epithelial Tumors. Cancers, 2023, 15, 289.	1.7	2
1439	Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario. Cancers, 2023, 15, 246.	1.7	8
1440	Nanoengineered drug delivery in cancer immunotherapy for overcoming immunosuppressive tumor microenvironment. Drug Delivery and Translational Research, 2023, 13, 2015-2031.	3.0	2
1441	IFNÎ³ signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity ofÂintra-tumoral stem-like T cells. Nature Communications, 2023, 14, .	5.8	12

#	Article	IF	Citations
1442	Imaging phenotypes from <scp>MRI</scp> for the prediction of glioma immune subtypes from <scp>RNA</scp> sequencing: A multicenter study. Molecular Oncology, 2023, 17, 629-646.	2.1	3
1443	Immunogenic Cell Death in Cancer. , 2023, , .		0
1444	Membrane-tethered activation design of a photosensitizer boosts systemic antitumor immunityviapyroptosis. Chemical Science, 2023, 14, 2562-2571.	3.7	7
1445	Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors: A Promising Option. Immuno, 2023, 3, 37-56.	0.6	2
1446	Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma. Nature Communications, 2023, 14, .	5.8	10
1447	Advances in Natural Killer Cells and Immunotherapy for Gastric Cancer. , 0, , .		0
1448	Immunomodulatory effect of locoregional therapy in the tumor microenvironment. Molecular Therapy, 2023, 31, 951-969.	3.7	8
1449	A signature-based classification of lung adenocarcinoma that stratifies tumor immunity. Frontiers in Oncology, 0, 12, .	1.3	0
1450	Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Antiâ€“PD-1 Antibody. Molecular Cancer Therapeutics, 2023, 22, 499-510.	1.9	3
1451	Metabolic rearrangements and intratumoral heterogeneity for immune response in hepatocellular carcinoma. Frontiers in Immunology, 0, 14, .	2.2	1
1452	Features of the microenvironment of oncourological tumors. Urologicheskie Vedomosti, 2023, 12, 313-331.	0.4	1
1453	<scp>IFNâ€³â€STAT1</scp> â€mediated <scp>NK2R</scp> expression is involved in the induction of antitumor effector <scp>CD8</scp> ⁺ T cells in vivo. Cancer Science, 0, , .	1.7	4
1454	Comprehensive Analysis of Necroptosis Landscape in Skin Cutaneous Melanoma for Appealing its Implications in Prognosis Estimation and Microenvironment Status. Journal of Personalized Medicine, 2023, 13, 245.	1.1	1
1455	Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma. Cancers, 2023, 15, 863.	1.7	6
1456	Engineered Living Bacteriophage-Enabled Self-Adjuvanting Hydrogel for Remodeling Tumor Microenvironment and Cancer Therapy. Nano Letters, 2023, 23, 1219-1228.	4.5	7
1457	Intertumoral Differences Dictate the Outcome of TGF-Î² Blockade on the Efficacy of Viro-Immunotherapy. Cancer Research Communications, 2023, 3, 325-337.	0.7	2
1458	The role of macrophages-mediated communications among cell compositions of tumor microenvironment in cancer progression. Frontiers in Immunology, 0, 14, .	2.2	6
1459	Optimization of cancer immunotherapy on the basis of programmed death ligandâ€1 distribution and function. British Journal of Pharmacology, 2024, 181, 257-272.	2.7	4

#	Article	IF	Citations
1460	mRNA-Based Therapeutics in Cancer Treatment. Pharmaceutics, 2023, 15, 622.	2.0	11
1462	Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report. World Journal of Surgical Oncology, 2023, 21, .	0.8	2
1463	YBX1-interacting small RNAs and RUNX2 can be blocked in primary bone cancer using CADD522. Journal of Bone Oncology, 2023, 39, 100474.	1.0	4
1464	Highlights into historical and current immune interventions for cancer. International Immunopharmacology, 2023, 117, 109882.	1.7	2
1465	Discovery of Podofilox as a Potent cGAMPâ€“STING Signaling Enhancer with Antitumor Activity. Cancer Immunology Research, 2023, 11, 583-599.	1.6	3
1466	Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial. Clinical Cancer Research, 2023, 29, 2456-2465.	3.2	1
1467	Nano based-oncolytic viruses for cancer therapy. Critical Reviews in Oncology/Hematology, 2023, 185, 103980.	2.0	8
1468	A hierarchical tumor-targeting strategy for eliciting potent antitumor immunity against triple negative breast cancer. Biomaterials, 2023, 296, 122067.	5.7	5
1469	Synergistic anti-cancer and attenuation effects of thymosin on chemotherapeutic drug vinorelbine in tumor-bearing zebrafish. Biomedicine and Pharmacotherapy, 2023, 162, 114633.	2.5	0
1470	Multi-omics profiling of papillary thyroid microcarcinoma reveals different somatic mutations and a unique transcriptomic signature. Journal of Translational Medicine, 2023, 21, .	1.8	2
1471	Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment. Biomedicine and Pharmacotherapy, 2023, 161, 114567.	2.5	5
1474	Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor Immune Microenvironment and Reflects the Prognosis of Bladder Cancer. Laboratory Investigation, 2023, 103, 100040.	1.7	1
1475	A Novel Triâ€Functional Liposome Reâ€Educates â€œCold Tumorâ€•and Abrogates Tumor Growth by Synergizing Autophagy Inhibition and PDâ€Ł1 Blockade. Advanced Healthcare Materials, 2023, 12, .	3.9	3
1476	Targeting of TAMs with freeze-dried monosialotetrahexosylganglioside and sialic acid-octadecylamine co-modified liposomes remodels the tumor microenvironment and enhances anti-tumor activity. European Journal of Pharmaceutics and Biopharmaceutics, 2023, 184, 50-61.	2.0	0
1477	Randomised phase II trial of stereotactic body radiotherapy in combination withcheckpoint inhibitors in metastatic castration-resistantprostate cancer (CheckPRO): a study protocol. BMJ Open, 2023, 13, e063500.	0.8	1
1478	Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity. , 2023, 11, e005545.		10
1480	IgG4 expression and IgG4/IgG ratio in the tumour invasion front predict long-term outcomes for patients with intrahepatic cholangiocarcinoma. Pathology, 2023, 55, 508-513.	0.3	2
1481	Comparison of Efficacy and Safety of First-Line Chemoimmunotherapy in Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Network Meta-Analysis. Journal of Clinical Pharmacy and Therapeutics, 2023, 2023, 1-12.	0.7	2

#	Article	IF	Citations
1482	Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nature Communications, 2023, 14, .	5.8	33
1483	Classification of Thyroid Diseases Using Machine Learning and Bayesian Graph Algorithms. IFAC-PapersOnLine, 2022, 55, 67-72.	0.5	1
1484	Genetic variants in the calcium signaling pathway participate in the pathogenesis of colorectal cancer through the tumor microenvironment. Frontiers in Oncology, 0, 13, .	1.3	3
1485	Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player. Cancers, 2023, 15, 1093.	1.7	4
1486	Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial. , 2023, 11, e005830.		9
1488	â€œColdâ€•colorectal cancer faces a bottleneck in immunotherapy. World Journal of Gastrointestinal Oncology, 0, 15, 240-250.	0.8	3
1489	Prediction of CD3 T cells and CD8 T cells expression levels in non-small cell lung cancer based on radiomic features of CT images. Frontiers in Oncology, 0, 13, .	1.3	1
1490	Photoactivatable nanoagonists chemically programmed for pharmacokinetic tuning and in situ cancer vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	11
1491	Evaluating tumor cell- and T cell-derived extracellular vesicles as potential biomarkers of cancer and immune cell competence. Expert Review of Molecular Diagnostics, 2023, 23, 109-122.	1.5	2
1492	Liposomal Delivery of MIW815 (ADU-S100) for Potentiated STING Activation. Pharmaceutics, 2023, 15, 638.	2.0	5
1493	Are charged particles a good match for combination with immunotherapy? Current knowledge and perspectives. International Review of Cell and Molecular Biology, 2023, , 1-36.	1.6	4
1495	Perioperative oncolytic virotherapy to counteract surgery-induced immunosuppression and improve outcomes in pancreatic ductal adenocarcinoma. Frontiers in Oncology, 0, 13, .	1.3	2
1496	Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance. Journal of Hepatocellular Carcinoma, 0, Volume 10, 267-279.	1.8	1
1497	LncRNA and its role in gastric cancer immunotherapy. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	2
1498	Immune surveillance of brain metastatic cancer cells is mediated by IFITM1. EMBO Journal, 2023, 42, .	3.5	2
1499	Therapeutic challenge for immunotherapy targeting cold colorectal cancer: A narrative review. World Journal of Clinical Oncology, 0, 14, 81-88.	0.9	2
1500	Effect of metabolism on the immune microenvironment of breast cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188861.	3.3	1
1502	A timeline of tumour-associated macrophage biology. Nature Reviews Cancer, 2023, 23, 238-257.	12.8	83

#	Article	IF	Citations
1503	Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome. Acta Pharmaceutica Sinica B, 2023, 13, 2176-2187.	5.7	17
1504	Construction of Two Independent RAB Family-Based Scoring Systems Based on Machine Learning Algorithms and Definition of RAB13 as a Novel Therapeutic Target for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 4335.	1.8	0
1505	Tailoring therapies to counter the divergent immune landscapes of breast cancer. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	3
1506	Promises and challenges for targeting the immunological players in the tumor micro-environment â€“ Critical determinants for NP-based therapy. OpenNano, 2023, 10, 100134.	1.8	1
1508	Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy. Frontiers in Oncology, 0, 13, .	1.3	1
1509	Artificial intelligence and digital biomarker in precision pathology guiding immune therapy selection and precision oncology. Cancer Reports, 2023, 6, .	0.6	1
1510	Confocal Microscopy for Diagnosis and Management of Cutaneous Malignancies: Clinical Impacts and Innovation. Diagnostics, 2023, 13, 854.	1.3	5
1511	Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. Cancer Immunology Research, 2023, 11, 558-569.	1.6	2
1512	An angiogenesis-related three-long non-coding ribonucleic acid signature predicts the immune landscape and prognosis in hepatocellular carcinoma. Heliyon, 2023, 9, e13989.	1.4	5
1513	Research advances of clinical application of oncolytic viruses in treatment of gynecologic cancers. Current Cancer Drug Targets, 2023, 23, .	0.8	0
1514	Metabolic classifications of renal cell carcinoma reveal intrinsic connections with clinical and immune characteristics. Journal of Translational Medicine, 2023, 21, .	1.8	2
1515	Characterization of cuproptosis identified immune microenvironment and prognosis in acute myeloid leukemia. Clinical and Translational Oncology, 2023, 25, 2393-2407.	1.2	3
1516	Deep learning in digital pathology for personalized treatment plans of cancer patients. Seminars in Diagnostic Pathology, 2023, 40, 109-119.	1.0	4
1517	Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future Challenges in Genitourinary Cancers. International Journal of Molecular Sciences, 2023, 24, 4601.	1.8	2
1518	Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancerâ€”current status and future directions. Translational Lung Cancer Research, 2023, 12, 322-336.	1.3	1
1519	Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment. Bone Research, 2023, 11, .	5.4	38
1520	Combining a machine-learning derived 4-lncRNA signature with AFP and TNM stages in predicting early recurrence of hepatocellular carcinoma. BMC Genomics, 2023, 24, .	1.2	7
1521	Simultaneous Knockdown of Immune Suppressive Markers by Tumor Microenvironment-Responsive Multifaceted Prodrug Nanomedicine. ACS Applied Materials & Interfaces, 2023, 15, 12864-12881.	4.0	2

#	Article	IF	Citations
1522	HSV: The scout and assault for digestive system tumors. Frontiers in Molecular Biosciences, 0, 10, .	1.6	0
1524	Opposite and dynamic regulation of the interferon response in metastatic and non-metastatic breast cancer. Cell Communication and Signaling, 2023, 21, .	2.7	5
1526	Are High Levels of Microsatellite Instability and Microsatellite Stability Identical in DNA Mismatch Repair-Deficient Colorectal Cancer Patients?. Canadian Journal of Gastroenterology and Hepatology, 2023, 2023, 1-6.	0.8	1
1527	Current Advances in Immune Checkpoint Therapy. , 0, , .		0
1528	cRGD-modified nanoparticles of multi-bioactive agent conjugate with pH-sensitive linkers and PD-L1 antagonist for integrative collaborative treatment of breast cancer. Nanoscale Horizons, 2023, 8, 870-886.	4.1	3
1529	Characterization of immune cell populations in syngeneic murine tumor models. Cancer Medicine, 2023, 12, 11589-11601.	1.3	1
1530	Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review. Oncology and Therapy, 0, , .	1.0	0
1531	The relationship between autophagy and PD-L1 and their role in antitumor therapy. Frontiers in Immunology, 0, 14, .	2.2	5
1532	Synthetic enforcement of STING signaling in cancer cells appropriates the immune microenvironment for checkpoint inhibitor therapy. Science Advances, 2023, 9, .	4.7	5
1533	Interplay between Signaling Pathways and Tumor Microenvironment Components: A Paradoxical Role in Colorectal Cancer. International Journal of Molecular Sciences, 2023, 24, 5600.	1.8	6
1535	Integrative analysis revealed that distinct cuprotosis patterns reshaped tumor microenvironment and responses to immunotherapy of colorectal cancer. Frontiers in Immunology, 0, 14, .	2.2	2
1536	Histone acetylation-related lncRNA: Potential biomarkers for predicting prognosis and immune response in lung adenocarcinoma, and distinguishing hot and cold tumours. Frontiers in Immunology, 0, 14, .	2.2	2
1539	PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer. Frontiers in Immunology, 0, 14, .	2.2	3
1540	Reactive oxygen species-powered cancer immunotherapy: Current status and challenges. Journal of Controlled Release, 2023, 356, 623-648.	4.8	28
1541	Re: Germline Variants Associated with Toxicity to Immune Checkpoint Blockade. European Urology, 2023, 84, 597.	0.9	0
1542	Biomarkers and Immunotherapy for Colorectal Cancer. , 0, 36, 1356-1366.		0
1543	Research Progress of Nanomedicine-Based Mild Photothermal Therapy in Tumor. International Journal of Nanomedicine, 0, Volume 18, 1433-1468.	3.3	9
1544	Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma. Frontiers in Immunology, 0, 14, .	2.2	0

#	Article	IF	Citations
1545	Arenaviruses: Old viruses present new solutions for cancer therapy. Frontiers in Immunology, 0, 14, .	2.2	1
1546	Metabolic syndrome-related prognostic index: Predicting biochemical recurrence and differentiating between cold and hot tumors in prostate cancer. Frontiers in Endocrinology, 0, 14, .	1.5	0
1547	Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study. Therapeutic Advances in Gastroenterology, 2023, 16, 175628482311606.	1.4	4
1548	Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer. Frontiers in Oncology, 0, 13, .	1.3	5
1549	DNA methylation profiling in early lung adenocarcinoma to predict response to immunotherapy. Translational Lung Cancer Research, 2023, 12, 657-660.	1.3	1
1550	Anthelmintic Drugs as Emerging Immune Modulators in Cancer. International Journal of Molecular Sciences, 2023, 24, 6446.	1.8	3
1551	Tumor Immunophenotypingâ€Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer. Advanced Science, 2023, 10, .	5.6	3
1552	Integrating single-cell and bulk RNA sequencing to develop a cancer-associated fibroblast-related signature for immune infiltration prediction and prognosis in lung adenocarcinoma. Journal of Thoracic Disease, 2023, 15, 1406-1425.	0.6	6
1553	Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment. International Journal of Molecular Sciences, 2023, 24, 6495.	1.8	6
1554	The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions. Cancers, 2023, 15, 2101.	1.7	3
1555	Quantification of 782 Plasma Peptides by Multiplexed Targeted Proteomics. Journal of Proteome Research, 2023, 22, 1630-1638.	1.8	1
1556	A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer. Genome Medicine, 2023, 15, .	3.6	2
1557	Immune Landscape of Pheochromocytoma and Paraganglioma: A Potentially Novel Avenue for Prognostic Reclassification?. Journal of Clinical Endocrinology and Metabolism, 2023, 108, e1456-e1457.	1.8	1
1558	Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma. Frontiers in Immunology, 0, 14, .	2.2	0
1559	Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut, 2023, 72, 1758-1773.	6.1	14
1560	An Endogenous Retrovirus Vaccine Encoding an Envelope with a Mutated Immunosuppressive Domain in Combination with Anti-PD1 Treatment Eradicates Established Tumours in Mice. Viruses, 2023, 15, 926.	1.5	4
1561	Machine learning-based construction of immunogenic cell death-related score for improving prognosis and response to immunotherapy in melanoma. Aging, 2023, 15, 2667-2688.	1.4	2
1562	Integrated analysis of circulating cell free nucleic acids for cancer genotyping and immune phenotyping of tumor microenvironment. Frontiers in Genetics, 0, 14, .	1.1	3

#	Article	IF	Citations
1563	Versatile biomimetic nanomedicine for treating cancer and inflammation disease. Medical Review, 2023, 3, 123-151.	0.3	0
1565	Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects. Cell Reports, 2023, 42, 112364.	2.9	0
1566	Light-activated arginine-rich peptide-modified nanoparticles for deep-penetrating chemo-photo-immunotherapy of solid tumor. Nano Research, 2023, 16, 9804-9814.	5.8	0
1567	Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager. Frontiers in Immunology, 0, 14, .	2.2	2
1568	Neoantigen-directed therapeutics in the clinic: where are we?. Trends in Cancer, 2023, 9, 503-519.	3.8	4
1569	Dynamics and specificities of T cells in cancer immunotherapy. Nature Reviews Cancer, 2023, 23, 295-316.	12.8	49
1570	Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach. Journal of Translational Medicine, 2023, 21, .	1.8	1
1571	Novel strategies for cancer immunotherapy: counter-immunoediting therapy. Journal of Hematology and Oncology, 2023, 16, .	6.9	14
1572	An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma. Cancer Cell, 2023, 41, 919-932.e5.	7.7	6
1574	Enhancedanti-tumor efficacy through a combination of intramuscularly expressed DNA vaccine and plasmid-encoded PD-1 antibody. Frontiers in Immunology, 0, 14, .	2.2	1
1575	Molecular Engineering of NIRâ€Ⅱ/Ⅱb Emitting AIEgen for Multimodal Imagingâ€Guided Photoâ€Immunotherapy. Small, 2023, 19, .	5.2	12
1576	Distinct genomic features between osteosarcomas firstly metastasing to bone and to lung. Heliyon, 2023, 9, e15527.	1.4	0
1577	m7Gâ€related genesâ€”NCBP2 and EIF4E3 determine immune contexture in head and neck squamous cell carcinoma by regulating CCL4/CCL5 expression. Molecular Carcinogenesis, 2023, 62, 1091-1106.	1.3	4
1578	Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions. Cancer Letters, 2023, 562, 216182.	3.2	15
1579	Proteolytically degradable PEG hydrogel matrix mimicking tumor immune microenvironment for 3D co-culture of lung adenocarcinoma cells and macrophages. Journal of Biomaterials Science, Polymer Edition, 2023, 34, 1981-1999.	1.9	1
1580	Methods for assessment of the tumour microenvironment and immune interactions in non-small cell lung cancer. A narrative review. Frontiers in Oncology, 0, 13, .	1.3	1
1581	Implications of the Organ-Specific Immune Environment for Immune Priming Effect of Radiotherapy in Metastatic Setting. Biomolecules, 2023, 13, 689.	1.8	0
1582	Conjugated Polymer Nanoparticles for Tumor Theranostics. Biomacromolecules, 2023, 24, 1943-1979.	2.6	5

#	Article	IF	Citations
1583	Necroptosis-related lncRNAs: establishment of a gene module and distinction between the cold and hot tumors in glioma. Frontiers in Oncology, 0, 13, .	1.3	2
1584	China special issue on gastrointestinal tumorsâ€Regulatoryâ€immunoscoreâ€”A novel indicator to guide precision adjuvant chemotherapy in colorectal cancer. International Journal of Cancer, 2023, 153, 1904-1915.	2.3	1
1585	AÂTumorâ€Microenvironmentâ€Activatable Molecular Proâ€Theranostic Agent for Photodynamic and Immunotherapy of Cancer. Advanced Materials, 2023, 35, .	11.1	14
1596	Modulating tumor mechanics with nanomedicine for cancer therapy. Biomaterials Science, 2023, 11, 4471-4489.	2.6	3
1626	Emerging evidence for adapting radiotherapy to immunotherapy. Nature Reviews Clinical Oncology, 2023, 20, 543-557.	12.5	36
1634	Engineering magnetotactic bacteria MVs to synergize chemotherapy, ferroptosis and immunotherapy for augmented antitumor therapy. Nanoscale Horizons, 0, , .	4.1	2
1662	Chromium Nanoparticles Improve Macrophage and T Cell Infiltration for Cancer Immunotherapy. , 2023, 5, 1738-1751.		2
1675	Oncolytic Virotherapy. Cancer Treatment and Research, 2023, , 105-126.	0.2	0
1679	Case Report: Clinical application of immunotherapy-based combination regimen in primary osteosarcoma of the uterus. Frontiers in Oncology, 0, 13, .	1.3	1
1684	Rational design of linkers in polymerâ€“drug conjugates. , 2023, , 39-57.		0
1703	The Promise of Immunotherapeutics and Vaccines in the Treatment of Cancer. , 2023, , 1-43.		1
1716	Drug delivery methods for cancer immunotherapy. Drug Delivery and Translational Research, 0, , .	3.0	1
1760	Stem-like exhausted and memory CD8+ T cells in cancer. Nature Reviews Cancer, 2023, 23, 780-798.	12.8	5
1786	Current status and frontier tracking of clinical trials on Metformin for cancer treatment. Journal of Cancer Research and Clinical Oncology, 2023, 149, 16931-16946.	1.2	1
1817	Camptothecin-based prodrug nanomedicines for cancer therapy. Nanoscale, 2023, 15, 17658-17697.	2.8	2
1827	CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. Experimental and Molecular Medicine, 2023, 55, 2287-2299.	3.2	7
1828	Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer. Nature Reviews Urology, 0, , .	1.9	0
1838	Immunotherapeutic strategies and immunotherapy resistance in prostate cancer. , 2024, , 235-253.		0

#	Article	IF	Citations
1848	How chemokines organize the tumour microenvironment. Nature Reviews Cancer, 2024, 24, 28-50.	12.8	0
1872	Editorial: Community series in novel insights into immunotherapy targeting tumor microenvironment in ovarian cancer: volume II. Frontiers in Immunology, 0, 14, .	2.2	0
1930	Immune System Influence on Hematopoietic Stem Cells and Leukemia Development. Advances in Experimental Medicine and Biology, 2023, , 125-135.	0.8	0
1947	Biomembrane-based nanoparticles for cancer immunotherapy. , 2024, , 299-316.		0
1950	A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives. Neurological Sciences, 0, , .	0.9	0
1984	Establishment of a murine hepatocellular carcinoma model by hydrodynamic injection and characterization of the immune tumor microenvironment. Methods in Cell Biology, 2024, , 79-97.	0.5	0
1986	Editorial: Reviews and advances in the molecular mechanisms of breast cancer. Frontiers in Cell and Developmental Biology, 0, 12, .	1.8	0